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DEFINITIONS 
 
Defervescence    “Abatement of a fever as indicated by a reduction in body 
temperature” (WordNet, 2011). 
Endemic  “The constant presence of a disease or infectious agent within 
a given geographic area or population group; may also refer to 
the usual prevalence of a given disease within such an area or 
group” (Last, 1988). 
Epidemic   “The occurrence in a community or region of cases of an 
illness with a frequency clearly in excess of normal expectancy” 
(Chin, 2000). 
Hyperendemic  “A disease that is constantly present at a high incidence and/or 
prevalence and affects most or all age groups equally” (Last, 
1988). 
Outbreak “An epidemic confined to a localized area, such as a town or 
within an institutional setting like a day-care center” (Oleckno, 
2002). 
Pandemic  “An epidemic occurring worldwide or over a very wide area, 
crossing international boundaries, and usually affecting a large 
number of people” (Last, 1988). 
Pantropics “Area between the tropics of Cancer and Capricorn, defined by 
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ABSTRACT 
 
 
Dengue, a group of four similar viruses transmitted through the bite of a 
mosquito, is estimated to infect upwards of 100 million annually in over 100 
nations throughout the global equatorial belt.  Distribution of global dengue is 
highly skewed as Southeast Asian and Western Pacific regions endure 75% of 
the global dengue burden.  Similar to other regional countries, Malaysia has been 
rapidly urbanizing, which has supported a hyperendemic dengue state.  
The biological pathway by which dengue infection causes a wide range of 
clinical manifestations, spanning asymptomatic to life-threatening severe 
complications, is not comprehensively understood.  Historically, severe dengue 
complications have primarily occurred in children.  Consequentially, the majority 
of the dengue biological pathway research has been conducted on children; 
however, extrapolation of research findings to adults may be inappropriate as 
dengue manifestations have differed between age groups.  As developing 
countries undergo epidemiologic transitions and dengue continues to spread 
geographically to non-endemic regions, youth and adult populations have been 
subjected to more of the severe dengue burden.  
Epidemiology and laboratory-based evidence has supported both memory 
T-cell and antibody independent enhancement hypotheses to explain the 
  
xiii 
 
biological pathway of severe dengue.  Both hypotheses employ the central idea 
that a primary infection alters immune components so that during a secondary 
heterotypic dengue infection, an individual is more at risk for severe 
complications.   
Monocytes, immune cells that are pivotal in both hypotheses, have been 
highly examined through in vivo and in vitro experimentation; however, 
epidemiological evidence for monocyte involvement is incomplete.  The primary 
objective of the study was to examine if a difference in absolute monocyte count, 
considering independent risk factors, is present in individuals with primary and 
secondary dengue infections. 
A secondary dengue infection was found to raise absolute monocyte count 
during the defervescence phase of dengue illness in individuals aged 15 years 
and older 0.71 ± 0.15 (x10^9) compared to those experiencing primary dengue 
infection.  Gender and distance of study participants’ residences from Hospital 
Ampang were found to be risk factors for the relationship of interest; whereas, 
age and race were not found to be significant risk factors. 
The study helps expand current knowledge of the severe dengue 
biological pathway with respect to immunological differences between primary 
and secondary dengue infections.  Further research is needed to confirm and 
expand the findings of this initial study, specifically to include infecting dengue 
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serotype, education, and socioeconomic status which are known dengue risk 
factors. 
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INTRODUCTION 
Dengue, a flaviviris transmitted by the bite of a mosquito (Aedes genus), is 
currently estimated to infect upwards of 100 million individuals worldwide 
annually.  There are four serotypes of the dengue virus, each capable of causing 
a range of manifestations from asymptomatic infection to life threatening 
complications (i.e. hemorrhage, shock, severe organ impairment).  Dengue is an 
emerging public health threat in over 100 tropical and sub-tropical countries, 
however, disproportionately burdens Southeast Asia and the Western Pacific 
nations with 75% of the annual global dengue incidence (WHO/TDR, 2009; CDC, 
2011).   
The first recorded outbreak of dengue in Malaysia, located in Southeast 
Asia, occurred in 1901 (Skae, 1902).  In the last century, dengue has become 
hyperendemic across much of Malaysia, meaning the disease is constantly 
present at a high incidence and affects most of the population (Last, 1988).  The 
financial cost of dengue in Malaysia has been estimated in 2006 at US$12.8 
million annually, with 54% allocated for dengue treatment and 46% towards 
vector control (Suaya, Shepard, & Beatty, 2006).  Even with increased vector 
control efforts by the Malaysian Ministry of Health, the burden of dengue 
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continues to grow as evident by the highest number of annual dengue mortality 
recorded to date of 134 individuals in 2010 (MMOH, 2011).   
The uncontrolled worldwide epidemics of dengue is cause for alarm; 
however, until the last half century dengue was a widely unknown, 
uncharacterized disease with little burden on the human population.  
 
Global Dengue History 
Due to disease similarities, the origins of the dengue virus are disputed 
and are divided into two lines of thinking: African and Asian.  The proponents for 
the African origin point to the current commensal relationship between the 
dengue virus and the primary vector Aedes aegypti, which originates from Africa.  
The Asian theory of dengue origin points to recent ecological, serological and 
phylogenetic evidence of Aedes aegypti and dengue virus emergence and 
evolution within Asia to make their ancestral claim (Smith, 1956; Rudnick & Lim, 
1986; Wang et al., 2000). 
Historical documents clinically describing a dengue-like illness first appear 
in China from the Chin Dynasty (265-420 Common era (CE)) (Gubler, 1998).  A 
gap of nearly seven centuries passes before descriptions reappear in the French 
West Indies in 1635 CE (Gubler, 1997).  By 1800 CE, many accounts of dengue-
like outbreaks along trading routes in the tropical and sub-tropical global belt had 
been documented.  Areas with documented dengue-like outbreaks during this 
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time period include Cuba, Brazil, Hawaii, East Africa, Syria, Egypt, United States, 
Indonesia, Panama, Spain, India, Burma, and Philippines (Vasilakis & Weaver, 
2008).  From the early 18th to 19th centuries, dengue-like epidemics traversed the 
globe including five known pandemics (Gubler, 1997).  While it is impossible to 
know which of the four dengue serotypes was responsible, it has been 
hypothesized that only one serotype was responsible due to the lack in severe 
manifestations that are currently observed to be associated with heterotypic 
secondary dengue infections (Gubler, 1997). 
  The wave of scientific breakthroughs in infectious disease research during 
the early 20th century brought empirical evidence of both the etiological agent 
and vector for dengue.   In 1907, U.S. Army Medical Corps Captain Ashburn and 
Lieutenant Craig were stationed in the Philippines to determine if dengue was a 
blood-borne disease transmitted through mosquitoes, as literature of the time 
suggested (Gubler, 2004).  Results of their studies were inconclusive towards the 
causal vector; however, they were able to determine that the dengue agent was 
in-filterable (i.e., a virus) (Gubler, 2004).  Aedes egypti was demonstrated to be 
the causal vector using human volunteers in 1926; followed by Aedes albopictus 
in 1931 (Vasilakis & Weaver, 2008). 
 World War II (WWII) is a defining moment in time for dengue.  Before 
WWII, dengue was a little-studied disease which caused a flu-like non-fatal 
illness that would typically pass within a week.  The war brought many changes 
which altered the environment and demographics, especially in the Asian theater 
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of war.  As the Empire of Japan expanded its regional borders into southern 
neighboring nations, and upon the United States of America entering the war 
against Japan, tens of thousands of dengue susceptible individuals flooded into 
dengue endemic regions.  Mass movement of supplies and troops inadvertently 
transferred dengue across much of the global tropical and sub-tropical belt 
(Gubler, 1997).  As a result of poorly designed urban military and civilian 
developments, increased in water storage tanks, and discarded war material 
serving as breeding sites for Aedes larvae dengue epidemics in Africa, 
Mediterranean region, and the Americas, along with a pandemic in the Pacific 
occurred throughout WWII (Gubler, 1997).  
As the effect of dengue on Allied and Axis troops increased, both sides 
invested resources into dengue research.  Dengue virus serotype 1 (DENV-1) 
was first isolated in Japan in 1943, which was quickly followed by the American 
isolation of DEN-1 and dengue virus serotype 2 (DENV-2) in 1944 (Sabin, 1952).  
Further investigations resulted in the development of the haemagglutination 
inhibition (HI) test (Sabin, 1952).  Haemagglutination inhibition allowed for a 
laboratory diagnosis of dengue infection using “homotypic” immunological 
responses in primary and secondary dengue infected individuals (Sabin, 1952).  
These pioneering scientific discoveries permitted dengue to be distinguished 
from other diseases presenting with similar clinical manifestations. 
As the war concluded and troops withdrew, dengue had taken hold in the 
Pacific and perceptions on the potential threat of dengue soon changed.  During 
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the post-war period, displaced war refugees concentrated in already crowded 
urban cities.  These rapidly expanding urban centers lacked infrastructure for 
sanitation and water distribution capabilities, which lead to a rise in household 
water storage tanks (Gubler, 1997).  Under these ideal breeding conditions 
Aedes aegypti populations soared and continued to spread geographically 
through military and civilian transport vehicles (Gubler, 1997).  The Pacific was 
now experiencing multiple co-circulating dengue serotypes contributing to the 
first recorded dengue hemorrhagic fever (DHF) epidemic in Manila, Philippines in 
1953 (Rigau-Perez et al., 1998).  Both dengue virus serotypes 3 and 4 (DENV-3 
and DENV-4) were isolated for the first time during the DHF outbreaks in the 
1950s (Rigau-Perez et al., 1998).  Prior to the 1953 dengue outbreak, DHF-like 
symptoms had been described in two historical accounts: United States in 1780 
and Greece in 1927 (Vasilakis & Weaver, 2008).  Unlike the 1953 DHF 
outbreaks, the historic outbreaks are thought not to have been a significant threat 
to public health.  Dengue fever epidemics have remained largely unobserved in 
the last 25 years due to the disease endemic nature in Asia; however, DHF 
epidemics have spread throughout much of the Pacific region mainly effecting 
children (Pinheiro & Corber, 1997).  Dengue surveillance in Malaysia 
corroborates the epidemiological patterns of dengue in Asia.  From 1987-1991, 
dengue fever incidence continually increased from 10.4 to 32.7 per 100,000 
individuals (Poovaneswari, 1993), and prior to 1982 over 50% of dengue 
mortalities were in children (George & Lam, 1997). 
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Historic dengue epidemiology in the Americas is in stark contrast to that 
experienced in Asia.  The first record of a dengue-like outbreak occurred in 
Martinique and Guadeloupe in 1635, followed by epidemics and pandemics 
mirroring similar levels seen in pre-WWII Asia (WHO, 1996).  However, in 1947, 
in an attempt to rid Yellow Fever Virus from the Americas, an Aedes aegypti 
eradication plan was implemented (WHO, 1996).  Continued sero-surveillance 
efforts first isolated DENV-2 in Trinidad in 1953 (WHO, 1996).  By 1962, a year 
before the program ended, 17 of the 47 Pan American Health Organization 
(PAHO) countries had been certified as Aedes aegypti free (WHO, 1996).  During 
the 1960s and 1970s dengue epidemics were few in PAHO countries as a result 
of the eradication program but once the program ended, countries quickly 
became re-infested with Aedes aegypti.  In 1999, Chile was the only country in 
PAHO that remained free of Aedes aegypti (Figure 1) (Arias, 2002).  In 1963, 
DENV-3 was isolated and in 1968 the Americas experienced their first outbreak 
of DHF in Curacao and Venezuela (WHO, 1996).  With isolation of DENV-1 in 
1977 and DENV-4 in 1981, the Americas, like Asia, have all four dengue 
serotypes co-circulating (WHO, 1996).   
As described above, the relationship between humans and dengue has 
been ongoing for at least the last 17 centuries, but not until recently has the 
overall interaction between species intensified due to expansion of trade, travel, 
population growth, and urbanization.  At present, an estimated 3 billion people 
are at risk for dengue infection, of which 100 million are estimated to become 
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infected with the dengue virus annually (WHO/TDR, 2009).  This level of risk will 
lead to approximately 500,000 worldwide cases of DHF and 22,000 deaths 
(WHO/TDR, 2009; CDC, 2011).   
 
 
Figure 1. Geographic spread of Aedes aegypti in Americas before and after the 
Aedes aegypti eradication program (Arias, 2002).  Areas shaded in light green 
indicate infestation with Aedes aegypti. 
 
History of Dengue in Malaysia 
The current relationship between Malaysia and dengue can only be fully 
understood when put in a historical context.  During the early 1900’s, Malaysia’s 
port cities along the Strait of Malacca rapidly expanded as a result from trade 
between India, China, and the European naval powers (Saw, 2007).  Global 
  
8 
 
trade brought wealth and influence to Malaysia, but in late 1901, it also brought 
the first outbreak of dengue fever to the port-city of Penang (Skae, 1902).  
Following occupation during WWII, dengue outbreaks were observed throughout 
the country (George, 1987).  Exactly when the four different serotypes arrived in 
Malaysia is unknown; however, dengue had become endemic near the time the 
first outbreak of DHF was documented in 1962 (George, 1987).  Today, Malaysia 
is endemic for all four distinct dengue serotypes (Vinomarlini et al., 2011). 
During the last half century, Malaysia’s economy has shifted from primarily 
agriculture to technology- and service-based industries, which have promoted an 
estimated rapid increase in urbanization from 20.4% in 1950, to 72.2% in 2010  
(UN, 2009b).  A rise in urban construction, litter accumulation, and poor drainage 
increases the number of breeding sites for the diurnal feeding primary urban 
dengue vector, Aedes aegypti (WHO/TDR, 2009).  Malaysia, unlike its southern 
neighbor Singapore, has experienced an increasing cyclic trend in both the 
number of cases and deaths (Figure 2).  The incidence rate of dengue in 
Malaysia displays an increasing hyperendemic pattern, while dengue is in a 
cyclic epidemic pattern in Singapore (Figure 3, A).  While climates are similar in 
both countries, a more comprehensive vector population control program, 
especially with regard to breeding site reduction, in Singapore may aid 
preventing the hyperendemic pattern of disease observed in Malaysia.  Cases-
fatality rates have dropped below 1% in both Malaysia and Singapore 
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demonstrating satisfactory rehydration treatment of dengue patients (Figure 3, B) 
(WHO/WPR, 2011). 
 
 
Figure 2.  Number of total cases (A) and deaths (B) in Malaysia (black) and 
Singapore (gray) from 2000 to 2010 (WHO/WPR, 2011). 
 
In a retrospective cross-sectional study from 1998 to 2003, Hussin and 
colleagues (2005) reported a 1.23 male/female ratio in hospitalized symptomatic 
dengue infections in Kota Bharu, Malaysia.  The pattern of higher rates of 
reported symptomatic infection in males has been observed in other Southeast 
Asia Region (SEAR) dengue studies (Yew et al., 2009).  Why male hospitalized 
dengue infections are reported more frequently than female has yet to be fully 
understood.  Potential risk factors for future investigation include increased 
outdoor activity by males, leading to increased vector exposure, and females 
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having more coverage of their body with clothing as dictated by religious beliefs, 
leading to decreased vector exposure.  
Studies have observed a protective effect amongst Africans and 
individuals with African decent (Halstead et al., 2001; Sierra, Kouri, & Guzman, 
2007).  Researchers have hypothesized genetic polymorphisms within this 
population maybe the contributing protective factor (Kyle & Harris, 2008).  
Research on Human Leukocyte Antigen (HLA), a region on human chromosome 
six that contains immune system genes, may play a major role in development of 
severe disease.  Recent research on Malaysian populations has identified 
several HLA types to be risk factors for development of severe dengue 
complications (Appanna, Ponnampalavanar, Lum Chai See, & Sekaran, 2010).  
The Malaysian population consists of 90% Malay, Chinese and Indian; the 
remaining 10% is mainly individuals from other SEAR countries and individuals of 
European descent with very few individuals with African ancestry (J. Sathar, 
personal communication, March 2011).   
In World Health Organization (WHO) SEAR and Western Pacific Region 
(WPR) member states, children (<15 years) have historically borne the majority 
of adverse outcomes, in quantity and severity, associated with dengue infection 
(WHO/TDR, 2009).  Research has suggested this maybe in part due to increased 
capillary fragility among children (Gamble et al., 2000).   From 1973, when 
dengue became a reportable disease in Malaysia, until 1981, the pattern of 
elevated mortality among children compared to adults persisted.  George and 
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Lam (1997) reported that since 1982 over 50% of dengue related mortality was 
observed among individuals over the age of 15 in Malaysia.  The increased 
pattern of dengue mortality in adults has also been observed in Thailand and is 
even more pronounced in Singapore (Cummings et al., 2009).  From 2004 to 
2008, 24 of the 28 adults who died of dengue in Singapore were older than 45 
years of age (Chua, 2010). 
 
 
Figure 3.  Incidence rate (per 100,000 population) (A) and case-fatality rate (per 
100 DF/DHF cases) (B) in Malaysia (black) and Singapore (gray) (WHO/WPR, 
2011). 
   
No study to date has undertaken why the average age of dengue mortality 
has been increasing in Malaysia, but studies have attempted this in other SEAR 
nations.  These studies have suggested the contributing factors to be urban 
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development, vector control practices, distribution changes in viral serotype and 
genotypes, change in age distribution, increased immigration and migration 
patterns, and increasing life expectancy with concurrent decreasing birth rate 
(Nagao, & Koelle, 2008; Halstead, 1994; Wichmann et al., 2004; Reves, 1985; 
Cummings et al., 2009).  Together these factors may decrease the dengue 
susceptible population, which reduces the rate that dengue susceptible 
individuals contract the disease (known as force of infection) (Cummings et al., 
2009).  Consequently, more individuals will contract a secondary heterotypic 
dengue infection later in life. 
Comparing to the above studies’ findings, Malaysia already displays many 
of the contributing trends that may reduce the force of dengue infection.  
Sustained socioeconomic improvements and a vector control program may 
decrease the number of people at risk of exposure.  Population structural 
changes also continue to contribute.  Since 1970, Malaysia’s crude death rate 
and crude birth rate have been declining, whereas, life expectancy has been 
increasing (Figure 4) (UNICEF, 2011).  These factors will lead to an overall 
increased median age of the Malaysian population (Figure 5) (UNICEF, 2011), 
along with increasing the number of non-susceptible dengue individuals further 
reducing the force of the infection.  Additional changes to the Malaysian 
population structure come as a result of adult immigration from surrounding 
countries and migration from rural Malaysia where the incidence rate of dengue 
may not be as high.   
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The above factors may combine to create longer intervals between 
dengue infections within the Malaysian population, resulting in a greater 
proportion of individuals acquiring a secondary infection during adulthood. 
Observations from Cuba have suggested that increased time between dengue 
infections increases the risk for severe dengue complications (Guzman et al., 
2002).   
 
 
Figure 4. Malaysian crude death rate (per 1000), crude birth rate (per 1000) and 
life expectancy in 1970, 1990 and 2009 (UNICEF, 2011). 
 
Hypotheses for the biological pathway by which severe dengue 
complications manifest, include antibody dependent enhancement and 
reactivation of memory T-cell.  Both hypotheses incorporate the notion that a 
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primary dengue infection alters the immune system, whereby severe 
complications arise during a secondary heterotypic dengue infection.  Integral in 
the mechanics of both hypotheses are various immune cells such as monocytes, 
dendritic cells, and T-cells (Halstead, 1994). 
 
 
Figure 5. Age-sex structure in Malaysia, 2000 & 2050 (UN, 2009a). 
 
As more countries within Asia, Africa, and Americas enter the second and 
third phase of Omran’s (1971) epidemiological transitions, populations will 
continue to age, increasing the severe dengue burden upon adults (See 
Appendix A for discussion of epidemiological transitions).  Epidemiological 
studies in Malaysia to date have described adult dengue manifestations, tried to 
determine the differences in symptomatic dengue manifestations between adults 
  
15 
 
and children, and identified potential serum markers in adults as potential 
biomarkers for early identification of severe dengue cases (Lum, Suaya, Tan, 
Sah, & Shepard, 2008; Tee et al., 2009; Thayan et al., 2009).  Historically, 
dengue studies have concentrated on the determinants and biological pathways 
of severe dengue development within the population aged less than 15 years.  
With the ongoing shift in burden of severe dengue mortality to individuals above 
15 years of age, there is an immediate need to expand investigations on the 
biological pathway of severe dengue in those above 15 years of age, especially 
within WHO SEAR & WPR member states. 
 
Statement of the Problem 
 Estimated to infect upwards of 100 million annually in over 100 nations 
throughout the pantropics, the equatorial region between the tropic of Cancer 
and Capricorn, dengue, within the last half century, has emerged as the principal 
arthropod-borne virus (arbovirus) public health threat.  Distribution of global 
dengue is highly skewed as Southeast Asian and Western Pacific regions endure 
75% of the global dengue burden.   
Similar to other regional countries, Malaysia has been rapidly urbanizing 
which has supported a hyperendemic dengue state.  A low death rate and high, 
yet decreasing birth rate has increased the Malaysian population size, median 
age, and life expectancy.  The ongoing epidemiological transition in Malaysia has 
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potentially raised dengue herd immunity. Consequently, this increases time 
between dengue infections, which is a risk factor for development of severe 
dengue, and age at which individuals experience a secondary heterotypic 
dengue infection.  Research has primarily examined severe dengue in children, 
and extrapolation of findings to adults may only be partial as dengue 
manifestations have differed between age groups. 
The severe dengue biological pathway is not comprehensively 
understood, although epidemiology and laboratory-based evidence has 
supported both memory T-cell and antibody independent enhancement 
hypotheses.  Monocytes, pivotal in both hypotheses, have been highly examined 
through in vivo and in vitro experimentation (Ubol & Halstead, 2010); however, 
epidemiological evidence for monocyte involvement is incomplete.  Previous 
dengue infection, determined by the hemagglutinin inhibition assay, is a principal 
severe dengue risk factor, however, epidemiological assessment of previous 
dengue infection status with venous absolute monocyte count is lacking.   
Uncontrolled capillary effusion, the loss of bodily fluid potentially leading to 
shock, is the primary cause of mortality from dengue.  Monocytes have been 
indicated as a possible predictor of severe dengue (Potts et al., 2010), although 
further epidemiological examination is needed to confirm the association taking 
into consideration independent risk factors. 
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Significance of the Study 
The study is a subset of a data from a larger cross-sectional study that 
was conducted in a previously un-described dengue population.  Dengue 
manifestations have shown to differ between populations.  Description of clinical 
manifestations during dengue disease of the study population will allow for 
comparison to the dengue literature.  Also, the descriptive undertaking remains 
important as the current dengue classification criteria was recently updated and 
there is still a need to ensure the criteria can be effectively used on all global 
dengue populations. 
The study attempted to clarify through epidemiological methods the 
relationship of venous absolute monocyte count with primary and secondary 
dengue infection status, taking into consideration the effects of independent risk 
factors, during the defervescence phase of illness.  Monocytes are of particular 
importance due to their in vitro and in vivo empirically determined involvement in 
both innate and adaptive dengue immunity.  Among dengue patients, monocytes 
have been previously observed to decrease in venous blood samples during 
defervescence.   As a previous dengue infection has been observed to be a 
significant risk factor for severe dengue complications during a heterotypic 
secondary dengue infection, determining if previous dengue infection status 
alters immunological responses, specifically venous absolute monocyte count, is 
of significant interest in elucidating the severe dengue biological pathway. 
Understanding how independent risk factors affect the relationship between 
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primary and secondary dengue infection and monocyte level, may provide 
currently absent epidemiological support and clarity on the antibody dependent 
enhancement and/or reactivation of memory T-cell severe dengue hypotheses.   
Additional epidemiological assessment of the association between 
monocytes and the outcome of vascular leakage/hemorrhage, while considering 
independent risk factors, may provide further insights into the severe dengue 
biological pathway with respect to monocyte involvement.  
 
Purpose of the Study 
The primary purpose of this cross-sectional study was to collect data and 
analyze the association of venous absolute monocyte count with primary and 
secondary dengue infection status during defervescence considering the role of 
independent risk factors (e.g. gender, age, race, and distance from patient 
residence to hospital) among hospital admitted dengue patients above 15 years 
of age in Federal Hospital Ampang, Selangor, Malaysia from June to December 
2010. 
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Aims of the Study 
 Primary aims of the study include:  
1) Describe the demographics, co-morbidities, manifestations, and 
laboratory results of the study population by primary & secondary 
dengue infection status and absence & presence of 
hemorrhage/vascular leakage. 
2) Determine the relationship of venous absolute monocyte count with 
primary and secondary infection considering the effects of the 
independent risk factors gender, age, race, and distance of 
residence from hospital, during defervescence. 
Secondary aims of the study include: 
1) Determine the relationship of venous absolute monocyte count with 
presence and absence of hemorrhage/vascular leakage, considering 
the effects of the independent risk factors gender, age, race, and 
distance of residence from hospital, during defervescence. 
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LITERATURE REVIEW  
 A literature review was performed using the following searchable 
published literature databases: PubMed, Web of Knowledge and Science Direct. 
The searches used the keywords: dengue, monocyte, macrophage, secondary 
infection, hemorrhage, and vascular leakage.  Results were limited to English 
written articles and were extracted by March 25th, 2011. 
 
The Unknown Severe Dengue Biological Pathway 
 A literature review on the development of severe dengue reveals multiple 
hypotheses all of which have biological plausibility (Rodenhuis-Zybert, Wilschut, 
& Smit, 2010).  The elusiveness of conclusive empirical evidence pointing toward 
a single hypothesis has prompted experts to suggest that the ultimate causal 
pathway for the development of severe dengue complications is most likely 
multifactorial (Whitehorn & Farrar, 2010).  Central hypotheses for the 
development of severe dengue include:  viral virulence, reactivation of memory 
T-cells, HLA type, and antibody-dependent enhancement (ADE) (Kyle & Harris, 
2008).  As the study is epidemiological in nature, the intended purpose of the 
below section is to not present a comprehensive review of the microbiology of 
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dengue pathogenesis; dengue pathogenesis reviews may be found elsewhere 
(Ubol & Halstead, 2010; Rothman, 2010; Kyle & Harris, 2008).  The intended 
purpose is to introduce a generalized platform of knowledge which allows for 
understanding of the current literature gap and interpretation of study results. 
 The hypothesis of viral virulence revolves around the central idea that a 
particular serotype or genotype of dengue virus is inherently more prone to cause 
severe dengue complications (Whitehorn & Farrar, 2010).  In 1997, an outbreak 
of DENV-2 was detected in Cuba which produced high incidence rates of severe 
dengue manifestations (Guzman, Kouri, & Halstead, 2000).   Genotyping of the 
1997 Cuban virus indicated mutations had occurred compared to a similar yet 
less severe Jamaican DENV-2 strain (Guzman et al., 2000).  Under the viral 
virulence hypothesis, a mutation in the 1997 Cuban DENV-2 strain increased the 
virulence of the virus.  The viral virulence hypothesis alone does not support 
observed epidemiological evidence as many people will be infected with dengue 
during an epidemic, however, only a fraction of cases will develop severe 
complications (Martina, Koraka, &Osterhaus, 1999). 
 Intrinsic risk factors, especially the involvement of the host immune 
response, provide a more promising explanation for why only a small proportion 
of dengue infected individuals develop severe dengue complications.  As 
previously explained, studies have identified associations between HLA type and 
dengue disease severity (Appanna et al., 2010).  Further research on HLA types 
have the potential to add knowledge to the pathogenesis theories of dengue, and 
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can also be used as a tool to identify individuals at an increased risk for dengue 
disease (Kyle & Harris, 2008).  Larger studies are needed to confirm and expand 
initial findings. 
 The reactivation of memory T-cells and ADE hypotheses are both based 
on the notion that following a primary infection, the host immune system is 
altered or primed such that upon a secondary infection, a severe immunological 
reaction occurs (Pang, Cardosa, & Guzman, 2007).  Central to both hypotheses 
are the involvement of monocytes.  Produced from progenitor cells in the bone 
marrow and stored in the spleen, monocytes are the parent cells found naturally 
in the circulatory system that undergo differentiation and activation into 
macrophages and dendritic cells once they enter tissues (Imhof & Aurrand-Lions, 
2004) (Figure 6).   
Antibody dependent enhancement in dengue is supported by the 
epidemiologic findings of increased risk during a secondary heterotypic dengue 
infection (Ubol & Halstead, 2010).  During a primary dengue infection the 
adaptive immunity pathway is activated and B-cells produce antibodies specific 
against the infecting serotype.  However, antibodies which are cross-reactive 
with the other dengue serotypes are also produced (Pang et al., 2007).  The 
cross-reactive antibodies provide a transient period of time that the individual is 
immune to all dengue serotypes.  After roughly three months the cross-reactive 
antibodies are no longer maintained at levels capable of providing complete 
dengue protection (Dengue Virus Net, 2011).  The primary dengue infection has 
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altered the immune system in that cross-reactive antibodies are present, but at 
non-neutralizing levels (Kyle & Harris, 2008). 
During a heterotypic secondary dengue infection, cross-reactive 
immunoglobulins from a primary dengue infection bind to the virus of the 
secondary infection.  As cross reactive antibodies have dropped below 
neutralizing levels, inactivation of the dengue virus is not achieved.  Instead, the 
dengue virus and cross-reactive antibody attach to macrophages/monocytes via 
their Fc-receptor (Pang et al., 2007).  Dengue virus has been shown to be 
capable of infecting dendritic cells, monocytes, macrophages, lymphocytes, 
hepatocytes and vascular endothelial cells (Leong, Wong, Leong, Tan, &  
Wannakrairot, 2007).  Replication of dengue virus has been observed in dendritic 
cells, but primarily occurs in monocytes & macrophages (Rodenhuis-Zybert et al., 
2010).   
Halstead and colleagues (2010) have suggested an intrinsic ADE model in 
which binding via the Fc-receptor on a monocytic cell of a cross-reactive antibody 
and dengue virus enhances dengue viral replication within the monocytic cell 
followed by proinflammatory cytokine output (Halstead, Mahalingam, Marovich, 
Ubol, & Mosser, 2010) (Figure 7).  The intrinsic ADE model is supported by 
epidemiological evidence in which high levels of viremia and proinflammatory 
cytokines are associated with increased risk of severe dengue complications 
(Kyle & Harris, 2008; Pang et al., 2007; Avirutnan et al., 2006; Endy et al., 2004; 
Libraty et al., 2002).  The ADE hypothesis can also explain the appearance of 
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severe dengue in infants.  Pengsaa and colleagues (2003) reported that 
maternally transferred dengue neutralizing antibodies were detectable at 
decreasing levels in infants until nine months after birth.  Under the ADE 
hypothesis, an infant with a primary dengue infection and non-neutralizing levels 
of maternal anti-dengue antibodies would be at increased risk for developing 
severe dengue complications.  
 
 
Figure 6. “Origin and haematopoietic differentiation of myeloid antigen-
presenting cells” (Imhof & Aurrand-Lions, 2004).  
 
The ADE hypothesis is supported by the epidemiological finding that 
secondary dengue infection is a risk factor for development of severe dengue; 
  
25 
 
however, key holes in the dengue ADE literature fail to explain all epidemiological 
evidence.  Severe dengue complications have been observed to manifest during 
the defervescence phase of dengue illness, which approximately occurs on day 
five of symptomatic illness (WHO/TDR, 2009).  ADE incorporates innate 
immunity, which has a rapid response time to infection.  As currently presented, 
dengue ADE does not explain the epidemiological evidence of delayed 
manifestations of severe dengue complications as viremia levels have been 
observed to decrease significantly by the onset of defervescence (WHO/TDR, 
2009).  
Under the reactivation of memory T-cells hypothesis, during a primary 
dengue infection the virus is phagocytized by macrophages/monocytes and viral 
antigens are presented on the cell membrane to activate memory T-cell 
production (Pang et al., 2007).  As the four dengue serotypes have 60-70% 
homology, cross-reactive memory T-cells will potentially be produced (Wong et 
al., 2007).  During a secondary heterotypic dengue infection, the virus will again 
be phagocytized by macrophages/monocytes and viral antigens displayed on the 
surface.  Cross-reactive memory T-cells produced during the primary infection 
recognize the viral antigens displayed by macrophages/monocytes during the 
secondary heterotypic dengue infection, which results in the activation of the 
memory T-cell and release of cytokines (Beaumier, Mathew, Bashyam, & 
Rothman, 2008).  Memory T-cell released cytokines have been observed to 
attract immunologic cells, such as: macrophages, monocytes and memory T-
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cells to the site of infection, subsequently increasing the level of cytokine release 
(King, Anderson, & Marshall, 2002).   
 
 
Figure 7. “Intrinsic antibody-dependent enhancement of dengue virus infection in 
THP-1 human monocytic cells.” ADE=antibody-dependent enhancement. 
Th2=Thelper 2. DENV=dengue virus (Halstead et al., 2010). 
 
Raised levels of activation and proliferation of memory T-cells in dengue 
infection has been associated with increased risk for severe dengue 
complications (Rothman, 2010).  Among the cytokines released by the memory 
T-cells are proinflammatory cytokines (i.e. interferon gamma & tumor necrosis 
factor alpha) (Pang et al., 2007; Rothman & Ennis, 1999).  Elevated levels of 
proinflammatory cytokines have been associated with increased vascular 
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permeability during dengue infection (Mongkolsapaya et al., 2006).  Vascular 
leakage is the primary mechanism for dengue infection resulting in mortality 
(Avirutnan et al., 2006).  As memory T-cell attraction and activation at the site of 
infection is a slower immunological process than the innate immune response 
hypothesized in ADE, the reactivation of memory T-cells hypothesis can better 
explain the epidemiological observation of delayed severe dengue complication 
manifestation (Nielsen, 2009). 
 While heavily investigated with in vitro and in vivo studies due to their role 
in both ADE and memory T-cell hypotheses, monocytes have remained poorly 
examined under epidemiological studies.  A literature review on 
monocytes/macrophages investigated under epidemiological studies has 
revealed the following.  In children (<15 years of age), clinical epidemiological 
studies have observed significantly lower absolute monocytes counts in dengue 
patients compared to other febrile illnesses (Kalayanarooj et al., 1997; Green et 
al., 1999).  Monocyte activation has been associated with severe dengue 
manifestations (Durbin et al., 2008).  Potts and colleagues (2010) have used 
classification and regression tree analysis to identify in Thai pediatric patients 
clinical laboratory predictor models for severe dengue.  Their results found that a 
percent monocyte cut-off of ≤ 9%, along with other variables, was capable of 
identifying patients with dengue shock syndrome (Potts et al., 2010).  An 
epidemiological study in adults found an association by dengue serotype of 
higher monocyte count in DENV-2 compared to DENV-1 (Tsai et al., 2009). 
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The literature review undertaken did not return an epidemiological study 
which investigated the relationship of venous absolute monocyte count with 
primary and secondary dengue infection status or relationship of venous absolute 
monocytes with absence or presence of hemorrhage/vascular leakage.  
Therefore, the study described here attempts to fill the literature gap of absolute 
monocyte count in primary versus secondary dengue infection during the 
defervescence phase of illness.  The study also attempts to assess the use of 
absolute monocyte count as an indicator of severe manifestations using novel 
outcome criteria. 
 
The Epidemiological Triad 
The epidemiological triad is a traditional model for infectious disease 
causation comprised of the components external agent, susceptible host, and an 
environment, which brings the agent and host in contact.  To model the complex 
relationships found in vector-borne diseases, the traditional infectious disease 
epidemiological triad has been supplemented to include a centralized vector 
component (Chadee, Williams, & Kitron, 2005).  The transmission cycle of an 
infectious disease can be interrupted with reduction or removal of a single model 
component; however, the presence of all model components in sufficient 
quantities can result in epidemics.   
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During the past 60 years, global components of the dengue 
epidemiological triad have all dramatically increased resulting in a significant rise 
in dengue incidence worldwide (Guha-Sapir & Schimmer, 2005) (Figure 8).  In 
the following section, the dengue epidemiological triad of disease causation is 
discussed by each contributing factor providing a background on the changing 
interactions. 
 
 
Figure 8. Dengue epidemiologic triad of disease causation (PSU, 2010) edited. 
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Agent 
Dengue virus is a member of the large pathogenic virus family Flaviviridae 
that includes more than 70 other medically important tropical diseases, including 
yellow fever, Japanese encephalitis, hepatitis C, and West Nile virus (Lupi, 2011) 
(Figure 9).  Within the virus genus Flavivirus, dengue virus is the culpable agent 
responsible for the highest human case-fatality rate (Qi, Zhang, & Chi, 2008).  
The mapped 11kb genome of the enveloped positive single stranded RNA 
dengue virus encodes for a viral particle composed of three structural and seven 
nonstructural proteins (Perera, & Khun, 2008).  There are four serologically 
similar dengue viruses (DENV-1, -2, -3, and -4) each with three to five genetic 
groups (genotypes).  Each serotype of dengue is genetically and anti-genetically 
diverse (Perera, & Khun, 2008).    
 
Vector  
Dengue is transmitted by the mosquito-vectors Aedes aegypti and Aedes 
albopictus.  Unlike the malaria vectors of the genus Anopheles, the dengue 
vectors are active during daylight hours with peak feeding activities occurring 
during at dawn and dusk (Jansen & Beebe, 2009).  Adult Aedes females favor 
human blood meals and are capable of biting multiple hosts in a single 
gonotrophic cycle (Jansen & Beebe, 2009).  Preferred breeding sites of Ae. 
albopictus are small natural or man-made stagnant fresh water containers in rural 
  
31 
 
or peri-urban areas (Paupy, Delatte, Bagny, Corbel, & Fontenille, 2009).  On the 
other hand, Ae. aegypti is found primarily in fast growing urban settings that allow 
for innumerable man-made breeding locations (Jansen & Beebe, 2009).  Aedes 
aegypti is an adaptive vector fully capable of sustaining a reproducing population 
within human dwellings (Jansen & Beebe, 2009).   
 
 
Figure 9.  “Flaviviridae phylogenetic tree (unrooted)” (UTMB, 2009) edited. 
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Life Cycle 
The Aedes vectors have a four stage lifecycle: egg, larvae, pupae, and 
adult (Figure 10).  The eggs of Aedes are highly durable surviving in desiccated 
states for over a year and remaining viable after wintering in frozen water.  Eggs 
must be laid in fresh water and hatch within 2-7 days when temperatures are 
greater than 12°C.  The development and survival of larvae is dependent on 
environmental conditions, including temperature, humidity, predation, and water 
depth (>10mm).  Larvae pupate after a minimum of 4 days after reaching a 
minimum weight.  The pupae stage lasts for 2 days in temperatures greater than 
18°C from which the adult mosquito emerges.  The avera ge lifespan of an adult 
Aedes is two weeks (CDC, 2011; Jansen & Beebe, 2009). 
 
Figure 10.  Lifecycle of Aedes aegypti & Aedes albopictus (CDC, 2011). 
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Natural History 
The dengue virus lifecycle is human-mosquito-human.  Dengue is also 
transmitted in a non-human primate-mosquito-non-human primate lifecycle (Kyle 
& Harris, 2008).  These sylvatic cycles have been demonstrated in both Asia and 
Africa (Gubler, 1998).  
The adult female Aedes mosquito, after taking a blood meal on a dengue 
viraemic host, has an extrinsic viral incubation period of 8-10 days.  The extrinsic 
incubation period refers to the time it takes for the dengue virus to replicate in the 
abdomen and disseminate into the mosquito’s salivary glands (Salazar, 
Richardson, Sánchez-Vargas, Olson, & Beaty, 2007).  During feeding, the 
mosquito injects saliva into the host that contains proteins to interrupt the host 
clotting cascade to allow the mosquito to take a blood meal.  The mosquito will 
remain infectious for the remainder of the normal one to two week Aedes 
lifespan, even after multiple feedings.  The human intrinsic incubation period 
lasts for 3-14 days, with an average of 4-7 days, after which viremia levels are 
elevated enough that a mosquito taking a blood meal can acquire the dengue 
virus (CDC, 2011).  Vertical transmission of dengue within vectors has been 
demonstrated (Thenmozhi et al., 2007). 
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Environment 
Climate 
 The dengue vector lifecycle (adult survival, reproduction rate, and egg, 
larvae, and pupae development) is highly influenced by climatic factors, including 
temperature, precipitation, and humidity.  Tropical conditions with high 
temperature, humidity levels, and precipitation are ideal conditions that promote 
elevated mosquito populations and rapid extrinsic incubation periods.  A 
shortened extrinsic period increases the risk for dengue infection to the human 
population as adult mosquitoes will be infectious for a longer duration of their 
lifespan (CDC, 2011).   
Due the reproductive nature of the dengue vectors, a cyclical pattern in 
dengue disease is observed in response to the monsoon season.  During the 
monsoons, breeding sites, both natural and man-made, become more abundant 
allowing for a spike in the mosquito population, subsequently increasing the risk 
for dengue infection.  This cyclic pattern of peaking dengue cases during the 
summer monsoon months can be observed in Figure 11, depicting the number of 
reported dengue cases in Thailand per month from 1990-2007.  Dengue vectors’ 
inherent propensity to thrive under tropical climatic conditions has concentrated 
the risk of dengue around the global equatorial belt; however, historic dengue 
surveillance has observed the worldwide distribution of dengue to not simply 
follow climatic conditions. 
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Figure 11. Thailand: Seasonal trend of dengue cases (1990-2007 April) 
(WHO/SEAR, 2011).  
 
Surveillance 
Dengue surveillance is an extremely beneficial practice that has 
elucidated temporal and spatial trends on global, regional, and local levels.  
Understanding the general trend of dengue over time has been achieved by 
graphing the total number of cases with dengue and countries reporting dengue 
cases to WHO from 1955 to 2005 (Figure 12) (WHO/TDR, 2007).  The number of 
countries reporting dengue cases jumped in the early 1960s, followed by a 
plateau until the early 1980s.  Since the early 1980s, countries reporting dengue 
cases have been gradually increasing.  The total number of cases did not begin 
to rise significantly until the late 1970s.  A cyclic increasing trend is noticeable in 
the number of countries reporting dengue cases and the total number of cases 
reported; however, their patterns do not mirror each other.  A definitive answer 
for why dengue total cases fluctuate with year is complex and geographically-
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specific, as there are many contributing factors (see Extrinsic Risk Factors) (Kyle 
& Harris, 2008).  
To investigate the trend of dengue at the country level, the incidence rates 
of reported dengue fever (DF)/DHF per 100,000 in selected WHO SEAR member 
states was graphed (Figure 13).   Each member state presents a cyclical pattern 
in their incidence rate, though the rate of that pattern varies within each state and 
between states.  Variation within dengue surveillance among geographically 
close countries allows for the inference that risk factors that operate within 
countries heavily influence the incidence rate of dengue. 
 
 
Figure 12. Dengue cases: Global annual number of cases reported and number 
of countries reporting to WHO by year, 1955 to 2005 (WHO/TDR, 2007). 
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Serotype-surveillance of dengue infections allowed for the discovery that 
typically only one or two serotypes are predominant for a period of one-three 
years (Figure 14) (Adams, et al., 2006).  This information has permitted insight 
on how dengue can maintain high incidence overtime.  A population experiencing 
high transmission of a serotype(s) for a period of time will result in a decrease of 
overall susceptibility within the effected population to that serotype(s).  The drop 
in transmission of the dominant serotype(s) will allow a different serotype, which 
has higher levels of susceptibility in the population, to emerge.  This relationship 
permits the serotypes to change, but will keep the incidence rate at elevated 
levels. 
 
 
Figure 13.  Incidence rates of reported dengue fever & dengue hemorrhagic 
fever per 100,000 in selected World Health Organization Southeast Asia Region 
member states (WHO/SEAR, 2011). 
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Total DHF cases reported to WHO have been graphed by year for both 
the Americas and Asia (Figures 15 & 16) (Arias, 2002).  Both regions display an 
increasing cyclic trend, although the Americas have fewer overall reported DHF 
cases.  As previously discussed, the lag time in the appearance of DHF in the 
Americas was primarily due to the Aedes aegypti eradication program run from 
1947 to 1963.  Overlaying the total reported DHF cases of the Americas and Asia 
by year starting for each at the first recorded observance of DHF presents a 
striking similar pattern (Figure 17) (Arias, 2002).  If risk factors of dengue 
continue to exacerbate the situation in the Americas, one can make an inference 
that DHF may approach that currently observed in Asia, after controlling for 
population differences. 
 
 
Figure 14. “Monthly confirmed cases of dengue by serotype at Queen Sirikit 
National Institute of Child Health, Bangkok 1980 to 2000” Red, DENV-1; blue, 
DENV-2; green, DENV-3; black, DENV-4 (Adams, et al., 2006). 
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Figure 15. Total reported cases of dengue hemorrhagic fever in the Americas by 
year from 1981-2001 (Arias, 2002). 
 
 
Figure 16. Total reported cases of dengue hemorrhagic fever in the Asia by year 
from 1955-1999 (Arias, 2002). 
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Figure 17. Total reported cases of dengue hemorrhagic fever in the Asia and 
Americas by year matched by first year of appearance (Arias, 2002). 
 
Plotting the dengue case fatality percent for DHF of the member states of 
the WHO Southeast Asia region by year from 1985 to 2006 demonstrates a clear 
cyclic decreasing trend (Figure 18) (WHO/SEAR, 2011).  The cyclic trend might 
be influenced by many risk factors, including viral strain, intrinsic factor (i.e., 
genetics), susceptible population, prevention practices, and climate factors.  
Reasons as to why some years see greater case fatality among DHF patients 
has yet to be fully deduced.  The overall decreasing trend observed in the case 
fatality percent since 1985, may in part be due to greater awareness of the 
disease among medical personnel and proper management of rehydration 
therapy.  Under proper medical care, DHF patients typically experience a case 
fatality rate of around 1% throughout the world (Kyle, & Harris, 2008).  Although 
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with absent or improper care, case fatality rates have been observed in DHF 
patients as high as 20% (Monath, 2007). 
 
 
Figure 18.  Case fatality rate of countries within the World Health Organization 
Southeast Asia region (WHO/SEAR, 2011). 
 
Extrinsic Risk Factors 
 Extrinsic risk factors for dengue are associated with the environment, and 
influence the amount of risk for acquiring a dengue virus infection at a particular 
location.  Recognized extrinsic risk factors for dengue include endemic dengue 
vector population, mass transportation, water access, urbanization, population 
growth, waste accumulation, dengue susceptibility of the population, climate, 
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circulating dengue viral strain, housing type, population density, and preventative 
measures implemented in the community (Gubler, 1997).   
World Health Organization marks the 10°C July and Janua ry isotherms as 
the year-round boundary of risk for dengue infection (Figure 19) (WHO, 2010).  
Concerns have been raised as to whether global warming will contribute to the 
geographic spread of dengue risk.  Researchers have modeled the hypothetical 
increase in risk from dengue with global temperature rise (Figure 20) (Hales, de 
Wet, Maindonald, & Woodward, 2002). 
Jansen and Beebe (2010) argue that global models based solely on 
climatic factors do not accurately model increased risk for dengue.  They present 
the example of southern Australia where climatic shifts have reduced rainfall 
totals significantly below historical levels.  A climatic model would indicate the 
region to be undergoing a reduction in risk for dengue, but the authors point the 
human element.  As southern Australia dries, the government and private 
citizens have created more water retention structures (i.e. dams, cattle troughs, 
rain barrels, etc.).  Aedes is highly adapted to human environmental intervention 
which in southern Australia may lead to an overall increased dengue risk if 
proper preventative steps to reduce breeding sites are not taken. 
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Figure 19. Countries reporting dengue in 2010 (WHO, 2010). 
 
The extrinsic risk factors that have and continue to hold the most potential 
for influencing the epidemiology of dengue are mass transportation, population 
growth, and urbanization.  The last half century has seen drastic changes in the 
global distribution of the dengue vectors (Guzman & Istúriz, 2010).  Mosquitoes 
have very limited self dispersion capabilities (Russell, Webb, Williams, & Richie 
2005), making the vast geographic spread of the dengue vectors attributed to 
increased international commerce and mass mobilization of the human 
population (Kyle & Harris, 2008).  In 2006, an estimated 2.1 billion individuals 
around the world boarded a plane (Mangill & Gendreau, 2005), while last year, 
there were 935 million international tourists (WTO, 2011).  As the human 
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population continues to grow in mobility, so do the chances that an infectious 
disease will breakout into a new geographic location (Armelagos, 1998). 
 
 
Figure 20. “Estimated baseline population at risk in 1990 (A) and estimated 
population at risk in 2085 (B)” Range: Dark Blue 0.0-0.1 to Red 0.9-1.0 (Hales et 
al, 2002). 
 
Since peaking in the mid-1960s, global population growth rates have been 
steadily declining (Figure 21); however, the small decreases in growth rate are 
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not enough to decrease the overall global population within the next 40 years 
(Figure 22) (US Census Bureau, 2011).   Continued growth of the world 
population will raise the risk for dengue infection as there will be more 
opportunities for transmission with dengue susceptible individuals. 
 
 
Figure 21. World population growth rate: 1950-2050 (US Census Bureau, 2011). 
 
Urbanization is a significant extrinsic risk factor for dengue infection (Kyle, 
& Harris, 2008).  The minimum population necessary to sustain dengue 
transmission is estimated between 10,000 to 1,000,000 individuals (Gubler, 
1997).  In these populations, there are enough dengue susceptible individuals 
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that come in contact with the infected vectors to allow for continued disease 
transmission.  In less developed nations, population growth may outstrip 
infrastructure for proper housing, sanitation, and potable water.  As a result, 
increase fresh water filled containers in and around human residences may 
occur.  These ideal breeding sites for dengue vectors will allow for greater vector 
populations within urban environments (Kyle, & Harris, 2008).  
 
 
Figure 22. “World Population: 1950-2050” (US Census Bureau, 2011). 
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The presence of multiple co-circulating dengue serotypes is a significant risk 
factor for the development of severe dengue.  Geographic distribution of dengue 
serotypes is uneven and should be taken into consideration during severe 
dengue predictive modeling.  Fried and colleagues (2010) found no statistically 
significant difference in development of dengue hemorrhagic fever by serotype.  
The relationship between the dengue and the environment is highly 
complex and cannot be modeled globally solely using climatic indicators.  With 
proper consideration to all extrinsic risk factors including “urbanization, 
socioeconomic factors, building design, water supply and management, and 
public health services,” Jansen and Beebe (2010, p.274) suggest that accurate 
modeling maybe possible at the local and regional levels. 
 
Global Burden of Dengue 
Currently, dengue has a global reach including developed and less 
developed nations; however, the burden of dengue is geographically highly 
stratified.  Today, the WHO SEAR and WPR contain 75% of the global of the 
global dengue burden (WHO/SEAR, 2011).  In the WPR, 25 of 37 states and 
territories reported dengue cases; whereas the Democratic Peoples Republic of 
Korea was the only SEAR dengue member state not reporting native 
transmission of dengue (WHO/SEAR, 2011; WHO/WPR, 2011). 
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Population growth and urbanization are risk factors that can increase the 
burden of dengue.   Population levels of more developed nations, both in urban 
and rural areas have and will continue to remain relatively constant; whereas less 
developed rural population levels are predicted to begin falling within the next 
decade.  Urban areas within developing nations are expected to have a 
continued significant increase during the coming decades (Figure 23) (UN, 
2009a).  Population growth of these less developed nations in urban settings is 
primarily a result of natural population growth, although migration within the 
country from rural settings and immigration from other countries contributes to 
urbanization (UN, 2010).   
The effect of urbanization has an entirely different set of outcomes 
depending on whether it occurs in a more or less developed nation.  Developed 
nations have relatively strong economy which permits the government ample 
resources to invest in water, drainage, and sanitation infrastructure.  These 
investments have allowed for a transition from primarily infectious diseases 
mortality within the state to chronic disease.  Many less developed nations do not 
possess the resources for infrastructure expansion to keep pace within the 
rapidly expanding cities.  The urban poor are disproportionately affected by 
infectious diseases as a result of disparities in healthcare, increased contact risk, 
and increased mobility within urban environments (Alirol, Getaz, Stoll, Chappuis, 
& Loutan, 2010).   
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Figure 23. Historic and predicted global population growth by development and 
rural/urban status (UN, 2009a). 
 
Prevention 
Without a licensed dengue vaccine, control and prevention of dengue has 
focused on vector eradication programs.  Vector control programs that have seen 
limited success focus on sustained local efforts to eliminate breeding sites and 
not large scale infrequent responses, such as communitywide fumigation 
(Ballenger-Browning & Elder, 2009).  Modern societies produce large quantities 
of disposable non-biodegradable containers which accumulate and retain 
rainwater.  Urban residences also have many containers which retain stagnant 
water ideal for breeding including potted plants, gutters, water storage, and air 
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conditioners (Kyle, & Harris, 2008).  Health department education programs and 
public service announcements continue to attempt to educate and organize the 
public to eradicate dengue breeding sites; however, until a widespread 
behavioral change occurs in the majority of a population, dengue will continue to 
a public health threat. 
 
Host 
Pathophysiology 
Dengue virus infection can cause a range of manifestations from 
asymptomatic infection to life threatening shock, hemorrhage, and organ failure 
(WHO/TDR, 2009).  Of the100 million annually estimated dengue infections, 10-
50% will develop a symptomatic response.  Only a small percentage of the 
individuals who develop symptomatic dengue infections will be captured by 
surveillance systems and/or develop severe complications (Figure 24) (Kyle, & 
Harris, 2008).  There is currently no way to determine how an individual will 
respond after being infected with dengue virus (Kyle, & Harris, 2008). 
Following infection from a dengue infected vector, an individual will 
experience a four to ten day incubation period (WHO/TDR, 2009).  Viremia levels 
reach detectable and transmittable levels approximately one day before 
manifestation of overt symptoms.   
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Symptomatic dengue disease progression is broken up into three phases: 
febrile, defervescence, and convalescence (Figure 25) (CDC, 2010).  The febrile 
phase typically lasts two to seven days and is characterized by the presence of a 
high grade fever (WHO/TDR, 2009).  Other symptomatic manifestations 
commonly include rash, headache and/or retro-orbital pain, nausea, vomiting, 
dehydration, and muscle and/or joint pain (WHO/TDR, 2009).  A ‘saddleback’ 
fever pattern is not uncommon in dengue patients and should be recognized by 
clinicians for proper diagnosis and treatment (Rigau-Pérez et al., 1998).  In most 
individuals a significant decline in platelet count and concurrent increase in 
hematocrit can be observed late in the febrile phase (Figure 26) (WHO/TDR, 
2009). 
 
 
Figure 24.  Breakdown of estimated 100 million annual dengue infections 
worldwide (Kyle, & Harris, 2008) edited. 
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Defervescence, also known as the critical phase, is a 24-48 hour period 
during which adverse clinical complications may present (CDC, 2010).  The 
critical phase is identified with a drop in fever that may progress into below 
normal body temperatures in some individuals.  Severe symptoms may appear 
during this time period include abdominal pain, fluid accumulation, mucosal 
bleed, lethargy or restlessness, and hepatomegaly.  If left untreated, individuals 
may develop severe complications including vascular leakage, severe 
hemorrhage, and organ impairment, which may lead shock and possibly death 
(WHO/TDR, 2009).  Adults and children have been observed to manifest 
differently during this time period with vascular leakage predominantly observed 
in children and severe hemorrhage observed more often in adults (Whitehorn & 
Farrar, 2010; Orthman, 2007).  
The last phase of dengue illness is convalescence or re-absorption (CDC, 
2010).  While the convalescence phase lasts 2-4 days by WHO standards, Lum 
and colleagues (2008) have shown that quality of life among dengue patients 
does not return to approximately normal levels until almost two weeks after the 
beginning of illness.  The finding suggests the recovery period for dengue is 
much longer than currently proposed (Lum, Suaya, Tan, Sah, & Shepard, 2008).  
During the convalescence phase, complications will begin to resolve. 
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Figure 25.  Phases of dengue infection (CDC, 2010). 
 
 
Figure 26.  “The course of dengue illness” (WHO/TDR, 2009). 
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Intrinsic Risk Factors 
Intrinsic risk factors for dengue are inherent within a person that 
predisposes them to biologically react in a particular manner towards a dengue 
infection, such as to develop symptomatic dengue, develop mild manifestations, 
or develop life threatening complications.  Intrinsic risk factors identified through 
epidemiological studies to be significant for development of dengue 
complications include age, gender, race, host genetics, co-morbidities, and a 
previous dengue infection (Appanna et al., 2010; WHO/TDR, 2009; Kyle & 
Harris, 2008; Liu et al., 2008; Ooi, Goh, & Gubler, 2006; Sierra et al., 2006).  A 
secondary heterotypic dengue infection is the most significant intrinsic risk factor 
associated with development of severe dengue complications.  Fried and 
colleagues (2010), found a 410% increase in odds for development of DHF in 
those individuals with a previous dengue infection compared to those with DF.   
 
Diagnostic Criterion 
 Following outbreaks of dengue hemorrhagic fever in the Philippines and 
Thailand during the 1950s, WHO developed criterion for the clinical diagnosis of 
dengue (Rigau-Perez, 2006).  Since its implementation, the dengue diagnostic 
criteria have undergone several revisions with the final version released in 1997 
(WHO, 1997).  The WHO 1997 dengue diagnostic criteria dichotomously classify 
dengue patients into individuals with dengue fever or dengue hemorrhagic fever 
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(Figure 27) (WHO, 1997).  Dengue hemorrhagic fever is subdivided into four 
classes of which classes 3 & 4 are collectively given the term dengue shock 
syndrome (WHO, 1997). 
After the release of the final revision of the 1997 WHO dengue diagnostic 
criteria, researchers and clinicians increasingly expressed dissatisfaction with the 
dengue diagnostic criteria (Rigau-Perez, 2006).  One of the major complaints 
was that individuals were observed to experience severe dengue complications, 
but due to the overly stringent dengue classification criteria a DHF classification 
was not permitted (Rigau-Perez, 2006).   
 
 
Figure 27. “Manifestations of Dengue Virus Infection” (WHO, 1997). 
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In 2009, the WHO and Special Programme for Research and Training in 
Tropical Diseases (TDR) suggested a new set of dengue classification criteria to 
address criticism of the 1997 WHO dengue criteria (Figure 28) (WHO/TDR, 
2009).  The suggested 2009 WHO dengue diagnostic criteria has been recently 
accepted as the new standard.  Also, the new diagnostic criteria has been 
verified to be much more flexible in the classification of patients over the 1997 
WHO diagnostic criteria (Barniol et al., 2011). 
 
 
Figure 28. “Suggested dengue case classification and levels of severity” 
(WHO/TDR, 2009) recreated. 
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Treatment & Prognosis 
Currently, there is no licensed medicine for dengue, and care for 
symptomatic dengue infection is palliative with closely managed rehydration 
therapy (WHO/TDR, 2009).  Immediate clinical management of fluid rehydration 
therapy can counteract the effects of plasma leakage, hemorrhage, and organ 
impairment.  Under trained clinical care, the dengue hemorrhagic case-fatality 
rate can drop below 1%; conversely, if left untreated, the case-fatality rate can 
climb to 20% (WHO/TDR, 2009; Monath, 2007).  Dengue fever is rarely fatal and 
typically resolves within a week of symptomatic onset. 
 
Prevention 
 Personal preventative measures to avoid a dengue infection to date have 
revolved solely around reducing contact with vectors as there is currently no 
licensed, market ready dengue vaccine.  Beyond reducing breeding sites for 
dengue vectors in and around the home, an individual can reduce their risk 
infection by wearing protective clothing and/or insect repellant.  These protective 
measures should be closely observed during dawn and dusk when dengue 
vectors are most active. 
 Corresponding in the May 2011 issue of The Lancet, Guy and colleagues 
update the ongoing progress of the efforts of several groups to develop a dengue 
vaccine.  The authors report there are many different techniques being employed 
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to develop a dengue vaccine, including cell passage, recombinant DNA 
technology, and subunit implementation.  In October, 2010, the first dengue 
vaccine went into phase 3 clinical trials. This vaccine was developed by Sanofi 
Pasteur and is a tetravalent vaccine that has been safely given to 5000 adults 
and children.  The only disadvantage of this vaccine so far is that two to three 
injections are needed to confer protection (Guy, Almond, & Lang,2011).   
 
Laboratory Assays 
Dengue Diagnostics 
Dengue infections in the acute phase mimic a flu-like illness making 
symptomatic clinical differentiation from other infectious diseases found in the 
same geographic regions as dengue extremely difficult (i.e. influenza, 
leptospirosis, chikungunya) (WHO/TDR, 2009).  Dengue diagnostic assays have 
been developed to detect several analytes; however, no single assay can yet 
detect a dengue infection throughout the disease course.  Until a single, 
affordable dengue diagnostic assay is developed to detect a current dengue 
infection, regardless of disease stage, extensive knowledge of dengue 
diagnostics advantages and limitations are needed to correctly use and interpret 
assay results.  Comprehensive descriptions of technology and methodology for  
the detection of viremia, non-structural protein one (NS1), immune response of 
Immunoglobulin M (IgM) and Immunoglobulin G (IgG) have been described 
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elsewhere (Peeling et al., 2010; Vaughn et al., 2000; Innis, 1997; Vornham & 
Kuno, 1997).  The following section will provide an overview of the presence of 
dengue analytes during dengue disease used in diagnostic assays.   
Viremia will be detectable from approximately one day before overt 
disease symptoms until the beginning of defervescence, or roughly the fifth day 
of symptomatic dengue illness (Figure 29) (PanBioDengue, 2011).  The first 
serological marker of a dengue infection is non-structural protein one (NS1).  
NS1 is present in detectable levels from Day 1 up to Day 9 of illness in both 
primary and secondary dengue infections. 
The human immune system has a heterotypic response with respect to 
anti-dengue immunoglobulin M (IgM) and Immunoglobulin G (IgG), dependent on 
primary or secondary dengue infection status.  In a primary dengue infection, IgM 
can be detected as early as Day 3 of illness, but usually is not detected until Day 
5.  Immunoglobulin M levels will peak around two weeks from the beginning of 
illness and will rapidly decrease to undetectable levels by three months post-
infection.  Immunoglobulin G will not be detected until early convalescence in a 
primary dengue infection, but can remain detectable for decades.  
Unlike a primary dengue infection immune response, IgG will typically 
precede IgM detection in a secondary heterotypic dengue infection.  Anti-dengue 
IgG may be detectable by Day 3 of illness, but is generally not until Day 5 or 6.  
The IgG antibody response in secondary infection is much greater than the 
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primary or past infection and will remain elevated for approximately one month 
before returning to levels observed in a primary infection.   
The immune response of anti-dengue IgM is varied among individuals with 
a secondary dengue infection.  Generally the IgM immune response is not 
detectable until late in the febrile phase of dengue illness.  The detected 
response is less than observed in a primary infection and, in a minority of 
individuals, no response may be detected.  A delayed immune response of anti-
dengue IgM antibodies, during a secondary dengue infection, might occur with 
detectable quantities not presenting until 20 days after onset of illness. 
 
 
Figure 29. “Dengue infection: Immune response” (PanBioDengue, 2011).  
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  The following sections will introduce the basic mechanics, advantages 
and limitations, and briefly discuss result interpretations of each of the commonly 
used dengue diagnostic assays.  A comprehensive discussion of all dengue 
diagnostic assays can be found elsewhere (Peeling et al., 2010; WHO/TDR, 
2009; WHO/TDR, 2004). 
 
Viral RNA Detection 
One of the most recent advances in dengue diagnostics has been the 
development of the reverse transcriptase – polymerase chain reaction (RT-PCR) 
assay able to detect the presence of dengue viral RNA in patient samples in real 
time (Peeling et al., 2010).  Before one can use this new, powerful technology, it 
is necessary to extract the viral RNA from the patient sample.  Commercialized 
kits can be obtained which allow for rapid simultaneous extraction from many 
samples.  After extraction, samples can be stored for later use or immediately run 
in batch groups on the RT-PCR machine, with results being obtained in a few 
hours. 
Results of the RT-PCR assay are reported as positive for dengue or 
indeterminate.  A positive result confirms a current dengue infection and will be 
reported with the infecting serotype (DENV1-4).  An indeterminate result may be 
the result of a true non-dengue sample, sample taken too late in dengue disease, 
improper handling or processing of patient sample, or improper execution of viral 
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RNA extraction and/or RT-PCR method.  If results are indeterminate, follow-up 
samples should be requested for antigen and/or serology testing to determine if a 
person is truly dengue-negative.  
Use of RT-PCR in dengue diagnostics allows for timely results that are 
highly specific and sensitive.  The principal advantage of RT-PCR over other 
dengue diagnostic assays is the ability to confirm a dengue diagnosis with a 
single patient sample. 
Due to the advanced technology and methods used in RT-PCR, there is 
need for a substantial initial investment of financial resources to acquire 
instrumentation and train personnel.  As RT-PCR is only useful during the febrile 
phase, the steep financial investment may not be cost-effective for some 
institutions as not all patients will arrive at the hospital during the febrile phase.  
 
Non-Structural Protein One Detection 
 Detection of the dengue NS1 protein is accomplished through a sandwich 
enzyme-linked immunosorbent assay (ELISA) (PanBioDengue, 2011).  Several 
economical commercial assays have been developed and validated using patient 
serum samples, however, the use of plasma samples has yet to be established.  
As the NS1 protein can be detected from Day 1 up till Day 9 of illness, the NS1 
ELISA provides a bridge to detect a dengue infection throughout disease course 
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as there is a potential gap between reduction of viremia and increase in dengue 
immunoglobulin (Dussart et al., 2006).   
 Results of the NS1 kit are reported as positive, fail to detect, or equivocal 
(PanBioDengue, 2011). Interpretation of a positive result is that the dengue NS1 
protein has been detected in the patient’s serum, which is indicative of a current 
dengue infection.  However, further serology testing on a follow-up serum sample 
should be completed to confirm a dengue diagnosis as there are limitations to the 
assay.  A fail to detect result means that NS1 to dengue has not been detected; 
however, this does not rule out a dengue infection.  Samples with results of fail to 
detect and equivocal should undergo a dengue IgM ELISA to further exclude a 
dengue diagnosis. 
The NS1 ELISA is rapid and useful for detecting a current dengue 
infection when RT-PCR and IgM ELISA analytes may not be present in 
detectable quantities.  The NS1 ELISA cannot by itself confirm a dengue 
diagnosis but can suggest the possibility of a current dengue infection.  Limiting 
the diagnostic capability is serological cross-reactivity between dengue and other 
flaviviruses (Peeling et al., 2010).  
 
Immunoglobulin M Detection 
Detection of dengue IgM antibodies is accomplished through a capture 
ELISA.  Like the NS1 ELISA, the IgM ELISA has been developed using patient 
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serum samples.  As anti-dengue IgM antibodies are present in detectable levels 
from approximately Day 5 of illness up to three months post-infection, they 
provide an ideal means of identifying individuals with a recent dengue infection 
(Peeling et al., 2010). 
Results of the IgM ELISA are reported as positive, fail to detect, and 
equivocal.  A positive result indicates that the IgM to dengue has been detected.  
Equivocal results should be re-run with a follow-up sample.  The interpretation of 
a fail to detect result is dependent on the onset date of clinical symptoms.  If the 
sample was collected 20 days after dengue-like disease onset, then the patient 
most likely did not have non-dengue.  However, if the sample was collected less 
than 20 days from onset of dengue-like clinical symptoms, then the result is 
reported as IgM to dengue not detected, and a request is made for a follow-up 
sample as the patient may have not yet seroconverted.  
 The dengue IgM ELISA is affordable, easy to run, and does not require 
large investments of financial resources to implement.  However, due to the 
inherent duration of the anti-dengue IgM antibodies in the body, dengue cannot 
be confirmed with a single positive IgM ELISA.  To confirm a dengue diagnosis 
using IgM ELISA, two temporally spaced patient samples must be obtained.  As 
anti-dengue IgM titers do not reach their peak until approximately two weeks 
after onset of symptoms, an increasing trend or seroconversion will confirm a 
dengue diagnosis in temporally-spaced paired-samples. 
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Immunoglobulin Detection 
The dengue haemagglutination inhibition (HI) quantitates the patient 
serum anti-dengue immunoglobulin (Ig) irrespective of Ig isotype (i.e. IgA, IgM, 
IgG) (De Paula & Fonseca, 2004).  Recently, with the development of sensitive 
IgG and IgM ELISA, HI popularity in dengue diagnostics has decreased as it is a 
time and labor intensive process (minimum two days).  HI also requires paired 
patient sera with removal of non-specific inhibitors and agglutinations from sera.  
However, minimal equipment to complete the assay, reliability, and that the 
assay is well-standardized keeps the dengue HI assay as the gold standard in 
determining if a dengue infection is primary or secondary in nature.  The 
distinction between primary and secondary dengue infection is possible as 
sustained levels of serum anti-dengue Ig are significantly different in primary and 
secondary cases.   
 Findings will be reported as positive for dengue with a primary or 
secondary dengue infection or dengue not detected. Patient samples with an 
acute sample HI titer <1280 and a convalescence sample HI titer <2560 are 
considered primary infections. Secondary infections will have an acute sample 
titer of <2560 and a convalescence sample titer of >2560 (De Paula & Fonseca, 
2004). 
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Laboratory Dengue Confirmation 
 Currently there is no laboratory assay capable of detecting a dengue 
infection regardless of disease progression.  Without this universal dengue tool, 
there is a need to fully understand dengue diagnostics to aid in diagnosis and 
correctly report cases for surveillance.  A single sample positive RT-PCR result 
can confirm a dengue diagnosis (Figure 31) (Peeling et al., 2010).  If the RT-PCR 
result comes back as indeterminate, then antigen and serology tests must be 
completed to confirm a dengue diagnosis.  Potential cross-reactivity of antigens 
and long lifespan of serological components make necessary the need to obtain 
two positive results to confirm a dengue diagnosis.   The use of one positive 
sample of antigen and serological dengue assays can suggest a dengue 
infection, but it is an incorrect practice to laboratory confirm a dengue infection. 
 
 
*Requires paired samples. 
Figure 30.  Criteria to laboratory confirm a dengue infection (Peeling et al., 
2010).  
  
67 
 
 
 
METHODOLOGY 
Study Location 
 The study location was Federal Hospital Ampang in Ampang, Selangor, 
Malaysia.   
 
Country 
Malaysia, located in Southeast Asia, is comprised of an area slightly larger 
than the US state of New Mexico at 329,847 sq km, is split into the two distinct 
land masses of Peninsular Malaysia and Borneo Malaysia by the South China 
Sea (CIA, 2011).  The majority of Malaysia experiences a tropical climate; 
however, sub-tropical conditions exist in the interior mountains in both Peninsular 
and Borneo Malaysia.  Annual monsoons drive changes in climatic conditions, 
typically seen in the southwest from April to October, and the northeast from 
October to February (CIA, 2011).  Total annual rainfall can accumulate to 
2,427millimeters (95.6 inches) in Peninsular Malaysia, though rainfall totals can 
be double this amount in Borneo Malaysia (WWIS, 2011).  Annual average 
temperatures have low variability throughout Malaysia; Kuala Lumpur annual 
high temperatures range from 31.5⁰C to 33.2⁰C (88.7F to 91.8F), and low 
temperatures range from 22.5⁰C to 23.9 ⁰C (72.5F to 75.0F) (WWIS, 2011). 
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The 2010 Malaysian Census reported the Malaysian population to be 28.3 
million with a 1.04 male/female ratio.  The main racial backgrounds of the 
Malaysian population include: Malays (60.3%), Chinese (22.8%), Indians (6.8%), 
and Others (10.0%, including expatriates).  The Malaysian population age 
groupings are skewed left with 27.2% aged 0-14, 68.1% aged 15-64, and 4.7% 
aged 65 and over in 2010 (Dr. J. Sathar, personal communication, March 2011).    
The average Malaysian household annual income is an estimated 
Malaysian Ringget $44,500 (~US$14,700) with 5.1% (est. 2002) of the population 
below the poverty line (CIA, 2011).  Literacy rate for the Malaysian population is 
88.7%, with females staying an average of 13 years, one year longer than males, 
in formal education (CIA, 2011). 
Malaysia is divided into 13 federal territories, of which the nine western 
federal territories are the most populated (Figure 31) (Encyclopedia Britannica. 
2009).  
 
City 
The formal capital city, Kuala Lumpur, resides in Kuala Lumpur Federal 
Territory in southwestern Peninsular Malaysia.  Surrounding Kuala Lumpur 
Federal Territory is the most populous federal territory, Selangor, with 5.1 million 
individuals in 2010 (Dr. J. Sathar, personal communication, March 2011). 
Selangor, save the new federal territory and governmental capital of Putra Jaya 
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(growth rate: 17.8%), is the fastest growing federal territory with a growth rate of 
3.17% in 2010 (national growth rate: 2.17%) (The World Bank, 2011).  The 
District of Ulu Langat is the westernmost of the 9 districts which comprise 
Selangor.     
 
 
Figure 31. Population density of Malaysia in 2009 (Encyclopedia Britannica. 
2009). 
 
Hospital 
Federal Hospital Ampang is located in the subdivision of Ampang, one of 
seven subdivisions which makeup the District of Ulu Langat.  Statistics from the 
2010 Malaysian Census for the District of Ampang will not be available till 2012 
(Dr. J. Sathar, personal communication, March 2011).  In 2000, the District of 
Ampang population numbered 357,925 which broken down by racial background:  
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Malay 45.2%, Chinese 40.2%, Indian 8.5%, Other 6.1% (Dr. J. Sathar, personal 
communication from Ministry of Statistics, March 2011).   
The Malaysian healthcare system is similar to the United States two-tier 
system of public and private services (MMOH, 2011).  Easy access to healthcare 
is provided to anyone in a public hospital after a co-pay of Malaysian Ringget $1 
(~US$0.33 March 2011).  Selangor currently has 20 private hospitals and 12 
public hospitals (MMOH, 2011); Federal Hospital Ampang is a public hospital 
with 560 beds (K. Khalid, personal communication from Hospital Ampang, March 
2011).  Opening in 2006, Hospital Ampang is modern 8-story structure complete 
with a two-story out-patient clinic, tri-stage (general, semi-critical, and critical) 
emergency department, comprehensive and rapid clinical laboratory with modern 
equipment, blood bank, and transplant capabilities.  Hospital Ampang retains a 
two-tiered patient room structure with dormitory style multi-bed wards throughout 
the hospital and private rooms located on the 8th floor.   
 
Dengue Ward 
Dengue has become a major burden to the healthcare system in Malaysia. 
At Hospital Ampang and other hospitals in Malaysia (e.g.  Klang Hospital), to 
facilitate a standard of care for individuals suspected or confirmed to be infected 
with dengue, a dengue ward has been established.  Admitted patients from the 
emergency department, clinics, other departments in Hospital Ampang and 
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surrounding area hospital transfers who are suspected or have been confirmed 
to have dengue, are transferred to the dengue ward as standard hospital 
procedure.  Patients who are in critical condition (i.e. hypovolemic shock), will be 
transferred to the Intensive Care Unit (ICU); however, after dengue cases have 
been stabilized, they are transferred back to the dengue ward.  The dengue ward 
is a dormitory style ward with 28 beds (2 isolation rooms) separated by gender.  
Under epidemic conditions, additional beds can be included as beds are 
generously spaced.  In-ward office and kitchen space allow for continued 
presence of medical staff.   
Due to the cyclical pattern of dengue outbreaks, dengue patient loads will 
vary potentially leaving the majority of the dengue ward unused.  To ensure the 
hospital efficiently uses all resources, patients without dengue will be transferred 
to the dengue ward for care.  Patients transferred typically have infectious 
diseases (tuberculosis, HIV, leptospirosis, etc.); although chronic diseases (heart 
disease, diabetes, etc.) can also be transferred.  To rapidly identify dengue cases 
wall name tags above the patient beds are green for dengue and blue for non-
dengue. 
 
Treatment & Care 
 Treatment and care of dengue ward patients are performed by hospital 
administration, senior doctors, junior doctors, head nurses (‘Sisters’), nurses, 
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junior nurses, medical technicians, student nurses, and janitorial staff.  Daily 
morning medical ‘rounds’ are completed by the single senior doctor overseeing 
the ward, two to three junior doctors (known as ‘housemen’), head nurses, and 
nurses.  Housemen are rotated between medical wards on a monthly schedule 
for comprehensive medical training.  Housemen and nurses are responsible for 
recording all medical information in the hospital electronic database. Three carts 
with laptops and wireless internet allow for bedside note taking, while three 
additional desktops provide comfort for more lengthy entries.  Hardcopy medical 
charts including vital statistics are kept updated at each patient’s bedside by 
junior nurses and student nurses in case of power or database failure.  Hardcopy 
charts are stored upon patient discharge.   
Junior doctors and/or nurses draw blood for clinical assessment four times 
a day at the six o’clock and twelve o’clock hours or as directed by the senior 
doctor.  Clinical laboratory tests typically include blood, kidney and liver profiles.  
A blood profile measures venous levels of the following: hemoglobin, hematocrit, 
platelet count, total white cells, neutrophils, lymphocytes, monocytes, eosinophils 
and basophils.  A liver profile assesses venous levels of total bilirubin, alkaline 
phosphatase, total protein, albumin, globulin and alanine aminotransferase.  A 
kidney profile indicates venous levels of urea, sodium, potassium chloride and 
creatinine.   
All patients are administered intravenous hydration saline solution, which 
are monitored to ensure patients are properly hydrated throughout disease 
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course.  Blood transfusions and platelet transfusions are no longer considered for 
dengue treatment in the dengue ward (practice changed in early 2010); different 
practices may be present in the ICU.  The tourniquet test is not administered as 
standard dengue diagnostic procedure.  Patients are not discharged before the 
end of the 48 hour defervescence phase of disease and may remain admitted for 
longer periods of time (i.e. days or weeks) if complications arise (e.g. severe viral 
hepatitis). 
 
Study Population 
The study is a subset within a larger cross-sectional medical microbiology 
study entitled: Genetic and Immunological Profiles during the Progression of 
Dengue Disease (further referred to as ‘source study’).  The source study is 
under the direction of Professor Dr. Shamala Devi of the Medical Microbiology 
Department, Faculty of Medicine, at the University of Malaya in Kuala Lumpur, 
Malaysia.  The source study was conducted from June to December 2010.   
To fully understand this study and the study population, it is necessary to 
first describe the purpose and study design used in the source study.  The 
source study was envisioned to fill a gap in the current dengue literature of a 
comprehensive clinical and laboratory profile of dengue disease to aid in the 
discovery and development of diagnostic assays, treatment, and vaccine.   
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The source study targeted the fraction of the dengue infected population 
who manifest with complications requiring medical intervention, as they are most 
in need of medical breakthroughs.   
The source study employed a cross-sectional design; however, the design 
does not fit the classical form of the study type.  Infectious diseases are unique 
from chronic diseases in that if a patient develops, say dengue, it is known they 
have been exposed to the dengue virus when they arrive at a hospital for 
treatment.  Consequently, the source study population consists of all new dengue 
cases, beyond patients who were suspected to have dengue on study 
recruitment and were later diagnosed with a similar manifesting disease (e.g. 
leptospirosis).  Exposure is therefore not regarded in the classical sense as 
exposure to the infecting agent or not, but is perhaps a pre-existing condition, 
such as previous infection with dengue virus that can be determined through 
laboratory analysis.  Outcome is also dissimilar to the classical case and control. 
The outcome might be defined, for example, as monocyte count or presence and 
absence of hemorrhage.  The discharge diagnosis was used in the source study.  
 The source study design also deviates from the classical form of a cross-
sectional design by the inclusion of a longitudinal dynamic in data collection.  As 
the purpose of the primary study was to develop a profile of dengue disease 
progression, patients were followed throughout their hospitalization.  For the 
source study, patient clinical and laboratory data was collected at three time 
points with one point in each of the three phases of dengue disease (febrile, 
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defervescence, and convalescence).  Even with the longitudinal dynamic of the 
source study, the design remains a cross-sectional study due the exposure and 
outcome of interest being determined at the same time. 
The present study only assesses patient data within the defervescence 
phase of illness.  Demographics of the source study are presented in the 
RESULTS section. 
   
Study Design 
The study design is an analytic cross-sectional study that has been subset 
within the source study completed from June to December 2010.  Subsetting the 
study within the source study allows for efficient use of resources as preliminary 
empirical justification for a standalone study has not yet been demonstrated.   
Few epidemiological studies have investigated the relationship of monocytes 
during dengue disease.  No studies were found in the literature review that 
examined the association of monocytes with primary and secondary dengue 
infection status.   
The target population of the study includes all individuals aged 15 years or 
older, who are susceptible to dengue and would develop severe complications as 
a result of infection, and live in Malaysia.  The target population is the population 
to which the study findings would ideally be inferred.  The source population, the 
population from which individuals will be selected for study inclusion, includes 
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individuals aged 15 years or older that have acquired a dengue infection and 
came to Hospital Ampang for medical treatment from June to December 2010.  
The study eligible population is comprised of those individuals from the source 
population who meet the study inclusion and exclusion criteria.  
Study inclusion criteria included admission to Hospital Ampang for 
dengue, and age of 15-17 years with written parental permission, or age of 18 
and above.  The study exclusion criteria excluded from the study those potential 
study participants that did not have the ability or willingness to provide informed 
consent in English, Malay, Chinese or Tamil; did not have consenting permission 
of the overseeing clinician for patient inclusion; or did not have a recorded 
venous absolute monocyte count in the Hospital Ampang computerized patient 
database for the defervescence stage of dengue disease.   
The study inclusion/exclusion criteria have allowed for targeting of a study 
population that will allow for ideal analysis of the association of interest.  
Defervescence is the critical time period during which severe dengue 
complications manifest.  Restricting the study to only hospitalized patients during 
defervescence, permits assessment of the relationship of interest on a highly 
burdened population that may provide insights that may not be observable in 
other populations or dengue disease phases. 
Dengue literature has primarily focused on individuals less than 15 years 
of age due to the suspected fragility of their undeveloped capillaries resulting in 
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increased risk for development of severe dengue manifestations (Kyle & Harris, 
2008).  The UN defines “children” as those less than 18 years of age (UN, 1990); 
however, for statistical purposes the UN has defined “youth” as those between 
the ages of 15-24 years (UNESCO, 1985).  A study population consisting of 
youth and adult, non-youth was recruited for the study as severe dengue has 
increasingly effected these populations.   
Unlike other infectious diseases (i.e. human immunodeficiency virus or 
tuberculosis), dengue is a non-chronic disease making the study population 
composed of all incidence cases.  In this study, the study exposure is not defined 
as having been exposed to the disease agent, but having a current primary or 
secondary dengue infection.  The use of the hemagglutinin inhibition laboratory 
assay allows for determination of a patient’s dengue infection status (primary or 
secondary).   
Studies have observed that a previous dengue infection is a risk factor for 
development of complications during dengue disease.  Biological pathway 
hypotheses have suggested that the primary dengue infection alters the immune 
system response to a secondary heterotypic dengue infection.  Using dengue 
infection status as the study exposure will permit observation of the primary 
objective on whether or not the predisposition has an association with venous 
absolute monocyte count. 
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Unlike the classical epidemiologic cross-sectional study outcome of case 
and control, the study outcome is a difference in the venous absolute monocyte 
count.  The study outcome has not been dichotomized by a cut point because no 
previous estimate of the relationship under investigation was found in the 
literature review.  The study’s null hypothesis is that there is no difference in 
venous absolute monocyte count by dengue infection status.  Absolute monocyte 
count is a reported clinical laboratory result given as part of a normal blood 
profile.  As a blood profile is a standard set of clinical laboratory assays 
administered to dengue patients in Hospital Ampang, most dengue patients were 
expected to undergo a blood profile during defervescence.  Monocytes are of 
interest due to their role in both innate and adaptive immunity. 
 The literature review identified several risk factors which needed to be 
included in the study analysis due to their association with the study exposure 
and outcome, not being part of the hypothesized causal pathway, and potential 
for being present in different degrees between study groups.  These risk factors 
are race, age, and gender.  Race was categorized by the major race observed in 
the Malaysian population, which are Malay, Chinese, Indian, and Other.  Gender 
was categorized as male or female.  A review of the dengue literature found 
many different cuts points by which age was categorized (groupings of 2, 3, 5, & 
10 years) with no clear indication given for the reasoning behind the selection.  
Whereas studies investigating children with dengue used smaller interval cut 
points, studies investigating adults tend to categorize the age demographic by 
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groupings of 5 or 10 years.  The study assessed the age demographic by both 5 
and 10 year groupings; however, only the 10 year groupings are displayed and 
assessed in the regression analysis as no significant results were observed using 
the 5 year grouping.  Age was categorized as 15-24 years, 24-34 years, 35-44 
years, and 45 years and above.  The last grouping was set as 45 years of age or 
above because few individuals were recruited for the study above 55 years of 
age.  Age was also assessed as a continuous variable to determine if the cut 
points were creating or masking an association. 
Known risk factors which were unable to be assessed in the analysis 
included infecting viral serotype, socioeconomic status, and education.  No data 
was available on these risk factors as current practice at Hospital Ampang does 
not take this information from the patient and the hospital laboratory does not 
possess the necessary assay. 
To consider the influence of these unattained risk factors a surrogate 
variable was used.  As Hospital Ampang is a new hospital (opened in 2006) and 
is a transfer hospital for other major diseases (i.e. thalassemia), there is potential 
that patients will travel themselves or be transferred to Hospital Ampang if they 
have severe dengue complications.  Distance between patient residence and 
Hospital Ampang, dichotomized at 12.5 kilometers was assessed for being a risk 
factor.  The 12.5 kilometer radial boundary was arrived at by averaging the 
distance between Hospital Ampang and the closest public hospitals.  This cut-off 
value will allow for approximate dichotomization of those individuals who are 
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travelling to the nearest hospital and those who are travelling extra distance to 
receive care at Hospital Ampang.  The use of this surrogate variable was not 
seen in the literature review and careful consideration is needed whether or not 
to include in the final regression models as results maybe artificial. 
 The study secondary objective was to assess the relationship of absence 
or presence of hemorrhage/vascular leakage with venous absolute monocyte 
count.  The literature review found few studies in which monocytes (absolute or 
percent) were found to be significantly associated with the outcome of the study, 
which is the absence or presence of hemorrhage/vascular leakage, when using 
the standard dengue classification criteria.  A hypothesis was formed that 
differences in absolute monocyte count maybe associated with severe dengue 
complications, but is unobservable or masked most of the time when using the 
dengue diagnostic criteria as an outcome.  Excessive effusion is the primary 
cause of death from dengue with vascular leakage and hemorrhage being the 
principal manifestations.   
The secondary objective analysis uses the absence or presence of 
hemorrhage/vascular leakage as an outcome with the aim to determine if an 
association exists with absolute monocyte count.  Hemorrhage was defined as 
presence of spontaneous gum bleed, epistaxis, menorrhagia, hematemesis, 
subconjunctive hemorrhage, renal hemorrhage, or melena.  Vascular leakage 
was defined as presence of pleural effusion, ascites, increase or decrease of 
hematocrit by 20%, hypotension (systolic blood pressure <90mmHg), or 
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narrowed pulse pressure (<20 mmHg) (WHO/TDR, 2009).  Risk factors for the 
association included age, race, gender, dengue infection status (primary or 
secondary), and distance from patient’s residence to Hospital Ampang. 
Loss to follow-up in the study could have occurred as a result of the 
patient no longer wanting to be part of the study, and medical staff not taking 
study samples.  To ensure patients continued to take part in the study, study 
recruiters took significant effort to explain to the patient the value of the study.  
As recruiters were in the hospital every weekday for several hours, they were 
encouraged to talk with participants providing them with anti-dengue educational 
material made and provided by the Malaysian Ministry of Health.  This interaction 
served to provide an opportunity for the patient to ask any further questions 
about the study and dispel any worries about the risks of study participation the 
patient may have developed.    
Loss to follow-up as a result of medical staff not taking samples 
necessitates maximum input on study staff to overcome the demanding and 
variant nature of medical care.  The primary obstacle to overcome occurred at 
the beginning of every month, when junior doctors transferred assigned wards.  
This required study staff to inform and then train the new medical staff on the 
procedures of the study.  To ensure minimum loss to follow-up, the study blood 
draws were incorporated within the established daily blood taking routine.  After 
the study staff had recruited patients they would label the appropriate blood 
collection tubes and place them in order on the blood collection cart, which was 
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used for all hospital blood collection.  The study staff then verbally communicated 
with the doctors on how many tubes and patients needed to be drawn for the 
study during the next scheduled collection time. 
No financial incentive was provided to participants.  To reduce the risk of 
potential infection and discomfort of the patient, the study blood draw was added 
on to the planned hospital blood draw.  Taking blood samples in this manner 
allowed for patients to participate without having to endure any additional needle 
sticks than what was required by the hospital.  The benefit provided by the study 
was to report the results of the dengue RT-PCR testing conducted at the 
University of Malaya laboratory.  The RT-PCR testing was part of the primary 
study design and the patient was not charged for testing.  RT-PCR results were 
made available to ward doctors to explain results to patients.  Hospital Ampang 
did not have RT-PCR capabilities, but patients who did not want to participate 
could obtain dengue infection status through anti-dengue IgM testing routinely 
completed by the Hospital Ampang clinical laboratory.  No additional needle-
sticks and free laboratory testing allowed for the benefits of study participation to 
outweigh the risks to the study participation. 
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Data Collection 
Data collection for both the source study and present study were carried 
out using the same protocol.  The following section presents an overview of the 
protocol for clinical and laboratory data collection. 
 
Clinical Data 
 After patients were admitted to the dengue ward in Hospital Ampang, 
study recruiters approached ward doctors to establish medical consent for study 
participation.  If the doctor gave medical consent, the patient was approached for 
informed consent.  After successful recruitment of the study participant, the 
hospital identification number was recorded on a standardized study participant 
clinical data form.  The patient clinical information was obtained using the study 
participant hospital identification number in the hospital electronic database 
system.  Use of the standardized clinical data form allowed for consistent 
recording of all study participant data.  The study participant clinical data forms 
were transferred back to the University Malaya laboratories of Professor Dr. 
Shamala and input into a database using Microsoft Excel© (Redmond, WA).  The 
electronic database was saved on a single computer and backed up using an 
external hard drive. 
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Laboratory Data 
 The participant study blood sample tubes were collected immediately from 
the dengue ward blood draw cart after medical staff had completed drawing 
blood.  Patient blood collection tubes were then stored in an onsite 4⁰C 
refrigerator before being transferred by cooler and gel freezer pack to the 
University Malaya laboratory of Professor Dr. Shamala Devi within 4 hours of the 
blood draw.  Upon arrival the samples were immediately processed, 
appropriately aliquoted, and stored at -80⁰C for long-term storage.  Received 
samples were recorded in a hard copy notebook to document their presence in 
storage. 
 Samples were assessed for the presence of dengue viral RNA, dengue 
NS1 protein, and anti-dengue immunoglobulin M and G.  Discussions and 
protocols for the use of dengue diagnostic assays can be found elsewhere 
(WHO/TDR, 2004; PanBioDengue, 2011).  Results of the assays were recorded 
in an electronic database and back-up on an external hard disk. 
 
Statistical Analysis 
 The laboratory and clinical databases were cleaned and analyzed in 
SAS© (Cary, NC).  Frequency and univariate procedures were used to identify 
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missing values and outliers.  All suspected errors were checked against hard 
copy documents.  
Chi-square tests for independence and Fisher’s exact test, used to 
examine if two populations contain the same proportion of observations of a 
single variable, and independent sample t-tests, used in the comparison of two 
populations’ mean on a single variable, were used in the assessment of variables 
across study populations.  Linear and logistic regression models were used in the 
assessment of the study primary and secondary objectives, while allowing for 
adjustment of the effects from independent risk factors on the relationship of 
interest.   
 
Sample Size Calculation Statement 
A sample size calculation is a necessary component of an epidemiological 
study and should be carried out during the planning phase of the study to ensure 
efficient use of limited public health resources.  As this study was a subset within 
the source study, it was not the main consideration during study planning phase.  
A power calculation was conducted retrospectively to determine if sufficient 
power existed for the analysis (see RESULTS). 
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RESULTS 
Retrospective Power Calculation 
The retrospective power calculation was completed to ensure that there 
are enough study participants to detect an association above a chance finding 
using estimates extracted from the literature.  While not ideal, the retrospective 
power calculation is an acceptable practice, but should be avoided if possible. 
Literature on youth or adult population monocyte levels during 
defervescence by primary and secondary dengue infection status was not found 
in the literature review.  In fact, monocyte levels by primary and secondary 
dengue infection status were not found among any population.  This again 
illustrates the need for the study, but also the difficulty in finding an acceptable 
estimate to base the retrospective power calculation. 
 All secondary heterotypic dengue infections do not result in development 
of dengue hemorrhagic fever, while some primary dengue infections have severe 
complications.  The use of the dengue clinical diagnostic classification in the 
study retrospective power calculation is imperfect, but remains the closest 
available option as secondary heterotypic dengue infection has been consistently 
observed to be a risk factor for severe dengue manifestations (WHO/TDR, 2009).  
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Green and colleagues (1999) presented findings of absolute monocyte 
count among 51 Thai children (<15 years of age) by clinical dengue diagnosis 
(dengue fever (n=29) and dengue hemorrhagic fever (n=22)) during 
defervescence.  The dengue fever population had an average absolute monocyte 
count of 193 ± 119, while the dengue hemorrhagic fever population was 226 ± 
196.   
 The power calculation employed an independent sample for means two-
sided formula, as previous hypothesis were not available to justify the use of a 
one-sided test.  A 0.05 significance level, or odds that the observed is due to 
chance, was used.  Population estimates of 193 and 226, along with a standard 
deviation for the population of 152 (averaged, ((119*29) + (226*22)/51)) were 
used from Green and colleagues (1999) findings.  With a study population of 197 
participants, the estimated power is 0.87.  This indicates that the odds that an 
association will be observed when one actually exists are 87%.  The power 
calculation was completed using SAS® and checked in an online power and 
sample size calculator (Statistical Solutions, 2011).  
 
Demography 
To aid in determining the external validity of the study, the source 
population and source study demography will be described first followed by the 
study demography to allow for comparisons.  The source population of the study 
  
88 
 
included all individuals above the age of 15 years who would come to and would 
be hospitalized at Hospital Ampang for a dengue infection from June to 
December 2010.  Information on this exact population could not be obtained; 
however, demographic information was acquired on all Hospital Ampang dengue 
patients, in- and out-patient, during the 2010 calendar year.  While not the exact 
source population for the primary study, the information provides a very good 
estimate on the entire population that would come to Hospital Ampang for 
treatment from a dengue infection. 
The source population consisted of 16,367 cases of dengue with one 
death reported from Hospital Ampang during the 2010 calendar year.  Deaths 
from dengue remain very low at Hospital Ampang with only two and three 
occurring in 2008 and 2009, respectively.  The single 2010 dengue death at 
Hospital Ampang occurred before the June start of the study.  Dengue cases at 
Hospital Ampang were 53.3% male and 62.0% Malay; 22.8% Chinese; 9.8% 
Indian; and 5.4% Other during 2010.  The age distribution was 33.4% aged 15 to 
24 years, 32.3% aged 25 to 34 years, 17.9% aged 35 to 44 years, and 16.5% 
aged 45 years and older (Table 1) (J. Sathar, personal communicate, April 2011). 
During the data collection time period of June through December 2010, 
the source study approached 381 patients at Hospital Ampang who met the 
study inclusion/exclusion criteria, of which, 94 declined to participate.  Patients 
who refused to participate (Source Study Refusals) tended to be male (53.3%); 
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Malay (62.0%); aged 15 to 24 years (35.7%); and lived within 12.5 km of Hospital 
Ampang (83.9%) (Table 1). 
With a participation rate (of those individuals who met inclusion/exclusion 
criteria and were asked to participate, those who agreed) of 80.2%, there were 
287 individuals who entered the source study (study entrants).  Four individuals 
refused to participate after they entered the source study and the medical staff 
did not draw blood serum samples for seven samples resulting in the 
participants’ inability to contribute to the study data.  With a retention rate (of 
those individuals who entered the study, those who contributed to the study data) 
of 96.2%, the final number of study participants for the source study was 276.  
Source study participants were more likely to be male (63.0%); Malay (61.6%); 
aged 15-24 years (38.1%); and lived within 12.5 km of Hospital Ampang (83.0%) 
(data not shown).  Source study participants were admitted to Hospital Ampang, 
on average, 4.08 ± 1.71 days after self-reported onset of illness and had a length 
of hospitalization of 4.26 ± 2.57 days.  Further descriptive statistics on the source 
study by blood profile, liver profile, kidney profile, and vital statistics profile are 
presented in Appendix B. 
Of the source study participants, 22 were not diagnosed with dengue.  
Non-dengue diagnosed individuals were more likely to be male (81.8%); Malay 
(68.2%); adult, aged 24-34 years (45.5%); and lived within 12.5 km of Hospital 
Ampang (86.4%) (data not shown).  Source study participants not diagnosed with 
dengue were admitted to Hospital Ampang, on average, 4.19 ± 3.12 days after 
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self-reported onset of illness and had a length of hospitalization of 4.47 ± 1.92 
days. 
Of the source study participants, 248 were diagnosed with dengue and 
above the age of 15 years.  Dengue diagnosed individuals were more likely to be 
male (63.0%); Malay (61.6%); aged 15-24 years (38.3%); and lived within 12.5 
km of Hospital Ampang (83.0%) (Table 1).  Source study participants diagnosed 
with dengue were admitted to Hospital Ampang, on average, 4.07 ± 1.58 days 
after self-reported onset of illness and had a length of hospitalization of 4.24 ± 
2.61 days.  
The study was a subset of the data from the source study by restricting 
the study population to only those participants who were laboratory confirmed 
with a dengue infection, and that had a recorded absolute monocyte value during 
the defervescence phase of illness.  The study population consisted of 197 
participants of which the majority were male (62.7%); Malay (64.0%); aged 25-34 
years (46.3%); and lived within 12.5km of Hospital Ampang (81.2%) (Table 1).  
Study participants were admitted to Hospital Ampang on average, 4.07 ± 1.55 
days after self-reported onset of illness, and had a length of hospitalization of 
4.54 ± 2.73 days. 
The chi-square test for independence was used to examine if the study 
population, source study participants (with a dengue diagnosis), and source 
study refusals contained the same proportion of observations by gender, race, 
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age, and distance between patient residence and Hospital Ampang.  No 
significant differences were detected among the populations at the 0.05 level of 
significance.   
Table 1. Demographics of Study Participants, Source Study Participants by 
Dengue Diagnosis, Source Study Non-Participants, and Source Population in 
Hospital Ampang, Selangor, Malaysia, 2010.  
  
 
Study 
Participants
 
  Source 
Study 
Participants* 
  
Source 
Study 
Refusals
#
 
 
  Source 
Population
^
 
 
 
 
      
 
 
N %  
  
N  %  
 
  N  %  
 
  
N  %    
Total  197 77.6    248 90.0     94 100     16367 100  
Gender                     
     Male  124 62.9   152 61.3   49 53.3   9503 58.1  
     Female  73 37.1   96 38.7   43 46.7   6864 41.9  
Race                     
     Malay  126 64.0   151 60.9   57 62   9272 56.7  
     Chinese  44 22.3   57 23.0   21 22.8   3678 22.5  
     Indian  13 6.6   17 6.9   9 9.8   2081 12.7  
     Other  14 7.1   23 9.3   5 5.4   1336 8.2  
Age (years)                    
     15-24  74 37.6   95 38.3   30 35.7   4495 33.4  
     25-34 69 35.0  85 34.3  25 29.8  4335 32.3 
     35-44  28 12.2  36 14.5  15 17.9  2399 17.9 
     >45  26 13.2  32 12.9  14 16.7  2213 16.5 
Distance
&
                     
     ≤ 12.5 160 81.2   203 81.9   73 83.9   -  -    
     > 12.5 37 18.8    45  18.2    14 16.1      -  -    
* Dengue clinical diagnosis only.  
#
 Difference to total reflect information refusal.  
^
 Hospital Ampang in-patient and out-patient dengue cases during 2010; 
Includes 2,925 children (<15 years); Total for Age excludes children. 
& 
Distance between patient residence and Hospital Ampang in kilometers. 
 
The source population was not included in chi-square analysis for gender 
and race as 17.9% of source population summary statistics obtained consisted of 
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children whose information could not be separated from those aged 15 years and 
older.  Chi-square tests for independence did not detect a significant difference 
between the source population and all other populations in Table 1 by age. 
The majority of participants within the study population had contracted a 
secondary dengue infection (79.2%) (Table 2).  The gender ratio (male: female) 
was 1.56:1.0 and 1.74:1.0 for secondary and primary dengue infections, 
respectively.  Among both primary and secondary dengue infection populations, 
the majority of participants were male, Malay, and lived within 12.5 km of 
Hospital Ampang.  The majority of individuals experiencing a primary dengue 
infection were aged 25-34 years, whereas those experiencing a secondary 
dengue infection were aged 15-24 years. 
Using chi-squared test for independence and fisher’s exact test were 
appropriate, there was no significant difference detected between infection status 
populations by gender, race, or distance between residence and Hospital 
Ampang. A significant difference was detected between primary and secondary 
infections among those aged 45 years and older. 
 Study participants stratified by dengue infection status were admitted to 
Hospital Ampang, on average, 4.17 ± 1.75 (primary) and 4.04 ± 1.49 (secondary) 
days after self-reported onset of illness and had an average length of 
hospitalization of 5.15 ± 3.93 (primary) and 4.39 ± 2.30 (secondary) days. 
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Table 2. Study Participants Demographics by Dengue Infection Status and 
Effusion Status in Hospital Ampang, Selangor, Malaysia 2010.    
 
 
Dengue Infection Status
 
 
Effusion Status
 
  
Total
 
 
 
 
 
Primary
 
 
Secondary
 
  
Absence
 
 
Presence
 
  
 
 
  
 N %   N %     N %   N %     N %   
Total 41 20.8  156 79.2   115 58.4  82 41.6   197 100   
Gender                   
     Male 25 61.0  99 63.5   77 67.0  47 57.3   124 62.9   
     Female 16 39.0  57 36.5   38 33.0  35 42.7   73 37.1   
Race                   
     Malay 24 58.5  102 65.4   75 65.2  51 62.2   126 64.0   
     Chinese 12 29.3  32 20.5   24 20.9  20 24.4   44 22.3   
     Indian 4 9.8  9 5.8   8 7.0  5 6.1   13 6.6   
     Other 1 2.4  13 8.3   8 7.0  6 7.3   14 7.11   
Age                   
     15-24 15 36.6  59 37.8   39 33.9  35 42.7   74 37.6   
     25-34 19 46.3  50 32.1   42 36.5  27 32.9   69 35.0   
     35-44 5 12.2  23 14.7   17 14.8  11 13.4   28 14.2  
      >45 2 4.9  24 15.4 ‡  17 14.8  9 11.0   26 13.2   
Distance
&
 
 
                 
 
     ≤ 12.5 33 80.5  127 81.4   95 82.6  65 79.3   160 81.2   
     > 12.5 8 19.5  29 18.6   20 17.4  17 20.7   37 18.8   
P-value: † <0.05; ‡ <0.01   
&
 Distance between patient residence and Hospital Ampang.   
 
Stratification of the study population found the majority of participants 
were free of hemorrhage/vascular leakage manifestations (57.3%) (Table 2).  
The gender ratio (male: female) was 2.03:1.0 and 1.34:1.0 for absence and 
presence of hemorrhage/vascular leakage, respectively.  Among both study 
categories of effusion status, the majority of participants were male, Malay, and 
lived within 12.5 km of Hospital Ampang.  Among those individuals with absence 
of effusion the majority were aged 25-34 years; whereas among those individuals 
with presence of effusion the majority were aged 15-24 years. 
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There was no significant difference detected between effusion status 
populations by gender, race, age, or distance between residence and Hospital 
Ampang.  Study participants stratified by effusion status were admitted to 
Hospital Ampang, on average, 4.04 ± 1.41 (absence) and 4.10 ± 1.72 (presence) 
days after self-reported onset of illness and had an average length of 
hospitalization of 4.67 ± 2.95 (absence) and 4.37 ± 2.39 (presence) days.  
 
Co-Morbidities 
Overall, co-morbidities were only observed in 7.6% of the study population 
(Table 3).  Hypertension was the most observed co-morbidity in the population 
(4.1%), followed by diabetes mellitus (3.1%).  One individual was found to have 
ischemic heart disease.  No chronic kidney disease or congestive heart failure 
was observed.   
Table 3. Study Participants Co-Morbidities by Dengue Infection Status and 
Effusion Status in Hospital Ampang, Selangor, Malaysia 2010. 
 
 
Infection Status   Effusion Status    
Total
 
  
Primary  Secondary   Absence  Presence     
N %  N %   N %  N %   N %  
Study Participants 41 20.8   156 79.2     115 58.4   82 41.6     197 100   
Diabetes mellitus 2 4.9  4 2.6    3 2.6   3 3.7    6 3.1   
Hypertension 2 4.9  6 3.9    4 3.5   4 4.9    8 4.1   
Other
*
 
 0 0.0 1 0.6   1 0.9   0 0.0   1 0.5   
Total Diseased 4 9.9   11 6.9     8 7.0   7 8.5     15 7.6   
* 
Chronic kidney disease, congestive heart failure and ischemic heart disease.   
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Manifestations 
 Among the study population, the most common manifestations were 
nausea/vomiting (86.3), arthraglia/myaglia (80.7%), and viral hepatitis (75.6%).  
The least common manifestations among the study population were rash 
(16.2%), hemorrhage (19.8%), and hepatosplenomegaly (27.4%).  Stratification 
by dengue infection status or effusion status did not find a significant difference 
by each manifestation. 
Table 4.  Study Participants Manifestations by Dengue Infection Status and 
Effusion Status in Hospital Ampang, Selangor, Malaysia 2010.   
 
  
Infection Status   Effusion Status    
Total 
  
Primary  Secondary   Absence  Presence     
N  %  N %   N  %  N %   N %   
Total Study Participants 41 20.8   156 79.2     115 58.4   82 41.6     197 100   
Abdominal Pain 29 70.7  101 64.7    73 63.5  57 69.5    130 66.0   
Arthraglia/Myaglia 31 75.6  128 82.1    91 79.1  68 82.9    159 80.7   
Diarrhea 21 52.2  89 55.8    68 59.1  42 51.2    110 55.8   
Hepatosplenomegaly 9 22.0  45 28.9    31 27.0  23 28.1    54 27.4   
Nausea/Vomiting 36 87.8  134 85.9    99 86.1  71 86.6    170 86.3   
Postural Giddiness 16 39.0  58 37.2    43 37.4  31 37.8    74 37.6   
Rash 8 19.5  24 15.4    20 17.4  12 14.6    32 16.2   
Retro-orbital/Headache 14 34.2  79 50.6    57 49.6  36 43.9    93 47.2   
Viral Hepatitis 29 70.7   120 76.9     88 76.5   61 74.4     149 75.6  
Hemorrhage 10 24.4  29 18.6   - -  - -   39 19.8  
Vascular Leakage 11 26.8  44 28.2   - -  - -   55 27.9  
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Clinical Laboratory Results 
The study population, on average, had an absolute monocyte count of 
1.22 ± 0.94 (x10^9/L), platelet count of 56.9 ± 38.4 (x10^9/L), and a hematocrit of 
41.6 ± 5.0 percent (Table 5).    Absolute monocyte count was observed to be 
higher in secondary (1.35 ± 0.98) infections compared to primary (0.65 ± 0.37); 
whereas, platelet count was observed to higher in primary (76.0 ± 38.7) 
infections compared to secondary (51.9 ± 36.5).  Stratification by dengue 
infection status found a significant difference in absolute monocyte count (p-
value= <0.0001) and platelet count (p-value= 0.0002).  No significant difference 
was detected when the study population was stratified by effusion status for 
absolute monocyte count, platelet count, or hematocrit.  An independent sample 
t-test was employed to determine significance. 
 
Table 5. Clinical Laboratory Manifestations of Study Participants by Dengue Infection 
Status and Effusion Status in Hospital Ampang, Selangor, Malaysia 2010.  
 
 
Infection Status
 
  Effusion Status
^
 
 
  
Total
 
 
 
 
 
Primary
 
 
Secondary
 
  
Absence
 
 
Presence
 
  
Avg. ± Std.
 
 
 
Avg. ± Std.
 
 
 
 
 
Avg. ± Std.
 
 
 
Avg. ± Std.
 
 
 
 
 
Avg. ± Std.
 
 
 
Absolute 
Monocyte Count* 0.66 ± 0.37  1.37 ± 0.98 ‡  1.18 ± 0.90  1.28 ± 0.99    1.22 ± 0.94 
 
 
Platelet Count * 
 
75.6 ± 39.1
 
 52.0 ± 36.8
 
‡ 
 
55.6 ± 38.0
 
 
58.8 ± 39.1
 
 
 
 
56.9 ± 38.4
 
 
 
Hematocrit (%)
 
41.1 ± 5.3
 
 
 
41.7 ± 4.9
 
 
 
 
 
42.1 ± 4.8
 
 
 
41.0 ± 5.1
 
 
 
 
 
41.6 ± 5.0
 
 
 
P-value: † <0.05; ‡ <0.01   
* x10^9/liter   
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Linear Regression Analysis 
A multivariable linear regression analysis was used to determine the 
association of venous absolute monocyte count with primary and secondary 
dengue infection.  A literature review provided the foundation for inclusion of the 
risk factors gender, race, and age.  A surrogate variable was assessed for 
inclusion in the model for the known risk factors of infecting viral serotype, 
socioeconomic status, and education.  The surrogate variable used was distance 
of participants’ residence from Hospital Ampang dichotomized by 12.5 km.  
To determine if the surrogate variable was a potential risk factor for the 
association stratification of the exposure and outcome by distance of participants’ 
residence from Hospital Ampang was completed.  The outcome (independent 
sample t-test, p-value = <0.001) and the exposure (chi-square, p-value=0.02) 
were both significantly associated with distance of participants’ residence from 
Hospital Ampang.  As a result, distance of participants’ residence from Hospital 
Ampang was considered a risk factor of the association and assessed for 
inclusion in the regression model. 
To assess the assumption that the data is normally distributed, graphical 
analysis was used to plot the regression model predicted values against the 
model residuals (Figure 32).  Residuals are a measure of variation within the 
dataset and are calculated by determining the difference between the observed 
and expected values.  A perfect fit of the model to the data would result in all 
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residuals being zero; however, this is almost never observed.  Under a 
hypothetical normal distribution, a plot of the model predicted values against 
model residuals will result in equal variance above and below zero.  Graphical 
analysis of the model predicted values against the model residuals of the dataset 
under the base model displays a distribution that approaches normality.  The 
determination that the normality is approximated suggests the correct use of the 
linear regression model for the analysis. 
 
Figure 32.  Scatter plot of residuals versus the predicted values of venous 
absolute monocyte levels based on linear regression model with age as 
categorical variable and without the distance variable.  
 
The regression coefficient (estimate), coefficient standard error, and p-
values are presented in Table 6 for the above regression model.  Regression 
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coefficients are estimates of the independent contribution of each independent 
variable to the prediction of the dependent variable, otherwise known as partial 
correlation.  Interpretation of the coefficients is first completed by observing the 
signs (plus/minus).  A positive coefficient delineates a positive relationship (as 
the independent variable increases, so does the dependent variable) of the 
independent variable with the dependent variable.  Whereas, a negative 
coefficient means the independent variable and dependent variable have a 
negative relationship (when the independent variable increases, the dependent 
variable decreases).  A coefficient of zero infers no relationship between the 
independent variable and dependent variable. 
  The value of the coefficient for each of the independent variables is a 
measure of the effect of that particular variable has on the dependent variable.  
In multivariable linear regression models, the coefficient is how much the 
dependent variable is expected to increase when the independent variable is 
increased by one, while holding all other independent variables constant. 
Under the base model, dengue infection status (p-value= <0.0001) was 
independently associated with venous absolute monocyte levels.  All other 
independent variables did not demonstrate a significant independent association 
with venous absolute monocyte levels. 
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Table 6.  Estimates from Linear Regression Model of 
Venous Absolute Monocyte Levels during Defervescence 
controlling for Dengue Infection Status, Age (categorical), 
Gender, and Race. 
Independent 
Variable Estimate 
Standard 
Error p-value 
  
Intercept -0.19 0.33 0.57   
Infection Status 0.72 0.16 <0.0001   
Age -0.08 0.06 0.22   
Gender 0.25 0.13 0.06   
Race 0.08 0.07 0.29   
 
The coefficient of determination (R-squared) is a measure of the how 
much of the data variance is explained by the linear model, or in other words, 
how well the model fits the data.  The coefficient of determination for the base 
model is 0.127, meaning the model explains 12.7% of the variability in the 
dataset. 
The distance of the participants’ residence from Hospital Ampang was 
added to the above model to assess any influence on the association of interest.  
Graphical analysis using a plot of model predicted values against residuals 
determined that under the model, the distribution approached normality 
suggesting correct use of linear regression for the analysis (Figure 33).  
A negative distance coefficient (β= -0.40 ± 0.16, p-value= 0.01) infers that 
greater distance from Hospital Ampang is significantly associated with lower 
monocyte levels (Table 7).  Infection status has a positive coefficient (β= 0.72 ± 
0.15, p-value= <0.0001), meaning that a secondary infection is significantly 
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associated with increased monocyte count.  A positive gender coefficient (β= 
0.26 ± 0.13, p-value= 0.05) infers that male gender is significantly associated 
with higher monocyte count.  Age (β= -0.09 ± -0.06, p-value= 0.14) and race (β= 
0.05 ± 0.07, p-value= 0.5) did not have a significant effect on the dependent 
variable. 
The addition of distance from the participants’ residence to Hospital 
Ampang improved the linear fit of the model to the data, explaining 15% of the 
dataset variability (r-squared = 0.15).   
 
 
Figure 33. Scatter plot of residuals versus the predicted values of venous 
absolute monocyte levels based on linear regression model with age as 
categorical variable and including distance variable.  
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Table 7.  Estimates from Linear Regression Model of 
Venous Absolute Monocyte Levels during Defervescence 
controlling for Dengue Infection Status, Age (categorical), 
Gender, Race, and Distance between Patient Residence 
and Hospital Ampang. 
Independent 
Variable Estimate 
Standard 
Error P-value 
  
Intercept -0.05 0.33 0.89   
Infection Status 0.72 0.15 <0.0001   
Age -0.09 -0.06 0.14   
Gender 0.26 0.13 0.05   
Race 0.05 0.07 0.49   
Distance -0.40 0.16 0.01   
 
 To determine if the age variable cut-points were masking or creating a true 
association, the model was re-assessed with the age as a continuous variable.  A 
model not including the distance variable was initially fit.  Graphical analysis 
using a plot of model predicted values against residuals determined that under 
the model, the distribution approached normality suggesting correct use of linear 
regression for the analysis (Figure 34).   
Infection status has a positive coefficient (β= 0.72 ± 0.16, p-value= 
<0.0001), meaning that a secondary infection is significantly associated with 
increased monocyte count (Table 8).  Gender (β= 0.25 ± 0.13, p-value= 0.06), 
age (β= -0.09 ± -0.06, p-value= 0.14), and race (β= 0.05 ± 0.07, p-value= 0.5) did 
not have a significant effect on the dependent variable. 
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Figure 34. Scatter plot of residuals versus the predicted values of venous 
absolute monocyte levels based on linear regression model with age as 
continuous variable and without distance variable. 
 
Table 8.  Estimates from Linear Regression Model of 
Venous Absolute Monocyte Levels during Defervescence 
controlling for Dengue Infection Status, Age (continuous), 
Gender, and Race. 
Independent 
Variable Estimate 
Standard 
Error p-value 
  
Intercept -0.07 0.34 0.84   
Infection Status 0.71 0.15 <0.0001   
Age -0.01 0.01 0.08   
Gender 0.25 0.13 0.06   
Race 0.08 0.07 0.24   
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Assessing the age as a continuous variable did have an impact on the 
model in that gender became non-significant and the r-square value was 0.13. 
The distance of the participants’ residence from Hospital Ampang was 
added to the above model to assess the variable’s influence on the association of 
interest.  Graphical analysis using a plot of model predicted values against 
residuals determined that under the model, the distribution approached normality 
suggesting correct use of linear regression for the analysis (Figure 35). 
 
 
Figure 35.  Scatter plot of residuals versus the predicted values of venous 
absolute monocyte levels based on linear regression model with age as 
continuous variable and including distance variable.  
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A negative distance coefficient (β= -0.40 ± 0.06, p-value= 0.02) infers that 
greater distance from Hospital Ampang is significantly associated with lower 
monocyte levels (Table 7).  Infection status has a positive coefficient (β= 0.71 ± 
0.15, p-value= <0.0001), meaning that a secondary infection is significantly 
associated with increased monocyte count.  A positive gender coefficient (β= 
0.26 ± 0.13, p-value= 0.04) infers that male gender is significantly associated 
with higher monocyte count.  Age (β= -0.01 ± -0.01, p-value= 0.06) and race (β= 
0.06 ± 0.07, p-value= 0.4) did not have a significant effect on the dependent 
variable. 
The addition of distance from the participants’ residence to Hospital 
Ampang improved the linear fit of the model to the data, explaining 16% of the 
dataset variability (r-squared = 0.16).   
 
Table 9.  Estimates from Linear Regression Model of 
Venous Absolute Monocyte Levels during Defervescence 
controlling for Dengue Infection Status, Age (continuous), 
Gender, Race, and Distance between Patient Residence 
and Hospital Ampang. 
Independent 
Variable Estimate 
Standard 
Error P-value 
  
Intercept 0.05 0.34 0.87   
Infection Status 0.71 0.15 <0.0001   
Age -0.01 0.01 0.06   
Gender 0.26 0.13 0.04   
Race 0.06 0.07 0.41   
Distance -0.37 0.16 0.02   
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 Overall, including the distance surrogate variable and using age as a 
continuous variable improved the linear fit of the model.  For this investigation, 
estimates from the model with age as a continuous variable and including 
distance in the model will be accepted as the final model.  However, future 
investigations should strive to capture infecting viral serotype, socioeconomic 
status, and education data to include in the model in place of the surrogate 
variable. 
 
Logistic Regression Analysis 
 A multivariable logistic regression model was used to determine the 
association between venous absolute monocyte levels and effusion status 
(presence or absence of hemorrhage/vascular leakage).  A literature review 
provided the foundation for inclusion of gender, race, age, and dengue infection 
status (primary or secondary) in the initial model.  Age was initially assessed as a 
categorical variable.  Assessment of distance of participants’ residence from 
Hospital Ampang reveled an association with the exposure (independent sample 
t-test, p-value = <0.001); however, no association was observed with the 
outcome (chi-square, p-value= 0.35).  While the criteria to be a confounder for 
the association was not met, distance of participants’ residence from Hospital 
Ampang was assessed in the analysis due to the need to control for other known 
risk factors (infecting viral serotype, socioeconomic status, and education).   
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Unlike linear regression models, logistic regression modeling does not 
make assumptions about the distribution of the independent variables; however, 
testing the fit of the model is important to avoid spurious results.  To determine if 
the fit of the base model was adequate, graphical analysis was used plotting 
model Pearson residuals against estimated probability (Figure 36).  If a model is 
adequately fit, an approximately horizontal line will connect the end points in the 
plot and have an intercept of zero.  As a deviation from these criteria was 
observed in the base model graphical analysis, this suggests the model is 
inadequate to predict the outcome. 
 
Figure 36. Scatter plot of Pearson residuals versus the predicted values of 
venous absolute monocyte levels based on logistic regression model with age as 
categorical variable.  
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All independent variables under investigation did not display an 
independent relationship with the dependent variable (absence and presence of 
hemorrhage/vascular leakage) (Table 10).   
  The Hosmer-Lemshow test for goodness-of-fit is a chi-square statistic 
testing whether or not the predicted model significantly differs from the observed 
data; the desired outcome of the test is non-significance.  The Hosmer-Lemshow 
test for goodness-of-fit for the base model is non-significant (χ2= 0.26) meaning 
that model accurately models the observed data.  
 
Table 10.  Estimates from Logistic Regression of Effusion Status Controlling for Venous 
Absolute Monocyte Count, Age (categorical), Gender, Race, and Dengue Infection 
Status. 
Independent 
Variable Reference 
 
Estimate 
 P-value   
  
Standard 
Error    
Intercept   -0.53 0.37  0.15  
Monocyte   0.17 0.17  0.33  
Age 15-24 >45 -0.50 0.49  0.31  
  35-44 -0.41 0.46  0.38  
  25-34 -0.39 0.35  0.26  
Gender Male  0.47 0.31  0.13  
Race Malay Other 0.13 0.59  0.82  
Race  Indian 0.05 0.62  0.93  
Race  Chinese 0.16 0.37  0.67  
Infection Status Secondary   0.08 0.40  0.83  
Hosmer and Lemeshow Goodness of fit = χ2 = 0.26 
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To determine if distance of participants’ residence from Hospital Ampang 
affects the relationship of interest, the variable was added to the above model.  
Graphical analysis of the logistic regression model plotting Pearson residuals 
against estimated probability determined that the model was inadequate to 
predict the outcome (Figure 37).  All independent variables under investigation 
did not display an independent relationship with the dependent variable (Table 
11).  The Hosmer-Lemshow test for goodness-of-fit for the base model is non-
significant (χ2= 0.07) meaning that model accurately models the observed data. 
 
 
Figure 37.  Scatter plot of Pearson residuals versus the predicted values of 
venous absolute monocyte levels based on logistic regression model with age as 
categorical variable and including distance variable.  
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Table 11.  Estimates from Logistic Regression of Effusion Status Controlling for Venous 
Absolute Monocyte Count, Age (categorical), Gender, Race, and Dengue Infection 
Status. 
Independent 
Variable Reference 
 
Estimate 
 P-value   
  
Standard 
Error    
Intercept   -0.65 0.41  0.11  
Monocyte   0.19 0.18  0.28  
Age 15-24 >45 -0.47 0.49  0.34  
  35-44 -0.39 0.46  0.40  
  25-34 -0.36 0.35  0.31  
Gender Male  0.48 0.31  0.13  
Race Malay Other 0.59 0.59  0.79  
Race  Indian 0.62 0.62  0.87  
Race  Chinese 0.37 0.37  0.58  
Infection Status Secondary  0.09 0.40  0.82  
Distance ≤12.5km    0.28 0.39  0.48  
Hosmer and Lemeshow Goodness of fit = χ2 = 0.07 
 
To determine if the age variable cut-points were masking or creating a 
spurious association, the model was re-assessed with the age as a continuous 
variable.  A model without the distance variable was initially assessed.  Graphical 
analysis of the logistic regression model plotting Pearson residuals against 
estimated probability determined that the model was inadequate to predict the 
outcome (Figure 38).  All independent variables under investigation did not 
display an independent relationship with the dependent variable (Table 12).  The 
Hosmer-Lemshow test for goodness-of-fit for the base model is non-significant 
(χ2= 0.64) meaning that model accurately models the observed data. 
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Figure 38.  Scatter plot of Pearson residuals versus the predicted values of 
venous absolute monocyte levels based on logistic regression model with age as 
continuous variable and without the distance variable.  
 
Table 12.  Estimates from Logistic Regression of Effusion Status Controlling for Venous 
Absolute Monocyte Count, Age (continuous), Gender, Race, and Dengue Infection 
Status. 
Independent 
Variable Reference 
 
Estimate 
 P-value   
  
Standard 
Error    
Intercept   -0.06 0.53  0.91  
Monocyte   0.11 0.17  0.52   
Age   -0.02 0.01  0.13   
Gender Male  0.48 0.31  0.12   
Race Malay Other 0.10 0.58  0.87   
Race  Indian 0.08 0.62  0.90   
Race  Chinese 0.18 0.36  0.62   
Infection Status Secondary   0.03 0.38  0.95   
Hosmer and Lemeshow Goodness of fit = χ2 = 0.64  
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To determine if distance of participants’ residence from Hospital Ampang 
affects the relationship of interest, the variable was added to the above model.  
Graphical analysis of the logistic regression model plotting Pearson residuals 
against estimated probability determined that the model was inadequate to 
predict the outcome (Figure 39).  All independent variables under investigation 
did not display an independent relationship with the dependent variable (Table 
11).  The Hosmer-Lemshow test for goodness-of-fit for the model is non-
significant (χ2= 0.59) meaning that model accurately models the observed data. 
 
 
Figure 39.  Scatter plot of Pearson residuals versus the predicted values of 
venous absolute monocyte levels based on logistic regression model with age as 
continuous variable and including distance variable.  
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Table 13.  Estimates from Logistic Regression of Effusion Status Controlling for Venous 
Absolute Monocyte Count, Age (continuous), Gender, Race, Dengue Infection Status, 
and Distance between Patient Residence and Hospital Ampang. 
Independent 
Variable 
Reference 
 
Estimate 
 
P-value 
  
  
Standard 
Error    
Intercept   -0.17 0.56  0.76  
Monocyte   0.13 0.17  0.46   
Age   -0.02 0.01  0.14   
Gender Male  0.49 0.31  0.12   
Race Malay Other 0.12 0.58  0.84   
Race  Indian 0.11 0.62  0.85   
Race  Chinese 0.22 0.36  0.54   
Infection Status Secondary  0.04 0.38  0.92   
Distance ≤12.5km    0.26 0.39  0.50   
Hosmer and Lemeshow Goodness of fit = χ2 = 0.59 
 
Overall, the inability of the model building process to produce significant 
findings speaks to the complex biological nature of dengue disease.  No 
acceptable final model was produced in this research for the secondary objective 
as all models were found inadequate to predict the outcome.  As researchers 
continue to unravel the complex dengue disease biological pathway future 
attempts to model disease outcome by including new variables might have better 
success. 
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DISCUSSION 
 Prior to the discussion of the study results, an assertion of the internal 
validity of the study is necessary.  Internal validity of a study is based around the 
premise of a high degree of precision in the association under investigation 
(Oleckno, 2002).  If a study does not maintain internal validity, external validity 
cannot be achieved.  In epidemiologic studies, three factors can affect internal 
validity: chance, bias, and confounding. 
Chance, also known as random error, can be separated into two primary 
sources: measurement and sampling error.  Measurement error occurs during 
the measurement of individual values for study analysis and is avoided through 
diligent study planning.  The two sources of data for the study were clinical data 
from Hospital Ampang and laboratory data from the Medical Microbiology 
Laboratory of Professor Dr. Shamala Devi.  All clinical data from Hospital 
Ampang was collected from the hospital electronic database.  Only trained 
medical professionals have access and can enter values into the hospital 
electronic database, providing a high degree of certainty about the 
measurements.  Both laboratories of Hospital Ampang and Professor Dr. 
Shamala Devi’s employed the use of standardized controls.  These controls 
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allowed the trained laboratory personnel to determine if the assay was working 
properly, reducing measurement error. 
 Sampling error is the “variation that can result when using sampling 
statistics to estimate population parameters” (Oleckno, 2002, p.152).  Sampling 
error is reduced by having a large enough study population to detect the 
association of interest above any random variation.  While one may haphazardly 
overestimate the study population needed, an efficient use of both time and 
limited financial resources is achieved through a priori sample size calculation.   
 As the study was subset within another study, an a priori sample size 
calculation was not feasible.  A retrospective power calculation conducted based 
on literature estimates ensures that if an association did exist, it could be detect 
above variations within sampling.  The retrospective power calculation 
determined that the study had a power of 0.87, meaning that if an association 
exists, it will be detected 87% of the time.  With studies typically aiming for a 
power of 0.80 (Oleckno, 2002), the study exceeds standards set for study power. 
 Bias is “nonrandom error in the design, conduct, or analysis” of an 
epidemiological study (Oleckno, 2002, p.125) and can be classified as selection 
or measurement.  As bias cannot be addressed after the data has been 
collected, careful study design planning is necessary to avoid spurious results.   
Selection bias is the nonrandom error by which study participants are 
selected or retained (Oleckno, 2002).  To avoid selection bias, collection of 
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subjects must be conducted so that the study population represents the target 
population, subject loses are kept to a minimum, and comparison groups within 
the study are similar except for the variables being investigated (Oleckno, 2002). 
 Data on the target population of the study were not available; however, 
summary statistics on the approximate (in- and out-patient) source population 
were obtained for the 2010 calendar year.  No significant difference was detected 
between the approximate source population, source study population, and study 
population by age, gender, and race. 
  Successful participant recruitment and reduction of loss to follow-up is 
critical to minimizing bias within the study.  With participation rate slightly above 
the standard cut-off of 20% (Galea & Tracy, 2007) and retention rate of 96.2%, 
the source study design was successfully executed, reducing a major source of 
bias.  To confirm this statement, chi-squared tests for independence were 
conducted between the source study population and the population of individuals 
who refused to participate by gender, race, age, and distance between residence 
and Hospital Ampang; no significant difference was observed.  The finding of no 
difference between populations infers that recruitment bias had negligible impact 
on the study, meaning patients decided to participate in the study in a non-
systematic way. 
 Ideally, a study will recruit a population which does not significantly differ 
by risk factors so that the association of interest can be correctly assessed.  
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When the study population was stratified by the exposure of interest, primary and 
secondary dengue infection, there was no significant difference detected by 
gender, race, or distance between residence and Hospital Ampang.  However, a 
significant difference was detected between primary and secondary infections 
among those aged 45 years and older.  This finding is understandable in that as 
a person ages they will have been at increased risk for multiple dengue infections 
compared to an individual of younger age while living in a dengue endemic 
environment.  Also, as an individual ages their immune system is less capable of 
handling disease stress necessitating more medical intervention compared to 
young populations.  The use of multivariable analysis will allow for consideration 
of this difference to correctly assess the association of interest.  The above 
findings provide assurance that negligible amounts of selection bias were 
introduced into the study as far as can be detected. 
 Measurement bias is the “nonrandom error in classifying subjects with 
regard to exposure or outcome status” that may result from inaccurate 
measurements (Oleckno, 2002, p.144).  As both the exposure and outcome of 
interest were determined through the use of standardized laboratory assays, both 
of which employed controls, the risk for differential misclassification is minimal.  If 
the assay standardized controls were not met, enough of the venous serum 
sample remained to repeat the assay several times until control verification was 
met. 
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Confounding is nonrandom error by the distortion of the association of 
interest by an incidental factor.  A confounder, termed risk factor in epidemiology, 
must be 1) associated with the exposure; 2) an independent risk factor for the 
outcome; 3) must not be an intermediate variable on the causal pathway; and 4) 
must be present in different degrees between study groups (Oleckno, 2002).  
Confounding can be controlled during the planning phase of the study through 
restriction, matching, and/or randomization.  Multivariable analysis during the 
analysis phase of the study can control for confounding effects only if they were 
measured during the study (Oleckno, 2002). 
Potential risk factors of the primary relationship of interest include gender, 
race, and age, which were determined through the literature review.  Knowledge 
of the study location suggested distance between patient residence and Hospital 
Ampang might be a potential risk factor.  Stratification of the exposure and 
outcome by the risk factor allowed for associations to be assessed.  As there was 
an association of the risk factor with the exposure and outcome, distance 
between the participants residence with Hospital Ampang was classified as a 
potential risk factor for the primary relationship of interest.  All risk factors were 
taken into account in the multivariable analysis. 
Having successfully addressed, as far as can be determined, the potential 
effects of chance, bias, and confounding on the study, the study internal validity 
has been maintained.  The following presents a discussion of the study 
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population disease duration, co-morbidities, manifestations, and clinical 
laboratory results with comparison to findings from the literature.   
 The duration of time from onset of illness to hospital admission and length 
of hospitalization was similar across the source study and study populations.  
From the literature, a 2008 cross-sectional study among 236 dengue patients 
from two hospitals in Federal Territory of Kuala Lumpur and State of Selangor, 
Malaysia, found the average length of time from onset of illness to admission to 
be 4.9 days (Ang, Rohani, & Look, 2010).  A separate prospective cohort study of 
77 dengue hospitalized adults in Kuala Lumpur, Malaysia, from December 2004 
to December 2005, observed the average length of hospitalization to be 2.4 ± 5.3 
days (Lum et al., 2008).  While the study population and literature findings had 
similar durations between onset of illness and admission, the length of 
hospitalization was longer in the study population compared to the literature.  The 
dissimilar findings might be due to differences in severity of dengue disease 
within the populations and/or standard of care between hospitals.  There are no 
exact criteria for patient discharge and is highly dependent on overall patient 
health.  Further research would be need to elucidate why discharge time periods 
differ.  
The low prevalence of co-morbidities (7.6%) within the study population is 
potentially reflective of the relative young overall age of study participants (31.2 ± 
11.7 years).  Comparable proportions of co-morbidities in the study population, 
when stratified by dengue infection and effusion status, indicates a comparatively 
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homogenous study population with respect to diagnosed chronic diseases.  From 
the literature, a study of 120 dengue patients aged 15 to 73 years in Singapore 
from 2000-2005 indicated a similar prevalence of co-morbidities within the study 
population (10%) (Lye, Chan, Lee, & Leo, 2008).  The low prevalence of co-
morbidities in both the study population and findings from literature, allow for the 
observation that dengue is affecting a mostly healthy population and inference 
that co-morbidities might not have a significant role in the development of severe 
dengue complications.   While not observed in the study population, co-
morbidities that have been associated with adverse dengue outcomes include 
obesity, diabetes mellitus, hypertension and chronic heart diseases (Farrar et al., 
2007). 
Dengue disease commonly manifests with rash, nausea/vomiting, and 
arthraglia/myaglia (WHO/TDR, 2009).  Study participants were observed in high 
proportions to have nausea/vomiting and arthraglia/myaglia; however, rash was 
the least observed manifestation.  The low presence of rash within the study 
population may be due to the overall late admission (~day 4 of illness) to Hospital 
Ampang by which time rash may have resolved.  Further dissimilarities between 
the study population and literature from Kuala Lumpur (Lum et al., 2008), include 
the low proportion of study participants manifesting with pleural effusion, 
bleeding, dizziness, and abdominal pain.  A review of dengue literature outside 
Malaysia has found populations with similar proportional manifestations to that of 
the study population (Thomas et al., 2010; Kumar et al., 2010).  The differences 
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and similarities in manifestations among the study population compared to 
findings in the literature, illustrates the high degree of variation in dengue disease 
clinical manifestations.  Clinicians must be aware of the wide-range of 
manifestations that can be observed during dengue disease.  Using the new 
dengue classification criteria proposed by WHO in 2009, all study participants 
were capable of being classified.  This finding supports the use of new 
classification criteria; however, future studies are needed to ensure continued 
flexibility of the classification criteria, especially as populations in dengue 
endemic counties begin to age. 
Analysis of each manifestation by both primary & secondary dengue 
infection and absence & presence of hemorrhage/vascular leakage did not 
observe a significant difference.  These findings are not unexpected as the study 
population is comprised of patients who were admitted to Hospital Ampang for 
severe dengue complications.  What is striking is the similarity between primary 
and secondary for presence of hemorrhage and vascular leakage.  Commonly, 
hemorrhage and vascular leakage are thought of as complications only observed 
in heterotypic secondary dengue infections.  The findings are a reminder that 
severe dengue complications are not just manifestations that occur in secondary 
heterotypic dengue infections.  However, the similar observed proportions of 
hemorrhage and vascular leakage in the study population are not representative 
of those experienced in the general population, as the study was designed to 
focus on those individuals who develop severe complications.  Among the 
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general population, the majority of primary dengue infections will not develop 
severe complications, whereas those experiencing a secondary infection will be 
at an increased risk for severe complications. 
The wide range of manifestations in dengue disease highlights the need 
for a highly flexible dengue diagnostic scheme to clinically classify dengue 
patients.  A recent review in 18 countries shows that the 2009 dengue diagnostic 
scheme could classify all but 1.7% of study participants; whereas the 1997 
dengue diagnostic classification criteria could not classify 13.7% of study 
participants (Barniol et al., 2011).  There is still a need for further research and 
possible re-structuring of the dengue classification criteria to ensure that all 
individuals who are laboratory diagnosed with dengue can be readily diagnosed. 
 A decreasing platelet count and concurrent increasing hematocrit, are 
early clinical warning signs of potentially severe dengue complications 
(WHO/TDR, 2009).  The study population mean hematocrit remained within the 
normal range of 36.0-48.0%, most likely as a result of the immediate and 
attentive rehydration therapy administered by the Hospital Ampang medical staff.  
As more medical facilities increase their rehydration therapy capabilities, 
hematocrit may not remain a commonly observed indicator of potential severe 
dengue complications.  Platelet count of the study population was well below the 
150-400 (x10^9/L) platelet count normal range.  As the majority of study patients 
were even below the 100 (x10^9) platelet count threshold, this gives more 
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evidence for the appropriate lowering of the platelet count dengue criterion 
(Rigau-Perez, 2006). 
The study population average absolute monocyte count was above the 
normal range of 0.1 - 0.8 (x10^9/L).  However, when the study population was 
stratified by infection status, the primary infection population average absolute 
monocyte count reduced back into the normal range, whereas the secondary 
infection population remained above the normal range.  The difference between 
the primary and secondary infection status absolute monocyte counts was found 
to be significant.  The literature review did not find a study which assessed a 
similar research relationship.  To fully analyze this association, potential risk 
factors of the association were assessed with multivariable linear regression 
analysis. 
An initial linear regression model was constructed with dependent variable 
absolute monocyte count and independent variables infection status (primary or 
secondary), race, age, and gender.  Assumptions of the methodology were 
graphically assessed and fit of the model determined.  Distance of the 
participants’ residence from Hospital Ampang was added to the initial model to 
determine if the variable influenced the association.  In the initial model, the age 
variable was assessed as categorical variable with cut-points used from the 
literature; however, it was necessary to determine if categorizing the age variable 
was masking or creating artificial findings.  The age variable was run in the initial 
model as a continuous variable.  The distance variable was again added to the 
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initial model, with a continuous age variable, for reassessment of the influence on 
the association. Comparing the assumptions of the methodology and fit of the 
model between the four models, it was determined that the final model would be 
the model using a continuous age variable and including the distance variable as 
the final model (Table 9). 
The final model finding that secondary dengue infection significantly 
increases absolute monocyte during defervescence is presumably a novel 
contribution to the dengue literature.  Specifically, a secondary dengue infection 
increases the venous absolute monocyte count by 0.71±0.15 (x10^9/L) 
compared to a primary dengue infection, while holding all other independent risk 
factors constant.  Among all independent variables considered in the model, 
infection status had the largest effect size and was most significant for the 
association.   
As the normal range of venous absolute monocyte count in adults is 0.1 to 
0.8 (x10^9/L), the average value observed in those with primary dengue infection 
is within these normal bounds; however, secondary dengue infections have an 
average abnormal elevated count.  The severe dengue biological pathway 
hypotheses of antibody-independent enhancement and memory T-cell 
reactivation, revolve around the central idea that a previous dengue infection 
alters the immune response.  As a result of the immune system alteration, during 
a secondary heterotypic dengue infection, severe dengue complications occur.  
The study does not validate either severe dengue hypothesis, but does provide 
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further evidence that monocytes are more abundant in a secondary heterotypic 
dengue immune response compared to a primary dengue immune response.  
Increased monocyte count is commonly observed in inflammatory disorders 
(Moore & Tabas, 2011), which supports the biological pathway of severe dengue 
complications potentially being caused by proinflammatory cytokines released by 
monocytes.  This information will prove valuable in formulating further study 
hypotheses that may eventually lead to a comprehensive understanding of the 
severe dengue biological pathway. 
 Furthermore, the study presents evidence to that while race and age do 
not significantly influence the relationship better absolute monocyte count and 
primary & secondary dengue infection, gender and distance of residence from 
Hospital Ampang do modify the association.   
The literature has found an increased risk of severe dengue in children 
compared to adults and suggests stress from the dengue disease on 
undeveloped capillaries to be a potential cause of the finding.  The study has 
observed a -0.01 ± 0.01 (x10^9/L) (p-value= 0.06) decrease in absolute 
monocyte count for each year a person ages, holding all other variables 
constant.  This finding, while non-significant, still remains important as it suggests 
another potential influence on the association for increased risk in younger aged 
individuals.  The immune system, while typically vibrant and strong in youth, 
weakens with age.  A youthful immune system may lead to an unnecessarily 
strong immune response causing damage to the capillaries.   
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The finding also raises the question about what happens in old age when 
the immune system has weakened so much that it cannot handle the dengue 
infection.  Few studies have investigated the effects of dengue on the elderly. 
More studies should be conducted on the elderly demographic as dengue is 
currently spreading to non-endemic regions where the vast majority of the elderly 
population has not experienced a dengue infection before. 
Literature has suggested that genetics (i.e. HLA types) may influence the 
outcome of a dengue infection.  As genetic analysis was not available for 
inclusion in the study, race was used as a surrogate variable. The analysis 
determined that race had negligible effect on the primary association of interest 
(0.06 ± 0.07 x10^9/L, p-value = 0.41), suggesting that race is an imperfect 
surrogate variable for genetic variation within the study population.  Research is 
needed to identify and confirm genes that increase the risk for severe dengue 
complications for proper consideration of the potential risk factor. 
Blood profiles have differing normal ranges for males and females on 
many components (e.g. hematocrit & hemoglobin); however, no such difference 
in normal range by gender exists for absolute monocyte count.  Among the study 
population, an individual of male gender increases the venous absolute 
monocyte count by 0.26 ± 0.13 (x10^9/L) (p-value=0.04) compared to an 
individual of female gender, while holding all other independent risk factors 
constant.  The significant influence of male gender on absolute monocyte count, 
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suggests physiological and/or genetic differences may play a role in the immune 
response. 
From knowledge of the study site, a concern developed that since some 
patients were being transferred to Hospital Ampang, they would differ from those 
individuals who go to Hospital Ampang because it was the closest location for 
medical treatment.  All four dengue serotypes are currently co-circulating within 
Malaysia. Individuals who were being transferred to Hospital Ampang may have 
contracted a different serotype or strain of dengue virus, which may cause a 
different immunological response than the predominant virus being circulated 
near Hospital Ampang.  As dengue viremia typically drops below detectable 
levels by Day 4 of symptomatic illness, and study participants were admitted on 
average to Hospital Ampang on Day 4.07 ± 1.55 of symptomatic illness, most 
study participants infecting dengue serotype could not be determined.  Only 17 of 
197 study participant’s dengue infecting serotype were determined through PCR 
analysis. 
Education and socioeconomic status are risk factors for increased 
incidence of dengue infection.  Individuals with higher education levels show 
protection against dengue infection for several potential reasons.  First, they are 
more likely to have been taught the dangers of dengue and how to prevent 
infection.  Secondly, individuals with higher education tend to earn more which 
allows them to move to a residence that may provide better protection from the 
dengue vectors.  Lastly, with increased socioeconomic status a family can afford 
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to take preventative steps to reduce vector breeding sites and can afford 
privatized medical care that may have better individualized care. 
As information on the above factors was not available or incomplete for 
the entire study population, the average distance (12.5 km) between Hospital 
Ampang and other public hospitals was used as a generalized surrogate 
variable.  This cut-point was arrived at by averaging the distance between 
Hospital Ampang and the five nearest public hospitals.  This cut-point provides a 
generalized boundary by which to identify those individuals who travel a further 
distance to receive care at Hospital Ampang, and those individuals who are 
travelling to the nearest public hospital. 
Among the study population, an individual with a residence of greater than 
12.5 km from Hospital Ampang is found to decrease the venous absolute 
monocyte count 0.37 ± 0.16 (x10^9/L) compared to an individual with a residence 
equal or less than 12.5 km from Hospital Ampang, while holding all other 
independent risk factors constant. The significant finding (p-value= 0.02) 
suggests that the study population differed on one of the above mentioned 
factors.  Future studies should include these three risk factors to better consider 
confounding effects of the relationship of interest. 
The analysis of the relationship between absolute monocyte count and 
primary & secondary dengue infection status considering the effects of 
independent risk factors has answered the second primary aim.  However, after 
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reviewing the results of the study, more questions have been raised.  
Hypothetically, if the study results had observed an elevated absolute monocyte 
count both in primary and secondary dengue infections, one may hypothesize 
that the elevated monocyte levels cause an increased release of proinflammatory 
cytokines.  The elevated levels of cytokines could then cause the study 
participant’s severe dengue manifestations.  While all study participants had 
severe dengue complications, the absolute monocyte count was significantly 
increased in secondary dengue infections compared to primary infections.  The 
foremost question that comes out of this finding is what is the biological pathway 
behind primary dengue infection development of severe dengue complications?  
As dengue virus can infect monocytes, and monocytes have been shown to 
release proinflammatory cytokines, normal levels of monocytes in primary 
dengue infections does not sequentially lead to severe complication development 
with current dengue knowledge.  So, are there multiple biological pathways by 
which severe dengue manifests? Even with a lower number of monocytes, do 
severe cases of dengue release similar levels of cytokines? Do monocytes in 
primary and secondary dengue infection cases release the same type of 
cytokines?  These are the questions which researchers may be able to 
immediately answer to further clarify the severe dengue biological pathway. 
 To investigate the secondary aim of the study, logistic regression analysis 
was used to investigate the relationship of presence and absence of 
hemorrhage/vascular leakage with absolute monocyte count considering the 
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potential confounding effects of independent risk factors.  The analysis included 
assessing the distance of study participant’s residence from Hospital Ampang 
and the age variable as both categorical and continuous.  Assumptions of the 
methodology were graphically assessed and fit of the model determined.   
 The logistic regression analysis did not produce an acceptable model to 
explain the observed relationship in the data and no significant or meaningful 
non-significant associations were established.  While disappointing, the outcome 
is not entirely unexpected with the variation in the literature findings and complex 
nature of the dengue immune response.  Future studies need to employ clear 
hypotheses that pick apart the biological pathway with well designed studies.  
After the a comprehensive severe dengue biological pathway has been 
hypothesized, a large study that has ample power to detect the association of 
interest maybe employed in a similar manner as the above analysis to determine 
the effect of each independent risk factor. 
 
Limitations 
 The primary objective of the study was to assess the relationship of 
absolute monocyte count with primary and secondary dengue infection status.  
The study findings have restricted inference due to several limitations.   
 The literature review did not find another published article examining the 
study’s hypothesis, potentially making this a novel investigation. As the study 
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was conducted in a single population in Malaysia, further research is necessary 
to assess applicability of the study findings to other populations within and 
outside of Malaysia.  
 Dengue infection is unpredictable and has a wide range of clinical 
manifestations, from asymptomatic to life threatening complications.  The study 
targeted individuals aged 15 years and above who had symptoms severe enough 
to require hospitalization. Therefore, study findings can only be inferred to this 
population as it does not consider the population of individuals who develop mild 
or asymptomatic dengue disease or are aged less than 15 years. 
 The Malaysian healthcare system is two tiered: public and private. 
Conducting the study in a public hospital necessitates special consideration 
when determining to which populations the study findings can be inferred.  Cost 
of care between public and private hospitals will undoubtedly dichotomize 
populations served.  Also, differences in standard of care or medical capabilities 
in equipment or personnel may affect disease outcome.   
There are opposing observations on whether or not SES and education 
are risk factors for dengue incidence, which suggests published results may be 
population dependent (Waterman et al., 1985; Spiegel et al. 2007; Da Gloria 
Teixeira et al., 2002).  Furthermore, nutritional status, which is highly dependent 
on SES, has conflicting findings for the presence of decreased risk for severe 
dengue among malnourished populations (Kalayanarooj & Nimmannitya, 2005; 
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Maron et al., 2010; Thisyakorn & Nimmannitya, 1993).  Consequently, the 
inability to include SES and education in the study analysis, as the data was not 
available in hospital records from which study data was collected, may limit the 
inference of study findings to the general population. 
Susceptibility for the development of severe dengue is largely dependent 
on the host immune response.  The inclusion of the risk factors race, gender, and 
age in the study analysis will allow for consideration of biological differences 
between study participants.  Inconsequentially, having not included education or 
SES will not have an effect on the internal validity of the study.  Even with the 
discussed limitations, the study still has significant potential to contribute to 
knowledge of dengue disease. 
 
Conclusions 
The antibody-dependent enhancement and reactivation of memory T-cell 
hypotheses are currently the most comprehensive biological pathway models in 
the development of severe dengue manifestations.  Under both hypotheses, a 
primary dengue infection modifies immunological components, which, during a 
secondary heterotypic infection, cause an excessive immune response resulting 
in disease complications.  The dengue literature has provided evidence that 
monocytes are involved in the development of severe dengue; however, lacking 
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was analysis of whether monocyte involvement differed based on previous 
exposure to the dengue virus.  
The study has observed a differential association of venous absolute 
monocyte count with primary and secondary dengue infection during 
defervescence.  Overall, absolute monocyte count is significantly increased in 
secondary compared to primary dengue infections.  The association is 
increasingly modified by male gender and a distance of less than 12.5 km of the 
participant residence from Hospital Ampang.  Additionally, no significant 
association was observed between absolute monocyte count with absence and 
presence of hemorrhage/vascular leakage. 
 The study epidemiological evidence that the monocyte immune response 
is enhanced in secondary infection compared to primary infection provides 
further support of both the involvement of antibody-dependent enhancement and 
reactivation of memory T-cell hypotheses in the development of severe dengue.  
The inability to detect a relationship of absolute monocyte count with absence 
and presence of hemorrhage/vascular leakage is not entirely unexpected and 
speaks to the complex multifactorial immune response resultant of a dengue 
infection.  
Currently, phase three clinical trials are ongoing for a dengue vaccine; 
however, even with a potential future licensed dengue vaccine, coverage of the 
entire human population at risk is years into the future, if ever.  Dengue has 
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shown to be able to be passed through vertical transmission within the vectors, 
meaning dengue, even in a population with complete vaccine coverage, will 
survive and remain a threat to future unvaccinated generations.   
  Beyond the development of an easily administrable and safe tetravalent 
dengue vaccine, the over-riding challenge of the dengue research community is 
to understand the severe dengue biological pathway.  A comprehensive 
understanding of the biological pathway will greatly aid researchers in developing 
medical interventions to lessen or prevent severe dengue complications after a 
dengue susceptible has been infected.  Having a tetravalent dengue vaccine and 
specific medicines to reduce the risk of severe complications will provide public 
health professionals the necessary tools to effectively reduce the burden of 
dengue on the human population.  
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Böttcher, H. M. (1964). Wonder drugs: A history of antibiotics. Philadelphia, PA: 
Lippincott. 
Burnet, F. M., & White, D. O. (1962). Natural History of Infectious Disease. 
Cambridge, UK: Cambridge University Press. 
Central Intelligence Agency (CIA). (2011). Malaysia. Retrieved from 
https://www.cia.gov/library/publications/the-world-factbook/geos/my.html 
Center for Disease Control and Prevention (CDC). (2010). Clinical Guidance. 
Retrieved from http://www.cdc.gov/dengue/clinicalLab/clinical.html 
Center for Disease Control and Prevention (CDC). (2011). Dengue. Retrieved 
from http://www.cdc.gov/Dengue/  
  
137 
 
Chadee, D. D., Williams, F. L. R., & Kitron, U. D. (2005). Impact of vector control 
on a dengue fever outbreak in Trinidad, West Indies, in 1998. Tropical 
Medical & International Health, 10, 748–754. 
doi:10.1111/j.1365.2005.01449.x 
Chin, J. (2000). Control of communicable diseases manual (17th ed.). 
Washington, D.C.: American Public Health Association.  
Chua, G. (2010, September 1). Dengue victims usually older. The Strait Times.  
Retrieved from 
http://www.straitstimes.com/BreakingNews/Singapore/Story/STIStory_573
660.html 
Cockburn A. (1963). The Evolution and Eradication of Infectious Diseases 
[Abstract]. The Bulletin of Hygiene, 39. Retrieved from 
http://www.cabdirect.org/abstracts/19642902283.html 
Cockburn, T. A. (1971). Infectious disease in ancient populations [Abstract]. 
Current Anthropology, 12, 45-62. Retrieved from 
http://www.jstor.org/stable/2740635?seq=1 
Cohen, M. L. (2000). Changing patterns of infectious disease. Nature, 406, 762-
767. doi:10.1038/35021206 
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. 
C., & Dye, C. (2003). The growing burden of tuberculosis - Global trends 
and interactions with the HIV epidemic. Archives of Internal Medicine, 163, 
1009-1021. Retrieved from http://archinte.ama-
assn.org.ezproxy.hsc.usf.edu/cgi/reprint/163/9/1009 
Cummings, D. A. T., Iamsirithaworn, S., Lessler, J. T., McDermott, A., 
Prasanthong, R., Nisalak, A., … Gibbons, R. V. (2009). The impact of the 
demographic transition on dengue in Thailand: Insights from a statistical 
analysis and mathematical modeling. PLoS Medicine, 6, e1000139. 
doi:10.1371/journal.pmed.1000139  
Davis, J. R., & Lederberg, J. (Eds.). (2000). Public health systems and emerging 
infections: Assessing the capabilities of the public and private sectors. 
Retrieved from http://www.nap.edu/openbook.php?record_id=9869 
 
  
138 
 
De Paula, S. O., & Fonseca, B. A. L. (2004). Dengue: A review of the laboratory 
tests a clinician must know to achieve a correct diagnosis. The Brazilian 
Journal of Infectious Diseases, 8, 390-398. doi:10.1590/S1413-
86702004000600002  
De Schweinitz, P. (2010). Is there a shaman in the house? The Journal of the 
American Board of Family Medicine, 23, 794-796. 
doi:10.3122/jabfm.2010.06.100064 
Dengue Virus Net. (2011). Antibody-dependent enhancement. Retrieved from 
http://www.denguevirusnet.com/antibody-dependent-enhancement.html 
Durbin, A. P., Vargas, M. J., Wanionek, K, Hammond, S. N., Gordon, A., Rocha, 
C, … Harris, E. (2008). Phenotyping of peripheral blood mononuclear cells 
during acute dengue illness demonstrates infection and increased 
activation of monocytes in severe cases compared to classic dengue 
fever. Virology, 376, 429–435. doi:10.1016/j.virol.2008.03.028 
Dussart, P., Labeau, B., Lagathu, G., Louis, P., Nunes, M. R. T., Rodrigues, S. 
G., … Baril, L. (2006). Evaluation of an enzyme immunoassay for 
detection of dengue virus NS1 antigen in human serum. Clinical and 
Vaccine Immunology, 13, 1185-1189. doi:10.1128/CVI.00229-06 
Encyclopedia Britannica, Inc. (2009). Population Density of Malaysia. In 
Encyclopedia Britannica online. Retrieved from 
http://www.britannica.com/EBchecked/topic-
art/359754/128347/Population-density-of-Malaysia  
Endy, T. P., Nisalak, A., Chunsuttiwat, S., Vaughn, D. W., Green, S., Ennis, F. 
A., … Libraty, D. H. (2004). Relationship of preexisting dengue virus (DV) 
neutralizing antibody levels to viremia and severity of disease in a 
prospective cohort study of DV infection in Thailand. The Journal of 
Infectious Diseases, 189, 990–1000. doi:10.1086/382280 
Epstein, P. (1995). Emerging diseases and ecosystem instability: New threats to 
public health. American Journal of Public Health, 85, 168-172.  Retrieved 
from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1615306/ 
Farlex, Inc. (2011). The free dictionary. Retrieved from 
http://www.thefreedictionary.com/ 
 
  
139 
 
Farrar, J., Focks, D., Gubler, D., Barrera, R., Guzman, M.G., Simmons, C., … 
Kalayanarooj, S. (2007).  Editorial: Towards a global dengue research 
agenda. Tropical Medicine and International Health, 12, 695-699. 
Doi:10.1111/j.1365-3156.2007.01838.x 
Fried, J. R., Gibbons, R.V., Kalayanarooj. S., Thomas, S. J., Srikiatkhachorn, A., 
Yoon, I … Cummings, D. A. T. (2010). Serotype-specific differences in the 
risk of dengue hemorrhagic fever: An analysis of data collected in 
Bangkok, Thailand from 1994 to 2006. PLoS Neglected Tropical Diseases, 
4,  e617. doi:10.1371/journal.pntd.0000617  
Galea, S., & Tracy, M. (2007). Participation rates in epidemiologic studies. 
Annals of Epidemiology, 17, 643-653. 
doi:10.1016/j.annepidem.2007.03.013 
Gamble, J., Bethell, D., Day, N. P., Loc, P. P., Phu, N. H., Gartside, I. B. … 
White, N. J. (2000). Age-related changes in microvascular permeability: A 
significant factor in the susceptibility of children to shock? Clinical Science, 
98, 211–216. Retrieved from 
http://www.clinsci.org/cs/098/0211/0980211.pdf 
George, R. (1987). Dengue haemorrhagic fever in Malaysia: A review [Abstract]. 
The Southeast Asian Journal of Tropical Medicine and Public Health, 18, 
278-283. 
George, R., & Lam, S. K. (1997). Dengue virus infection--the Malaysian 
experience [Abstract]. Annals of the Academy of Medicine, Singapore, 
26(6), 815-819.  
Green, S., Pichyangkul, S., Vaughn D. W., Kalayanarooj, S., Nimmannitya, S.,  
Nisalak, A.,  … Ennis, F. A. (1999). Early CD69 expression on peripheral 
blood lymphocytes from children with dengue hemorrhagic fever. The 
Journal of Infectious Diseases, 180, 1429-1435. doi:10.1086/315072 
Gubler, D. J. (1997). Dengue and dengue hemorrhagic. New York, NY: CAB 
International Press.  
Gubler, D. J. (1998). Dengue and dengue haemorrhagic fever. Clinical 
Microbiology Reviews, 11, 480–496. Retrieved from 
http://cmr.asm.org/cgi/content/full/11/3/480 
  
140 
 
Gubler, D. J. (2004).  The changing epidemiology of yellow fever and dengue, 
1900 to 2003: full circle? Comparative Immunology, Microbiology and 
Infectious Diseases, 27, 319-330. doi:10.1016/j.cimid.2004.03.013 
Guha-Sapir, D., & Schimmer, B. (2005). Dengue fever: New paradigms for a 
changing epidemiology.  Emerging Themes in Epidemiology, 2, 1-10. 
doi:10.1186/1742-7622-2-1 
Guy, B., Almond, J., & Lang, J. (2011). Dengue vaccine prospects: A step 
forward. The Lancet, 377, 381-382. doi:10.1016/S0140-6736(11)60128-1  
Guzman, A.,& Istúriz, R. E. (2010). Update on the global spread of dengue. 
International Journal of Antimicrobial Agents, 36S, S40–S42. 
doi:10.1016/j.ijantimicag.2010.06.018 
Guzman, M. G., Kouri, G., & Halstead, S. B. (2000). Do escape mutants explain 
rapid increases in dengue case-fatality rates within epidemics? The 
Lancet, 355, 1902–1903. doi:10.1016/S0140-6736(00)02303-5 
Guzman, M. G., Kouri, G., Valdes, L., Bravo, J., Vazquez, S., & Halstead, S. B. 
(2002). Enhanced severity of secondary dengue-2 infections: Death rates 
in 1981 and 1997 Cuban outbreaks. Pan American Journal of Public 
Health, 11, 223-227. Retrieved from 
http://www.scielosp.org/pdf/rpsp/v11n4/10467.pdf 
Hales, S., de Wet, N., Maindonald, J., & Woodward, A. (2002). Potential effect of 
population and climate changes on global distribution of dengue fever: An 
empirical model. The Lancet, 360, 830–834. doi:10.1016/S0140-
6736(02)09964-6 
Halstead, S. B. (1994). Dengue and dengue hemorrhagic fever. In G. W. Beran 
(Ed.), Handbook of Zoones, Section B: Viral (2nd ed) (89-100). Retrieved 
from 
http://books.google.com/books?hl=en&lr=&id=hDxeXDisYKEC&oi=fnd&pg
=PA89&dq=Halstead,+1994+dengue&ots=cX2GaqtJHq&sig=2PY3Lh2mg
2anl5N71fGBgb6OBWA#v=onepage&q=Halstead%2C%201994%20deng
ue&f=false 
Halstead, S. B., Mahalingam, S., Marovich, M. A., Ubol, S., & Mosser, D. M. 
(2010). Intrinsic antibody-dependent enhancement of microbial infection in 
macrophages: Disease regulation by immune complexes. The Lancet 
Infectious Diseases, 10, 712-22. doi:10.1016/S1473-3099(10)70166-3. 
  
141 
 
Halstead, S. B., Streit, T. G., Lafontant, J. G., Putvatana, R., Russell, K., Sun, 
W., … Watts, D. M. (2001). Haiti: Absence of dengue hemorrhagic fever 
despite hyperendemic dengue virus transmission. The American Journal 
of Tropical Medicine and Hygiene, 65, 180–183. Retrieved from 
http://www.ajtmh.org/cgi/reprint/65/3/180 
Hayward, A. C., & Coker, R. J. (2008). Could a tuberculosis epidemic occur in 
London as it did in New York? Emerging Infectious Diseases, 6, 12-16. 
Retrieved from http://www.cdc.gov/ncidod/eid/vol6no1/hayward.htm 
Hempel, S. (2007). The strange case of the Broad Street pump: John Snow and 
the mystery of cholera. Berkeley, CA: University of California Press.  
Hussin, N., Jaafar, J., Naing, N. N., Mat, H. A., Muhamad, A. H., & Mamat, M. N. 
(2005). A review of dengue fever incidence in Kota Bharu, Kelantan, 
Malaysia during the years 1998-2003. The Southeast Asian Journal of 
Tropical Medicine and Public Health, 36, 1179-1186. Retrieved from 
http://www.tm.mahidol.ac.th/seameo/2005_36_5/16-3538.pdf 
Imhof B. A., & Aurrand-Lions, M. (2004). Adhesion mechanisms regulating the 
migration of monocytes. Nature Reviews Immunology, 4, 432-444. 
doi:10.1038/nri1375 
Innis, B. L. (1997). Antibody response to virus infection. In Gubler, D. J. and 
Kuno, G. (Eds.), Dengue and Dengue Hemorrhagic Fever, New York, NY: 
CAB International. 
Jansen, C. C., & Beebe, N. W. (2010). The dengue vector Aedes aegypti: What 
comes next. Microbes and Infection, 12, 272-279. 
doi:10.1016/j.micinf.2009.12.011 
Jones, K. E., Patel, N. G., Levy, M. A., Storeygard, A., Balk, D., Gittleman, J. L., 
& Daszak, P. (2008). Global trends in emerging infectious diseases. 
Nature, 451, 990-994. doi:10.1038/nature06536 
Jouanna, J. (1999). Hippocrates. Baltimore, MD: Johns Hopkins University 
Press. 
Kalayanarooj, S. & Nimmannitya, S. (2005). Is dengue severity related to 
nutritional status? The Southeast Asian Journal of Tropical Medicine and 
Public Health, 36, 378-384. 
  
142 
 
Kalayanarooj, S., Vaughn, D. W., Nimmannitya, S., Green, S., Suntayakorn, S., 
Kunentrasai, N., … & Ennis F. A. (1997). Early clinical and Laboratory 
indicators of acute dengue illness. The Journal of Infectious Diseases, 
176, 313–321. doi: 10.1086/514047 
Kaplan G., & Keil, J. (1993). Socioeconomic actors and cardiovascular disease: 
A review of the literature. Circulation. 88, 1973-1988. Retrieved at 
http://circ.ahajournals.org.ezproxy.hsc.usf.edu/cgi/reprint/88/4/1973 
King, C. A., Anderson, R., & Marshall, J. S. (2002). Dengue virus selectively 
induces human mast cell chemokine production. Journal of Virology, 76, 
8408-8419. doi: 10.1128/JVI.76.16.8408-8419.2002 
Klevens, R. M., Morrison, M. A., Nadle, J., Petit, S., Gershman, K., Ray, S. … 
Fridkin, S. K. (2007). Invasive methicillin-resistant staphylococcus aureus 
infections in the United States. The Journal of the American Medical 
Association, 298, 1763-1771. doi: 10.1001/jama.298.15.1763 
Knapp, V. J. (1989). Disease and its impact on modern European history (Vol. 
10). Lewiston, NY: Mellen. 
Kumar, A., Rao, C. R., Pandit, V., Shetty, S., Bammigatti, C., & Samarasinghe, 
C. M. (2010). Clinical manifestations and trend of dengue cases admitted 
in a tertiary care hospital, Udupi district, Kamataka. Indian Journal of 
Community Medicine, 35, 386-390. doi: 10.4103/0970-0218.69253 
Kupperberg, P. (2008). The influenza pandemic of 1918-1919. New York, NY: 
Chelsea House Publishers. 
Kyle, J. L., & Harris, E. (2008). Global spread and persistence of dengue. Annual 
Review of Microbiology, 62, 71-92. 
doi:10.1146/annurev.micro.62.081307.163005 
Last, J. M. (1988). A dictionary of epidemiology (2nd ed.). Oxford, UK: Oxford 
University Press. 
Lederberg, J. (1997). Infectious disease as an evolutionary paradigm. Emerging 
Infectious Diseases, 3, 417-423. Retrieved from 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2640075/pdf/9366592.pdf 
  
143 
 
Leong, A. S., Wong, K. T., Leong, T. Y., Tan, P. H., & Wannakrairot, P. (2007). 
The pathology of dengue hemorrhagic fever [Abstract].  Seminars in 
Diagnostic Pathology 24, 227-236. doi:10.1053/j.semdp.2007.07.002 
Libraty, D. H., Endy, T. P., Houng, H. S., Green, S., Kalayanarooj, S., 
Suntayakorn, S., … Rothman, A. L. (2002). Differing influences of virus 
burden and immune activation on disease severity in secondary dengue-3 
virus infections. The Journal of Infectious Disease 185, 1213-1221. doi: 
10.1086/340365 
Link, K. (2005). The vaccine controversy: The history, use, and safety of 
vaccinations. Westport, CT: Praeger Publishers. 
Liu, C., Huang, K, Huang, M, Lin, J. J., Wang, S. M., Liu, J., … & Lei, H. (2008). 
High case-fatality rate of adults with dengue hemorrhagic fever during an 
outbreak in non-endemic Taiwan: Risk factors for dengue-infected elders. 
American Journal of Infectious Diseases, 4, 10-17. Retrieved from 
http://www.scipub.org/fulltext/ajid/ajid4110-17.pdf 
Lowy, F. D. (2010). Mapping the distribution of invasive staphylococcus aureus 
across Europe. PLoS Medicine, 7, e1000205. 
doi:10.1371/journal.pmed.1000205 
Lum, L. C., Suaya, J. A., Tan, L. H., Sah, B. K., & Shepard, D. S. (2008). Quality 
of life of dengue patients. The American Journal of Tropical Medicine and 
Hygiene, 78, 862-867. Retrieved from 
http://www.ajtmh.org/cgi/reprint/78/6/862 
Lupi, O. (2011). Mosquito-borne hemorrhagic fevers. Clinics in Dermatology, 29, 
33–38. doi:10.1016/j.det.2010.09.009 
Lye, D. C., Chan, M., Lee, V. J., & Leo, Y. S. (2008). Young adults with 
uncomplicated dengue fever need hospitalization? A retrospective 
analysis of clinical and laboratory features. Singapore Medical Journal, 49, 
476-479. 
Malaysian Ministry of Health (MMOH). (2011). Ministry of Health. Retrieved from 
http://www.moh.gov.my/  
Mangill, A., & Gendreau, M. A. (2005). Transmission of infectious diseases 
during commercial air travel. The Lancet, 365, 989–996. 
doi:10.1016/S0140-6736(05)71089-8 
  
144 
 
Maron, G. M., Clara, A. W., Diddle, J. W., Pleites, E. B., Miller, L., Macdonald, G., 
& Adderson, E. E. (2010). Association between nutritional status and 
severity of dengue infection in children in El Salvador. The American 
Journal of Tropical Medicine and Hygiene, 82, 324-329. 
Martina, B. E., Koraka, P., & Osterhaus, A. D. (2009). Dengue virus 
pathogenesis: An integrated view. Clinical Microbiology Reviews, 22, 564–
81. doi:10.1128/CMR.00035-09 
McNeill, W. H. (1976). Plagues and People. Garden City, NY: Anchor/Doubleday. 
Metchnikoff, E. (1971). The founders of modern medicine: Pasteur, Koch, Lister. 
Freeport, NY: Books for Libraries Press. 
Moellering, R. C. Jr. (1995). Past, present, and future of antimicrobial agents. 
The American Journal of Medicine, 29, 11S-18S. 
Monath, T. P. (2007). Dengue and yellow fever - Challenges for the development 
and use of vaccines. New England Journal of Medicine, 357, 2222-2225. 
Retrieved from http://www.nejm.org/doi/pdf/10.1056/NEJMp0707161 
Mongkolsapaya, J., Duangchinda, T., Dejnirattisai, W., Vasanawathana, S., 
Avirutnan, P., Jairungsri, A. … Screaton, G. (2006). T cell responses in 
dengue hemorrhagic fever: Are cross-reactive T cells suboptimal? Journal 
of Immunology, 176, 3821–3829. Retrieved from 
http://www.jimmunol.org.ezproxy.hsc.usf.edu/content/176/6/3821.full.pdf+
html 
Moore, K., & Tabas, I. (2011). Macrophages in the pathogenesis of 
atherosclerosis. Cell. 145, 341-355. doi:10.1016/j.cell.2011.04.005 
Nagao, Y., & Koelle, K. (2008). Decreases in dengue transmission may act to 
increase the incidence of dengue hemorrhagic fever. Proceedings of the 
National Academy of Sciences of the United States of America, 105, 
2238–2243. doi: 10.1073/pnas.0709029105 
National Institute of Allergy and Infectious Diseases (NIAID). (2010). Emerging 
and re-emerging infectious diseases: List of NIAID emerging and re-
emerging diseases group I—pathogens newly recognized in the past two 
decades. Retrieved form 
http://www.niaid.nih.gov/topics/emerging/Pages/list.aspx 
  
145 
 
National Institutes of Health (NIH). (2011). Regulations and ethical guidelines: 
The Belmont report: Ethical principles and guidelines for the protection of 
human subjects of research. Retrieved from 
http://ohsr.od.nih.gov/guidelines/belmont.html  
Newland, K. (1981). Infant mortality and the health of societies. Washington, D.C: 
Worldwatch Institute. Retrieved from 
http://www.eric.ed.gov/PDFS/ED210114.pdf 
Nielsen, D, G. (2009). The relationship of interacting immunological components 
in dengue pathogenesis. Virology Journal, 6, 211. doi:10.1186/1743-422X-
6-211. 
Nunn, J. F. (2002). Ancient Egyptian medicine. Norman, OK: University of 
Oklahoma Press. 
Oleckno, W. A. (2002). Essential epidemiology: Principles and applications. Long 
Grove, IL: Waveland Pres, Inc. 
Ooi, E., Goh, K., & Gubler, D. J. (2006). Dengue prevention and 35 years of 
vector control in Singapore: Dengue in adults. Emerging Infectious 
Diseases, 12, 887-893. Retrieved from 
http://www.cdc.gov/ncidod/EID/vol12no06/05-1210.htm 
Omran, A. R. (1971). The epidemiologic transition: A theory of the epidemiology 
of population change. The Milbank Memorial Fund Quarterly, 49, 509-538. 
Retrieved from http://www.milbank.org/quarterly/830418omran.pdf 
Orthman, N. (2007). Clinical profile of dengue infection in children versus adults 
[Abstract]. Paediatric viral infections, S435. Retrieved from 
http://www.blackwellpublishing.com/eccmid17/abstract.asp?id=57346 
PanBioDengue. (2011). History of dengue. Retrieved from 
www.panbiodengue.com 
Paupy, C., Delatte, H., Bagny, L., Corbel, V., & Fontenille, D. (2009). Aedes 
albopictus, an arbovirus vector: From the darkness to the light. Microbes 
and Infection, 11, 1177-1185. doi:10.1016/j.micinf.2009.05.005  
 
 
  
146 
 
Pang, T., Cardosa, M. J. & Guzman, M. G. (2007). Of cascades and perfect 
storms: The immunopathogenesis of dengue haemorrhagic fever-dengue 
shock syndrome (DHF/DSS). Immunology and Cell Biology, 85, 43–45. 
doi:10.1038/sj.icb.7100008 
Peeling, R. W., Artsob, H., Pelegrino, J. L., Buchy, P., Cardosa, M. J., Devi, S…. 
Yoksan, S. (2010). Evaluation of diagnostic tests: Dengue. Nature 
Reviews Microbiology, S30-S38. doi:10.1038/nrmicro2459 
Pengsaa, K., Yoksan, S., Limkittikul, K., Wisetsing, P., Sirivichayakul, C., 
Hutacharoen, P. … Sabchareon, A. (2003). Maternally transferred 
neutralising dengue antibodies in Thai infants: A pilot study. Annals of 
Tropical Pediatrics, 23, 159-165. doi:10.1179/027249303322296466 
Pennsylvania State University (PSU). (2010). Epidemiological Triad. Retrieved 
from https://onlinecourses.science.psu.edu/stat507/node/25 
Perera, R., & Kuhn, R. J. (2008). Structural proteomics of dengue virus. Current 
Opinion in Microbiology, 11, 369–377. doi:10.1016/j.mib.2008.06.004  
Pinheiro, F. P., & Corber, S. J. (1997). Global situation of dengue and dengue 
haemorrhagic fever, and its emergence in the Americas [Abstract]. World 
Health Statistics Quarterly Report, 50, 161-169. Retrieved from 
http://www.ncbi.nlm.nih.gov.ezproxy.hsc.usf.edu/pubmed?term=Pinheiro%
20%26%20corber%2C%201997%20dengue 
Polgar, S. (1964). Evolution and the ills of mankind. Horizons of Anthropology, 
(Ed.) Sol Tax. Chicago, IL: Aldine. 
Poovaneswari, S. (1993). Dengue situation in Malaysia. Malaysian Journal of 
Pathology, 15(1), 3-7. Retrieved from 
http://www.mjpath.org.my/past_issue/MJP1993.1/dengue%20situation%2
0in%20malaysia.pdf 
Potts, J. A., Gibbons, R. V., Rothman, A. L., Srikiatkhachorn, A., Thomas, S. J., 
Supradish, P. … Kalayanarooj, S. (2010). Prediction of Dengue Disease 
Severity among Pediatric Thai Patients Using Early Clinical Laboratory 
Indicators. PLoS Neglected Tropical Diseases, 4, e769. 
doi:10.1371/journal.pntd.0000769 
PubMed Health. (2009). Severe acute respiratory syndrome (SARS). Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004460/ 
  
147 
 
Qi, R. F., Zhang, L., & Chi, C. W. (2008). Biological characteristics of dengue 
virus and potential targets for drug design. Acta biochimica et biophysica 
Sinca, 40, 91-101. doi: 10.1111/j.1745-7270.2008.00382.x 
Reves, R. (1985). Declining fertility in England and Wales as a major cause of 
the 20th-century decline in mortality - the role of changing family-size and 
age structure in infectious-disease mortality in infancy [Abstract]. 
American Journal of Epidemiology, 122, 112–126. Retrieved from 
http://aje.oxfordjournals.org/content/122/1/112.abstract 
Rigau-Perez, J. (2006). Severe dengue: the need for new case definitions. The 
Lancet Infectious Diseases, 6, 297–302. doi:10.1016/S1473-
3099(06)70465-0  
Rigau-Perez, J. G., Clark, G. C., Gubler, D. J., Reiter, P., Sanders, E. J., & 
Vorndam, A. V. (1998). Dengue and dengue haemorrhagic fever. The 
Lancet, 352(9132), 971-977. doi:10.1016/S0140-6736(97)12483-7. 
Rodenhuis-Zybert, I. A., Wilschut, J. & Smit, J. M. (2010). Dengue virus life cycle: 
Viral and host factors modulating infectivity. Cellular and Molecular Life 
Sciences, 67, 2773-2786. doi:10.1007/s00018-010-0357-z  
Rothman, A. L. (2010). Cellular immunology of sequential dengue virus infection 
and its role in disease pathogenesis [Abstract]. Current Topics in 
Microbiology and Immunology, 338, 83-98. doi: 10.1007/978-3-642-02215-
9_7 
Rothman, A. L., & Ennis, F. A. (1999). Immunopathogenesis of dengue 
hemorrhagic fever. Virology, 257, 1–6. doi:10.1006/viro.1999.9656 
Rudnick, A., & Lim, T. W. (1986). Dengue fever studies in Malaysia. Institute for 
Medical Research Malaysia Bulletin, 23, 51–152. Retrieved from 
http://infosvr.moh.gov.my:8070/vital/access/manager/Repository/EJ:6?exa
ct=creator%3a%22T.W.+%28ed%29%2c+Lim%22 
Russell, R.C., Webb, C.E., Williams, C. R., & Richie, S.A. (2005). Mark-release-
recapture study to measure dispersal of the mosquito Aedes aegypti in 
Cairns, Queensland, Australia. Medical and Veterinary Entomology, 19, 
451-457. doi:10.1111/j.1365-2915.2005.00589.x 
  
148 
 
Sabin, A. B. (1952). Research on dengue during World War II [Abstract]. The 
American Journal of Tropical Medicine and Hygiene, 1, 30–50. Retrieved 
from http://www.ajtmh.org/cgi/content/abstract/1/1/30 
Salazar M. I., Richardson, J. H., Sánchez-Vargas, I., Olson, K. E. & Beaty, B. J. 
(2007).  Dengue virus type 2: Replication and tropisms in orally infected 
Aedes aegypti mosquitoes. BMC Microbiology, 7, 9. doi:10.1186/1471-
2180-7-9 
Saw, S. H. (2007). The Population of Malaysia. Retrieved from 
http://books.google.com/books?hl=en&lr=&id=e4Yp2QJNVWgC&oi=fnd&p
g=PR5&dq=The+Population+of+Malaysia,+Saw+Swee-
Hock&ots=FbmW0LkABq&sig=LxtHt2oKWenBn7W4CVGd0gYjyfg#v=one
page&q&f=false 
Shilts, R. (1988). And the band played on: Politics, people, and the AIDS 
epidemic. New York, N.Y.: Penguin Books. 
Sierra, B., Kouri, G., & Guzman, M. G. (2007). Race: A risk factor for dengue 
hemorrhagic fever. Archives of Virology, 152, 533–542. 
doi:10.1007/s00705-006-0869-x 
Skae, F. M. T. (1902). Dengue fever in Penang. British Medical Journal, 2, 1581-
1582. Retrieved from 
http://www.ncbi.nlm.nih.gov.ezproxy.hsc.usf.edu/pmc/articles/PMC240211
2/pdf/brmedj08482-0009b.pdf 
Smith, C. E. (1956). The history of dengue in tropical Asia and its probable 
relationship to the mosquito Aedes aegypti. The Journal of Hygiene, 59, 
243-251.  
Snowden, F.  M. (2008). Emerging and reemerging diseases: A historical 
perspective. Immunological Reviews, 225, 9-26. doi:10.1111/j.1600-
065X.2008.00677.x 
Spellberg, B. (2008). Dr. William H. Stewart: Mistaken or maligned? Clinical 
Infectious Diseases, 47, 294. Retrieved from 
http://cid.oxfordjournals.org.ezproxy.hsc.usf.edu/content/47/2/294.1.full.pd
f+html 
 
  
149 
 
Spiegel, J. M., Bonet, M., Ibarra, A., Paglicca, N., Ouellette, V., & Yassi, A. 
(2007). Social and environmental determinants of Aedes aegypti 
infestation in Central Havana: results of a case–control study nested in an 
integrated dengue surveillance programme in Cuba. Tropical Medicine 
and International Health, 12, 503-510. doi:10.1111/j.1365-
3156.2007.01818.x 
Statistical Solutions. (2011). Power and sample size calculator. Retrieved from 
http://www.statistical solutions.net/pss_calc.php 
Suaya, J. A., Shepard, D. S., & Beatty, M. A. (2006). Dengue: Burden of disease 
and costs of illness. Scientific working group report on dengue: Meeting 
report, 1-5 October 2006, Geneva, Switzerland. Retrieved from 
http://apps.who.int/tdr/svc/publications/tdr-research-publications/swg-
report-dengue 
Teo, D. & Ng, L. C. & Lam, S. (2009). Is dengue a threat to the blood supply? 
Transfusion Medicine, 19, 66–77. doi: 10.1111/j.1365-3148.2009.00916.x 
Tee, H. P., How, S. H., Jamalludin, A. R., Safhan, M. N., Sapian, M. M., Kuan, Y. 
C., & Sapari, S. (2009). Risk factors associated with development of 
dengue haemorrhagic fever or dengue shock syndrome in adults in 
Hospital Tengku Ampuan Afzan Kuantan. Medical Journal of Malaysia, 
64(4), 316-320. Retrieved from http://www.e-
mjm.org/2009/v64n4/Dengue_Haemorrhagic_Fever.pdf 
Thayan, R., Huat, T. L., See, L. L., Tan, C. P., Khairullah, N. S., Yusof, R., & 
Devi, S. (2009). The use of two-dimension electrophoresis to identify 
serum biomarkers from patients with dengue haemorrhagic fever. 
Transactions of the Royal Society of Tropical Medicine and Hygiene, 103, 
413-419. doi:10.1016/j.trstmh.2008.12.018 
The University of Texas Medical Branch (UTMB). (2009). Flaviviridae Family. 
Retrieved from http://www.utmb.edu/discoveringdenguedrugs-
together/Flaviviridae%20Family.htm 
The World Bank. (2011). World development indicators. Retrieved from 
http://data.worldbank.org/data-catalog/world-development-
indicators?cid=GPD_WDI 
 
  
150 
 
Thenmozhi, V., Hiriyan, J. G., Tewari, S. C., Samuel, P. P., Paramasivan, R., 
Rajendran, R. … Tyagi, B. K. (2007). Natural vertical transmission of 
dengue virus in Aedes albopictus (Diptera: Culicidae) in Kerala, a 
southern Indian state. Japanese Journal of Infectious Diseases, 60, 245-
249. Retrieved from http://www.nih.go.jp/JJID/60/245.pdf 
Thisyakorn, U., & Nimmannitya, S. (1993). Nutritional status of children with 
dengue hemorrhagic fever. Clinical Infectious Diseases, 16, 295-297. 
Thomas, L., Brouste, Y., Najioullah, F., Hochedez, P., Hatchuel, Y., Moravie, V., 
… Cabie, A. (2010). Predictors of severe manifestations in a cohort of 
adult dengue patients. Journal of Clinical Virology, 48, 96-99. 
doi:10.1016/j.jcv.2010.03.008 
Tsai J. J., Chan K. S., Chang J. S., Chang K., Lin C. C., Huang J. H., … Lin C. Y. 
(2009). Effect of serotypes on clinical manifestations of dengue fever in 
adults. Journal of Microbiology, Immunology and Infection, 42, 471-478. 
Retrieved from 
http://www.ejmii.com/article_pdf.php?code=PDT4be0ff4e4cc8b 
Ubol, S., & Halstead, S. B. (2010). How innate immune mechanisms contribute to 
antibody-enhanced viral infections. Clinical and vaccine immunology, 17, 
1829–1835. Retrieved from 
http://www.jimmunol.org.ezproxy.hsc.usf.edu/content/176/6/3821.full.pdf+
html 
United Nations Educational, Scientific and Cultural Organization (UNESCO), 
(1985). World Congress on Youth. Retrieved from 
http://unesdoc.unesco.org/images/0006/000647/064796EB.pdf   
United Nations Educational, Scientific and Cultural Organization (UNESCO). 
(1985). Activities of the United Nations system in the field of youth. World 
Congress on Youth. Retrieved from 
http://unesdoc.unesco.org/images/0006/000647/064796EB.pdf   
UNICEF. (2011). Malaysia: Statistics. Retrieved from 
http://www.unicef.org/infobycountry/malaysia_statistics.html#75 
United Nation (UN). (1990). Article 1, United Nation convention on the right of 
child. Retrieved from http://www2.ohchr.org/english/law/crc.htm  
  
151 
 
United Nations (UN). (2009a). UN: World population prospects: The 2009 
revision and world urbanization prospects. Retrieved from 
http://esa.un.org/unpd/wup/index.htm 
United Nations (UN). (2009b). World population prospects: The 2008 revision 
population database. Retrieved from http://esa.un.org/unpp 
United Nations (UN). (2010, March). World urbanization prospects: The 2009 
revision.  Geneva, Switzerland: World Health Organization. Retrieved from 
http://esa.un.org/unpd/wup/index.htm  
US Census Bureau. (2011). International data base: World population summary. 
Retrieved from http://www.census.gov/ipc/www/idb/worldpopinfo.php 
Vasilakis, N. & Weaver, S. C. (2008). Chapter 1: The history and evolution of 
human dengue emergence. Advances in Virus Research, 72, 1-76. doi: 
10.1016/S0065-3527(08)00401-6 
Vaughn, D. W., Green, S., Kalayanarooj, S., Innis, B. L., Nimmannitya, S., 
Suntayakorn, S., … Nisalak, A. (2000). Dengue viremia titer, antibody 
response pattern, and virus serotype correlate with disease severity. 
Journal of Infectious Disease, 181, 2-9. doi: 10.1086/315215 
Vinomarlini, G., Rogayah, T., Saraswathy, T. S., Thayan, R., Apandi, M., 
Fauziah, M. K., & Saat, Z. (2011). Molecular typing of dengue viruses 
circulating on the east coast of peninsular Malaysia from 2005 to 2009 
[Abstract]. The Southeast Asian Journal of Tropical Medicine and Public 
Health, 42, 94-99. Retrieved from 
http://www.tm.mahidol.ac.th/seameo/2011-42-1/13-4865.pdf 
Vornham, V. & Kuno, G. (1997). Laboratory diagnosis of dengue virus infections. 
In Gubler, D. J. and Kuno, G., Dengue and Dengue Hemorrhagic Fever, 
New York, NY: CAB International. 
Wade, R. (2010, October 31). Europe’s plagues came from China, study finds.  
The New York Times. Retrieved from 
http://www.nytimes.com/2010/11/01/health/01plague.html?adxnnl=1&adxn
nlx=1300122069-zc6FBSRuUaj96CxXSSmHwQ 
 
  
152 
 
Wang, E., Ni, H., Xu, R., Barrett, A. D., Watowich, S. J., Gubler, D. J., & Weaver, 
S. C. (2000). Evolutionary relationships of endemic/epidemic and sylvatic 
dengue viruses. Journal of Virology, 74, 3227-3234. Retrieved from 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC111823/pdf/jv003227.pdf 
Waterman, S. H., Novak, R. J., Sather, G. E., Bailey, R. E., Rios, I., & Gubler, D. 
J. (1985). Dengue transmission in two Puerto Rico communities in 1982. 
The American Journal of Tropical Medicine and Hygiene, 34, 625-632. 
Whitehorn, J. & Farrar, J. (2010). Dengue. British Medical Bulletin, 95, 161-173. 
doi: 10.1093/bmb/ldq019  
Wichmann, O., Hongsiriwon, S., Bowonwatanuwong, C., Chotivanich, K., 
Sukthana, Y., & Pukrittayamee, S. (2004). Risk factors and clinical 
features associated with severe dengue infection in adults and children 
during the 2001 epidemic in Chonburi, Thailand. Tropical Medicine & 
International Health, 9, 1022–1029. Retrieved from 
http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3156.2004.01295.x/pdf 
Wong, C. W., Wah Heng, C. L., Wan Yee, L., Soh, S. W. L., Kartasasmita, C. B., 
Simoes, E. A. F., … Miller, L. D. (2007). Optimization and clinical 
validation of a pathogen detection microarray. Genome Biology, 8, R93. 
doi:10.1186/gb-2007-8-5-r93 
WordNet. (2011). WordNet: A lexical database for English. Retrieved from 
http://wordnet.princeton.edu/ 
World Health Organization (WHO). (1969). The international health regulations. 
Retrieved from http://www.who.int/ihr/current/en/index.html 
World Health Organization (WHO). (1996). The rise and spread of dengue, 
dengue hemorrhagic fever and its vectors, 1950-1990. Retrieved from 
http://www.searo.who.int/en/Section10/Section332/Section519_2401.htm 
World Health Organization (WHO). (1997). Dengue haemorrhagic fever: 
diagnosis, treatment, prevention and control. 2nd edition. Retrieved from 
http://www.who.int/csr/resources/publications/dengue/Denguepublication/e
n/index.html 
World Health Organization (WHO). (2005). Preventing chronic diseases: A vital 
investment: WHO global report. Retrieved from 
http://www.who.int/chp/chronic_disease_report/contents/en/index.html 
  
153 
 
World Health Organization (WHO). (2007). The world health report 2007: A safer 
future: Global public health security in the 21st century. Retrieved form 
http://www.who.int/whr/2007/whr07_en.pdf  
World Health Organization (WHO). (2008). The World Health Report 2008: 
Primary health care: Now more than ever. Retrieved from 
http://www.who.int/whr/2008/en/index.html 
World Health Organization (WHO) (2010). Dengue, countries or areas at risk, 
2010. Retrieved from 
http://gamapserver.who.int/mapLibrary/Files/Maps/Global_DengueTransm
ission_ITHRiskMap.png 
World Health Organization/Southeast Asia Region (WHO/SEAR). (2011). 
Dengue/DHF: Case Fatality Rate(%) of DF/DHF in the South-East Asia 
Region (1985-2006). Retrieved from 
http://www.searo.who.int/en/Section10/Section332_1102.htm 
World Health Organization / Special Programme for Research and Training in 
Tropical Diseases (WHO/TDR). (2004). Dengue Diagnostics: proceedings 
of a joint TDR/WHO and PDVI workshop. Retrieved from 
http://apps.who.int/tdr/publications/tdr-research-publications/dengue-
diagnostics-proceedings/pdf/dengue_diagnostics.pdf 
World Health Organization / Special Programme for Research and Training in 
Tropical Diseases (WHO/TDR). (2007). Scientific working group report on 
Dengue, 1–5 October 2006, Geneva, Switzerland. Retrieved from 
http://www.who.int/tdr/publications/publications/swg_dengue_2.htm 
World Health Organization/ Special Programme for Research and Training in 
Tropical Diseases (WHO/TDR). (2009). Dengue: Guidelines for diagnosis, 
treatment, prevention and control. Retrieved from 
http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf 
World Health Organization / Western Pacific Region (WHO/WPR). (2011). 
Dengue in the Western Pacific. Manila, Philippines: World Health 
Organization. Retrieved from 
http://www.wpro.who.int/health_topics/dengue/ 
World Tourism Organization (WTO). (2011). International Tourism 2010: Multi-
speed recovery. Retrieved from 
http://85.62.13.114/media/news/en/press_det.php?id=7331&idioma=E 
  
154 
 
World Weather Information Service (WWIS). (2011). Malaysia. Retrieved from 
http://worldweather.wmo.int/020/c00082.htm 
Yew, Y. W., Ye, T., Ang, L. W., Ng, L. C., Yap, G., James, L., … Goh, K. T. 
(2009). Seroepidemiology of dengue virus infection among adults in 
Singapore. Annals Academy of Medicine Singapore, 38, 667-675. 
Retrieved from 
http://www.annals.edu.sg/pdf/38VolNo8Aug2009/V38N8p667.pdf 
Zakharov, S. V., & Ivanova, E. I.  (2010). Fertility decline and recent changes in 
Russia: on the threshold of the second demographic change.  Retrieved 
from 
http://www.rand.org/pubs/conf_proceedings/CF124/CF124.chap2.html#fn0 
Ziegler, P. (1969). The Black Death. New York, NY: John Day Co. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
155 
 
 
 
 
APPENDICES 
Appendix A: Epidemiological Transitions: The Human and Disease 
Relationship 
 An understanding of epidemiological transitions during human history will 
provide a foundation to the reader upon which to grasp and interpret the 
empirical evidence discerned in this study.  The intended objective of the 
following section is to present a historic overview of the relationship between 
humans and disease as a backdrop for further, more in depth analysis of dengue 
epidemiology.  The framework for the following discussion will use a theory 
expansion presented by Barrett and colleagues of Abdel Omran’s originally 
presented theory of “epidemiological transition” or “health transition” (Omran, 
1971; Barrett, Kuzawa, McDade, & Armelagos, 1998).   
The epidemiology transition theory concentrates on major human 
morbidity and mortality patterns along with the “demographic, economic and 
sociologic determinants and consequences” (Omran, 1971).  Barrett and 
colleagues (1998) identify three major epidemiological transitions during the 
period of time from our common hominoid ancestors until today, which 
incorporate many of Omran’s original findings.  To describe the period of time 
before the first epidemiological transition, Omran (1971) coined the phrase: “The 
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Age of Pestilence and Famine.”  This period of time began with the first hominoid 
ancestors on the African savanna lasting until the late-17th century. 
Characterizing “The Age of Pestilence and Famine” was a high mortality and 
birth rate.  Population patterns were defined by epidemics and famine while 
remaining low in total population, as compared with the 20th & 21st centuries 
(Figure 1A, Phase 1).  
 
 
Figure 1A.  Epidemiological transitions (UN, 2009a) edited. 
 
“The Age of Pestilence and Famine” can be analyzed by conceptualizing a 
dichotomous break along food collection methods: foraging and agriculture.  
From the interpretations of archeologists and anthropologists, modern human 
pre-historic ancestors on the African savanna are thought to have lived in small 
nomadic tribes who foraged for food (Burnet & White, 1962).  Population 
dynamics would have not favored disease organisms of low pathogenicity or high 
virulence as the organism would have not encountered a large enough 
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population to sustain transmission.  Diseases which were likely to affect the early 
hominoids were enteric bacterium, transferred by the oral-fecal route, and head 
and body lice (Cockburn, 1971, as cited in Barrett et al., 1998).  As early 
hominids increased tool usage and dispersed throughout Europe, Asia and 
eventually colonizing much of the globe, they would have disturbed different 
ecological niches increasing their risk for contracting novel diseases.  Sustained 
transmission of an emerging diseases resulting in an endemic nature in the 
hominoid population would have remained low during this period of foraging as 
populations would have remained below sustainable disease thresholds of 
transmission (Barrett et al., 1998). 
 Approximately 10,000 years ago, the early nomadic tribes began to 
establish permanent settlements and no longer used foraging as a primary 
method for food collection, turning to agriculture (Barrett et al., 1998).  The 
transition to food cultivation had no significant effect on the high mortality and 
birth rates, however; they allowed for the development of slightly larger 
populations which introduced a number of new disease threats.  An enlarged, 
sessile population allowed for increased contact between individuals and 
accumulation of waste (Barrett et al., 1998).  Furthermore, increased population 
densities would have allowed viral infections such as measles, smallpox and 
respiratory infections, along with vector-borne diseases (e.g. plague and typhus) 
to thrive.  Cholera epidemics would have occurred with accumulated waste 
(Knapp, 1989).  During this period, zoonotic diseases (e.g. tuberculosis, anthrax 
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and Q fever) would have emerged due to increased contact with domesticated 
animals (Polgar, 1964, as cited in Barrett et al., 1998)  
 The first accounts on the origin of disease come from documents written 
by the great ancient civilizations of modern day Egypt, India, and China. Disease 
was generally thought of an external affliction caused either by the wrath of a well 
intentioned god(s) who the individual had upset, or the hex from an evil demon.  
This supernatural stance on the origin of disease was in turn treated with highly 
superstitious remedies, many of which did more harm than good to the afflicted 
(Nunn, 2002).  Supernatural disease origin has not faded with antiquity but 
remains in present times, most observably in the practices of shamanism (de 
Schweinitz, 2010).  Not until approximately 400 Before Common Era (BCE) in 
Greece, did a shift in philosophy towards a natural or internal origin of disease 
occur.  Hippocrates, known as the “Father of Modern Medicine,” has been given 
credit for this shift in disease philosophy, among many other significant 
contributions, forming a foundation for medical advancement (Jouanna, 1999).   
 By the 14th century of the Common Era (CE), humans had formed 
regional populations, interacting through trading routes over land and on the high 
seas (McNeill, 1976).  While trade spurred economies, within the trading vessels 
tradesmen and vector alike carried diseases to new populations.  Originating in 
China, the plague or Black Death travelled across the Asian continent and then 
throughout Europe (Wade, 2010).  Plague, caused by the bacterium Yersinia 
pestis, is transmitted to humans through the bite of a flea, direct contact or 
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indirect droplet inhalation.  The Black Death peaked during 1348-1350CE and is 
estimated to have killed 1/3 of the European population (Ziegler, 1969).  The 
increasingly crowded and unsanitary conditions in combination with poor 
nutritional diets brought destructive epidemics throughout the remainder of the 
“Age of Pestilence and Famine” (McNeill, 1976).  
 The first major historical epidemiological transition began in the late 
seventeenth century in Europe which entered “The Age of Receding Pandemics” 
(Omran, 1971).  As the name suggests, pandemics, while not absent, become 
less devastating as dietary, sanitation and hygiene efforts increase.  Defining the 
era is a drastic drop in mortality rate and increase in life-expectancy which, when 
combined with a very high birth rate, resulted in a substantial natural increase in 
the total population (Figure 1A, Phase 2) (Omran, 1971).  While increases in 
basic standards of living aided in the decreased mortality rate, without the 
intellectual contributions of John Snow, Louis Pateur and Robert Koch, 
improvements in human health may not have been sustained.   
John Snow, an English physician, is considered to be one of the fathers of 
epidemiology for his work on a cholera outbreak in Soho, England (Hempel, 
2007).  A skeptic of the miasma theory, which stated that diseases where caused 
by “bad air,” Snow used mapping of cholera cases and statistical analysis to 
show an association with the outbreak point source, a water pump (Hempel, 
2007).  Refuting “bad air,” the disease origin dogma of the day, John Snow 
provided bases for further disease origin investigations. 
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Not until Louis Pastuer’s experiment to refute spontaneous generation and 
subsequent statement of the Germ Theory of Disease during the 1860’s, did the 
true causal relationship between disease and humans begin to become evident 
(Metchnikoff, 1971).  The Germ Theory is based on the idea that disease is 
caused by the invasion of the body by microorganisms.  In 1880, Robert Koch 
empirically validated Louis Pastuer’s Germ Theory and proposed his own 
postulates on the matter of disease origin (Metchnikoff, 1971).  Still used today, 
Koch’s Postulates are a set of four criteria used to empirically determine if a 
microorganism is the causal agent for a disease. 
 Late into the 19th century and beginning of the 20th century, medical 
science was rapidly advancing the understanding of disease and beginning to 
produce effective primary prevention in the form of vaccines.  Edward Jenner is 
given credit for having created the first vaccine against the smallpox virus 
through the method of variolation of cowpox scabs in 1796 Current Era (CE) 
(Allen, 2007).  After a gap of almost a century, vaccine development progressed 
to address rabies (1884), cholera and typhoid (1896), plague (1897), and 
pertussis (1915) (Link, 2005).  During this time period, medical science was 
beginning to feel they could solve infectious diseases; however, with the world at 
war the influenza pandemic of 1918 took the world and field of science by 
surprise.  Unlike most infectious diseases which target the very young, elderly 
and immunocompromised, pandemic influenza of 1918 targeted healthy young 
adults (Kupperburg, 2008).  Researchers of the day rushed to develop a vaccine 
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for influenza. Unfortunately, these vaccine attempts would prove unsuccessful 
dampened by the initial hypothesis that the pandemic was caused by a bacterium 
(Kupperburg, 2008). 
 Although the influenza pandemic of 1918 had exposed the medical and 
scientific communities for their limited prevention capabilities, following World 
War II North America was soon undergoing a second epidemiological transition.  
The transition was as a result in a surge of scientific and public health triumphs, 
including: the eradication of polio, improved sanitation requirements, federal 
oversight to further protect consumables in America (e.g. Federal Food, Drug, 
and Cosmetic Act, 1938, USA) and the continued discovery of new more 
powerful antibiotics (Bo ttcher, 1964). 
”The Age of Degenerative and Man-Made Diseases”, is the second 
epidemiologic transition defined by a constant low mortality rate and decreasing 
birth rate (Omran, 1971).  The decreasing birth and infant mortality rates are 
generally a result of increased access to healthcare and education for women 
and children (Newland, 1981).  During this third transition period, the total 
population expands rapidly in the beginning, but as the birthrate drops, the 
population growth rate slows (Figure 1A, Phase 3).  Sustained public health 
efforts see a continued drop in infectious disease mortality, combined with the 
increased lifespan, results in chronic diseases, for the first time, becoming the 
leading cause of mortality (Omran, 1971).  Chronic diseases with high 
prevalence in this stage include cancer, diabetes, coronary artery disease and 
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chronic obstructive pulmonary disorder (Kaplan & Keil, 1993).  These diseases 
have a multitude of risk factors, including tobacco, alcohol, human made 
environment pollution (i.e. air, water & noise), diet and decreased exercise.   
The transition between the receding pandemic and man-made disease 
eras is not typically as abrupt as written in this thesis.  Low-income countries may 
not have been able to afford to invest enough in their public health infrastructure 
to rid their country of infectious disease epidemics.  At the same time, 
globalization (e.g. increased pollution, availability of tobacco and alcohol) and the 
westernization of the diet (i.e. increased sugar, salt and fat [especially from 
animals] intake) increase the burden of chronic diseases on the population.  This 
double burden is evident by the WHO reporting that 80% of chronic disease 
deaths occur in low and middle income nations (WHO, 2005).  There is a 
continued need to address both chronic and infectious disease problems 
simultaneously. 
 Snowden (2008) has deemed the period since the discovery of antibiotics 
in the 1940’s: “The Age of Hubris.”  While the tenth Surgeon General of the 
United States has been incorrectly quoted as saying it was “time to close the 
books on infectious diseases” (Spellberg, 2008), this attitude was in fact the 
overwhelming mood of world leaders of the day demonstrated by the US 
Secretary of State George Marshall declaring in 1948 that the world had the 
ability to rid itself of infectious diseases (Lederberg, 1997; Snowden, 2008).  Also 
during this period, Aidan Cockburn, an epidemiologist at John Hopkins University 
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and WHO advisor, even went as far as to give a timetable for complete infectious 
disease eradication: achieved by “2060” (Cockburn, 1963, as cited in Barrett et 
al., 1998).   
The feeling of inevitable conquest over infectious diseases was being 
fueled by the post-World War II social uplift in earnings, education, diet and 
sanitation, food production, the discovery of the “magic bullet” for malaria - 
quinine, WHO announcing in 1979 the eradication of smallpox, and the discovery 
of penicillin and streptomycin.  Beyond public euphoria over accomplishments, 
the scientific community’s incorrect view of the stagnant or slow-paced 
evolutionary process towards benign microbes further eroded the perceived 
threat of infectious diseases (Snowden, 2008).  Feelings translated into action as 
the 1969 International Health Regulations only required three reportable 
diseases: yellow fever, plague and cholera (WHO, 1969).   
As global conditions changed, researchers have expanded Omran’s 
original model to fit and explain developments.  One such expanded model, 
described by Zakharov and Ivanova (2010), attempts to explain changes to 
Russian epidemiology.  Russia, having undergone a social upheaval, has seen a 
drop in its population as a result of stagnate to decreasing birth rate with an 
increased death rate.  Seen in other developed nations with social upheaval, the 
increased death rate is not only due to chronic diseases, but resurgence in 
infectious diseases as a result of a failure in governmental public health 
programs.  These factors have lead to an overall decrease in the total population.  
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The above model, while imperative to understanding overall global 
epidemiological transitions, does not explain the emerging and re-emerging 
pattern in infectious diseases observed within the last half century on a global 
level.  
In post-World War II, individuals who held the belief that infectious 
diseases would drive themselves by means of natural selection towards a benign 
existence were termed “eradicationists” (Snowden, 2008).  The decrease 
virulence of syphilis from the 16th century compared to the mid-twentieth century 
was a pillar for the support of their theory (Snowden, 2008).  Doubt in the validity 
of the decreasing virulence theory began with novel disease discoveries during 
the 1970s; however, the tipping point arrived in 1983 with the discovery of the 
Human Immunodeficiency Virus (Shilts, 1988).  Successive epidemics occurred 
throughout the 1990’s.  In 1991, an epidemic of cholera swept across Central 
and South America (WHO, 2007).  The US “four-corner” region was struck by a 
mysterious severe pulmonary illness which rapidly killed 83 individuals in 1993.  
Later identification of Hantavirus gave a name to the disease which had struck 
apprehension into the United States population (Epstein, 1995).  Finally, with an 
epidemic of plague in India (1994) and the well publicized Ebola outbreak in 
Zaire during 1995, a clear epidemiological transition was occurring (Snowden, 
2008); but what was occurring and why was it taking place? 
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Epidemiological Transition Theory: Model Expansion 
Barrett and colleagues (1998), present a third epidemiological transition 
the Age of “Emerging and Re-emerging Infectious Diseases”.  Emerging 
diseases, defined by Davis and Lederberg (2000) are “diseases of infectious 
origin whose incidence in humans has increased within the past two decades or 
threatens to increase in the near future.”  The emerging and re-emerging 
infectious disease theory is based on the following three defining criteria: 1) 
numerous new diseases detected which are contributing to mortality, 2) 
increasing prevalence and incidence of diseases previously thought to be 
controlled, and 3) re-emerging diseases are developing anti-microbial resistance 
faster than new drugs to combat them can be developed.   
 The first criteria is easily observable as 31 emerging infectious diseases 
were identified from 1973-1995 (Lederberg, 1997).  Currently, the United States 
National Institute of Allergy and Infectious Diseases (NIAID) lists 16 emerging 
and five re-emerging infectious diseases identified within the last two decades 
(Table 1A, NIAID, 2010).  Defending the second criteria is the estimate that more 
people are infected with tuberculosis than at any time in human history (Hayward 
& Coker, 2008).  Microbial resistance was first discovered in 1917 during the 
testing of the organic chemical Optochine (C21H28N2O2) in the treatment of 
pneumococcal pneumonia (Moellering, 1995, as cited in Barrett et al., 1998).  
Microbial resistance continues to be a major public health hazard seen in the 
estimated 19,000 deaths in the US during 2005 caused by strains of 
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Staphylococcus aureus resistant to commonly administered antibiotics (Klevens 
et al., 2007).  
As a result of highly publicized infectious disease outbreaks (e.g. ebola, 
necrotizing fasciitis (e.g. Streptococcus pyogenes), human immunodeficiency 
virus (HIV)) and food recalls as a result of contamination with Escherichia coli 
O157:H7, popular opinion may point towards an overwhelming increase in the 
incidence and prevalence of infectious diseases; however, is the infectious 
disease apprehension we are experiencing today simply a result of increased 
surveillance capabilities?  Until 2008, no analytic study had been published which 
undertook this question in a systematic manner.  Jones (2008) published a study 
in which he compiled data on infectious diseases and surveillance capabilities 
from 1940 to 2004.  Results of the study show that infectious diseases have been 
emerging at a rate above expected increases due to improved surveillance 
coverage.  Furthermore, infectious disease emergence was shown to peak in the 
1980’s, but emergence today still exceeds that in the 1940’s (Jones, 2008).  
 Decreased funding for infectious disease public health programs during 
the 1960’s and 1970’s played a large role in the emergence and re-emergence of 
infectious diseases, but many other factors have significantly contributed.  Cohen 
(2000) has presented a graphic representation of the risk factors which have 
contributed to infectious disease emergence and re-emergence (Figure 2A).   
These risk factors include changes to human behavior; demographics changes, 
of which population increase and urbanization are significant contributors; 
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technological changes; industry changes; environmental changes; travel, and 
more specifically mass travel; decreases in public health infrastructure; and 
microbial adaptation (Cohen, 2000). 
 
Table 1A.  NIAID Global Emerging and Re-emerging Infectious Diseases: 1990-
Present.  
Emerging Re-Emerging 
Acanthamebiasis  Enterovirus 71 
Australian bat lyssavirus Clostridium difficile 
Babesia, atypical Mumps virus 
Bartonella henselae Streptococcus, Group A 
Ehrlichiosis Staphylococcus aureus 
Encephalitozoon cuniculi   
Encephalitozoon hellem   
Enterocytozoon bieneusi   
Helicobacter pylori   
Hendra or equine morbilli virus   
Hepatitis C   
Hepatitis E   
Human herpesvirus 8   
Human herpesvirus 6   
Lyme borreliosis   
Parvovirus B19   
 
 
While the risk factors to increased infectious disease outcomes have been 
identified, the consequences on birth rates, death rates, and total population 
have yet to fully manifest as the emerging and re-emerging epidemiological 
transition is ongoing.  Currently, public health efforts have been relatively 
successful in reducing the impact of acute infectious disease pandemics (e.g. 
SARS in 2003 and Influenza in 2009).  However, a great disparity has arisen with 
regard to chronic infectious disease pandemics, such as HIV and tuberculosis.  
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These chronic infectious diseases, which have long latency and infectious 
periods, have increasingly affected all countries, but middle- and low- income 
countries have incurred the majority of the burden (Corbett, 2003).  Ongoing 
vaccination development research and other similar public health endeavors help 
but do not fix the underlying causes of health disparity, being poverty, education, 
dietary needs and access to affordable healthcare (Snowden, 2008).  Even with 
all the advances in health technology, Lederberg (1997) suggests that we are 
currently more susceptible to pandemic and communicable diseases threats than 
at any time in human history. 
 
 
Figure 2A. “Changes in society, technology, environment and microorganisms 
are leading to increases in host susceptibility and/or disease transmission and 
the evolution of new or drug-resistant microorganisms” (Cohen, 2000). 
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WHO is predicting that non-infectious diseases will be responsible for little 
more than 5% of all global deaths by 2030 (WHO, 2008) (Figure 3A).  When 
international organizations and governments decide to distribute aid and 
research funding the increasing prevalence on chronic diseases must be taken 
into consideration.  Controlling chronic diseases must be met with the same, if 
not greater, monetary and cooperative effort seen in taking on infectious 
diseases in post-World War II.  In the same breath, infectious diseases must not 
be forgotten, as history has already shown us their ability to emerge and re-
emerge if public health infectious disease programs are de-funded.  Unlike most 
chronic diseases, many infectious diseases have the potential to be eradicated 
by-well designed vaccines.  Vaccine development should continue to be at the 
forefront of infectious disease funding.  Understanding the biological pathway 
behind infectious disease pathogenesis is imperative for vaccine and treatment 
advancement.  The effort to understand infectious disease pathogenesis must 
not be limited to funding of laboratory endeavors.  Sponsorship of field and 
clinical epidemiology provides crucial evidence on the population effected.  
Epidemiology has aided in the discovery that diseases are not caused by “bad 
air”, that HIV is not a disease limited to homosexuals, and that Severe Acute 
Respiratory Syndrome (SARS) is spread through direct or indirect transmission 
(Hempel, 2007; Shilts, 1988; PubMed Health, 2009). 
Epidemiological studies, whether through surveillance or well-designed 
targeted studies, should not be thought of as a one-time undertaking to 
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comprehend an infectious disease as they have shown an uncanny ability to 
mutate and spread to novel geographic regions (Lowy, 2010).  To fully 
understand a disease, epidemiological studies must encompass all potentially 
effected individuals in regards to place, but also time.  The following section 
presents a historic review of dengue epidemiology. 
   
 
Figure 3A. The shift towards noncommunicable diseases and accidents as 
causes of death. (WHO, 2008) edited. 
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Appendix B: Primary Study Population Descriptive Tables 
 
Table 1B. Dengue Manifestations in Source Study Participants by 2009 WHO Dengue 
Diagnostic Scheme from Hospital Ampang, 2010.
^
  
  
Non-
Dengue
 
  
Without                
Warning 
Signs
 
 
With                       
Warning 
Signs
 
 
Severe
 
  
Dengue 
Total
 
Manifestation
*
  n
 
%
 
 
 
 
 
n
 
%
 
 
 
 
 
n
 
%
 
 
 
 
 
n
 
%
 
 
 
 
 
n
 
%
 
  
Total Study Participants 22 8.0     27 9.8     222 80.4     5 1.8     254 92.0   
Abdominal Pain 12 54.6   
 
1 3.7 ‡ 
 
161 72.5 ¥ 
 
2 40.0   
 
164 64.6   
Arthraglia/Myaglia 17 77.3   
 
20 74.1 
  
184 82.9 
  
3 60.0   
 
207 81.5   
Diarrhea 7 31.8   
 
11 40.7 
  
130 58.6 
  
2 40.0   
 
143 56.3   
Hepatosplenomegaly 5 22.7   
 
2 7.4 
  
65 29.3 
  
3 60.0   
 
70 27.6   
Nausea/Vomiting 15 68.2   
 
10 37.0 
  
203 91.4 ‡¥ 5 100.0 ‡¥  
 
218 85.8   
Postural Giddiness 6 27.3   
 
9 33.3 
  
86 38.7 
  
2 40.0   
 
97 38.2   
Rash 1 4.6   
 
3 11.1 
  
39 17.6 
  
4 80.0   
 
46 18.1   
Retro-orbital/Headache 10 45.5   
 
16 59.3 
  
112 50.5 
  
2 40.0   
 
130 51.2   
Viral Hepatitis 3 13.6   
 
16 59.3 ‡ 
 
162 73.0 ‡ 
 
2 40.0   
 
180 70.9 ‡ 
Bleeding Tendency 
(Any)
#
  5 22.7     2 7.4     62 27.9     3 60.0     67 26.4   
^
 Fisher's exact test (2-tails) with Bonferroni correction. 
* Other: Ascites (n=2), Pleural Effusion (n=7), & Petechiae/Bruises (n=4) 
#
 Includes: epistaxis, gum provocative & spontaneous, hemetemesis, melena, menorrhagia, 
retinal and subconjunctival. 
 'Non-Dengue' control with level of significance: † ≤0.05 ; ‡ ≤0.01 
 'Without Warning' control with level of significance: ¥ ≤0.05 
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Table 2B.
 Blood Profile of Source Study Participants by 2009 WHO Dengue Diagnostic Scheme from Hospital Ampang, 2010.
^
 
 
Profile Component 
Non-Dengue
 
  
Without Warning
 
 
With Warning
 
 
Severe
 
  
Total Dengue
 
n
 
Avg. ± S.D.
 
 
 
 
 
n Avg. ± S.D.
 
 
 
n
 
Avg. ± S.D.
 
 
 
n
 
Avg. ± S.D.
 
 
 
 
 
Avg. ± S.D.
 
Hemoglobin
#
 
 
 
 
 
 
 
  
 
 
   
 
 
     
 
 
  
     Febrile 13 13.1 ± 1.5    18 14.3 ± 1.4   154 13.9 ± 1.8   4 13.0 ± 2.3    13.9 ± 1.7  
     Defervescence 20 13.4 ± 1.8    25 13.7 ± 1.6   219 13.6 ± 1.8   5 13.8 ± 1.7    13.6 ± 1.8  
     Convalescence 16 13.0 ± 1.9    23 14.0 ± 1.4   201 13.7 ± 1.7   5 12.6 ± 1.9    13.7 ± 1.7  
Hematocrit
&
 
 
   
 
 
            
 
 
  
     Febrile 14 39.2 ± 4.1    15 43.3 ± 3.5 †  155 42.1 ± 4.9   4 39.4 ± 7.7    42.1 ± 4.8  
     Defervescence 20 40.0 ± 5.2    26 41.2 ± 5.9   221 41.0 ± 5.5   5 41.5 ± 5.6    41.0 ± 5.4  
     Convalescence 17 38.2 ± 5.1    22 42.0 ± 5.9   202 41.5 ± 4.7 † 5 38.8 ± 5.8    41.5 ± 4.9 † 
Platelet
*
 
 
   
 
 
           
 
 
  
     Febrile 14 107.9 ± 58.3    18 85.9 ± 52.9   155 77.1 ± 42.4 † 4 107.3 ± 8.4    78.7 ± 43.2  
     Defervescence 20 96.7 ± 44.0    26 70.1 ± 36.2   222 61.3 ± 43.2 ‡  5 82.8 ± 37.1    62.6 ± 42.4 ‡ 
     Convalescence 17 198.2 ± 71.8    23 209.7 ± 118.7   202 228.6 ± 140.9   5 324.4 ± 191.2    228.8 ± 140.2  
Total White Cell
*
 
 
   
 
 
            
 
 
  
     Febrile 14 5.7 ± 3.1    18 3.6 ± 1.6   155 3.5 ± 1.9 ‡  4 5.7 ± 3.3    3.6 ± 1.9  
     Defervescence 20 5.4 ± 3.2    26 4.2 ± 2.1   220 5.0 ± 2.4   5 6.7 ± 4.9    4.9 ± 2.4  
     Convalescence 17 6.5 ± 2.2    22 6.3 ± 2.2   202 7.0 ± 5.4   5 7.1 ± 2.8    6.9 ± 5.1  
Neutrophil
*
 
 
   
 
 
            
 
 
  
     Febrile 12 4.1 ± 2.3    12 1.5 ± 0.8 ‡  142 1.9 ± 1.4 ‡  4 4.4 ± 3.6    1.9 ± 1.5 † 
     Defervescence 17 3.7 ± 3.3    22 1.3 ± 0.8 †  218 1.7 ± 1.3 ‡  5 3.7 ± 4.3    1.7 ± 1.4  
     Convalescence 15 3.9 ± 1.7    22 2.5 ± 1.0 †  210 2.9 ± 1.7   5 3.2 ± 1.9    2.8 ± 1.6 † 
Lymphocyte
*
 
 
    
 
             
 
  
     Febrile 12 1.5 ± 1.7    12 1.2 ± 0.7   142 1.0 ± 0.6   4 0.7 ± 0.7    1.0 ± 0.6  
     Defervescence 17 1.4 ± 0.5     22 1.8 ± 1.1   218 1.9 ± 1.0   5 1.5 ± 1.0    1.9 ± 1.0†  
     Convalescence 15 2.5 ± 1.2    22 2.8 ± 0.9   210 2.7 ± 1.0   5 2.9 ± 1.1    2.7 ± 1.0  
Monocyte
*
 
 
    
 
 
           
 
 
  
     Febrile 11 0.6 ± 0.3    10 0.7 ± 0.5   125 0.6 ± 0.7   4 0.5 ± 0.1    0.6 ± 0.7  
     Defervescence 17 0.6 ± 0.3    21 1.1 ± 0.9   199 1.2 ± 0.9   5 0.9 ± 0.3    1.2 ± 0.9 ‡ 
     Convalescence 12 0.7 ± 0.4    18 0.9 ± 0.9   182 0.9 ± 0.7   5 0.7 ± 0.4    0.9 ± 0.7  
Eosinophil
*
 
 
     
 
            
 
  
     Febrile 11 0.03 ± 0.07    10 0.03 ± 0.09   125 0.01 ± 0.06   4 <0.0 ± <0.0    0.01 ± 0.06  
     Defervescence 17 0.06 ± 0.09    21 0.03 ± 0.08   199 0.05 ± 0.10   5 0.02 ± 0.05    0.05 ± 0.09  
     Convalescence 12 0.13 ± 0.11    18 0.12 ± 0.14   182 0.15 ± 0.17   5 0.06 ± 0.09    0.14 ± 0.16  
Basophil
*
 
 
    
 
            
 
  
     Febrile 11 <0.00 ± <0.00    10 <0.00 ± <0.00   125 0.01 ± 0.03   4 <0.00 ± <0.00    0.01 ± 0.03  
     Defervescence 17 <0.00 ± <0.00    21 <0.00 ± <0.00   199 0.01 ± 0.03   5 <0.00 ± <0.00    0.01 ± 0.03  
     Convalescence 12 <0.01 ± 0.03     18 0.01 ± 0.03     182 0.02 ± 0.04     5 0.02 ± 0.05     0.02 ± 0.04   
^ Independent student t-test with Bonferroni correction. 'Non-Dengue' control group. 
Level of Significance: † ≤0.05; ‡ ≤0.01 
*
 (x10^9) ; & % ; # (g/dL) 
Note: Significant associations were not detected between Without & With Warning groups. 
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Table 3B.
 Renal Profile of Source Study Participants by 2009 WHO Dengue Diagnostic Scheme from Hospital 
Ampang, 2010.
^
 
 
Profile Component 
Non-Dengue
 
  Without Warning
 
 With Warning
 
 
 
 Severe
 
  Total Dengue
 
n
 
Avg. ± S.D.
 
 
 
 
 
n
 
Avg. ± S.D.
 
 
 
n
 
Avg. ± S.D.
 
 
 
 
 
n
 
Avg. ± S.D.
 
 
 
 
 
Avg. ± S.D.
 
Urea
*
 
 
   
 
           
 
   
 
     Febrile 11 5.3 ± 3.2    11 3.9 ± 1.7  132 3.2 ± 1.6 ‡  3 3.3 ± 0.8    3.2 ± 1.6   
     Defervescence 17 4.5 ± 3.7    22 2.5 ± 1.2  215 2.4 ± 1.0 ‡  5 2.9 ± 1.4    2.5 ± 1.1   
     Convalescence 14 4.1 ± 1.8    17 2.8 ± 1.1  173 2.5 ± 1.1 ‡  5 3.1 ± 1.4    2.5 ± 1.1 † 
Sodium
*
 
 
   
 
           
 
   
 
     Febrile 11 136.3 ± 7.3    11 135.5 ± 3.9  132 136.2 ± 3.5   3 133.3 ± 4.5    136.1 ± 3.5   
     Defervescence 17 138.4 ± 4.3    22 140.4 ± 4.8  215 139.1 ± 2.9   5 138.0 ± 2.4    139.2 ± 3.1   
     Convalescence 14 139.9 ± 2.6    17 140.6 ± 2.6  172 139.8 ± 2.6   5 140.6 ± 2.1    139.9 ± 2.6   
Potassium
*
 
 
   
 
           
 
   
 
     Febrile 10 3.9 ± 0.4    11 3.5 ± 0.2 † 132 3.6 ± 0.4   3 4.4 ± 1.0 †   3.6 ± 0.4   
     Defervescence 17 3.7 ± 0.4    22 3.7 ± 0.4  214 3.7 ± 0.5   5 3.7 ± 0.4    3.7 ± 0.5   
     Convalescence 14 3.7 ± 0.4    17 3.8 ± 0.3  173 4.0 ± 2.3   5 3.8 ± 0.4    4.0 ± 2.1   
Chloride
*
 
 
   
 
           
 
   
 
     Febrile 11 102.7 ± 7.0    11 102.2 ± 4.6  132 101.6 ± 4.4   3 97.0 ± 6.1    101.6 ± 4.4   
     Defervescence 17 105.6 ± 4.7    22 107.2 ± 5.3  215 105.8 ± 4.0   5 102.6 ± 5.6    105.8 ± 4.2   
     Convalescence 14 106.0 ± 4.2    17 105.1 ± 4.2  173 104.3 ± 3.8   5 103.0 ± 1.2    104.3 ± 3.8   
Creatinine
&
 
 
   
 
           
 
   
 
     Febrile 11 94.1 ± 49.7    11 94.6 ± 27.0  132 74.1 ± 23.3 ¥  3 92.0 ± 22.6    76.0 ± 24.1   
     Defervescence 17 84.7 ± 52.9    21 66.6 ± 18.6  215 63.3 ± 17.1 ‡  5 75.8 ± 35.4    63.8 ± 17.7   
     Convalescence 14 82.1 ± 29.0     17 69.8 ± 21.8   173 62.1 ± 16.3 ‡    5 60.8 ± 33.0     62.7 ± 17.0   
^
 Independent student t-test with Bonferroni correction.  
† ≤0.05 level of significance with 'Non-Dengue' control group. 
¥ ≤0.05 level of significance with 'Without Warning' control group. 
*
 mmol/L ; 
& 
umol/L 
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Table 4B.
 Liver Profile of Source Study Participants by 2009 WHO Dengue Diagnostic Scheme from Hospital Ampang, 
2010.
^
 
 
 
 Non-Dengue
 
  
Without Warning 
 
 
With Warning
 
 
 
 
Severe
 
  
Total Dengue
 
Profile Component n
 
Avg. ± S.D.
 
 
 
 
 
n
 
Avg. ± S.D.
 
 
 
n
 
Avg. ± S.D.
 
 
 
n
 
Avg. ± S.D.
 
 
 
 
 
Avg. ± S.D.
 
Total Bilirubin
*
 
 
  
 
 
          
 
 
  
 
 
     Febrile 11 34.0 ± 52.9    11 10.6 ± 8.0  132 8.1 ± 4.9 ‡  3 12.7 ± 11.7    8.4 ± 5.4   
     Defervescence 15 14.0 ± 12.1    22 7.3 ± 3.8  215 8.7 ± 4.8 ‡  5 12.8 ± 8.3    8.6 ± 4.9   
     Convalescence 14 15.0 ± 11.8    21 8.6 ± 3.5  210 10.1 ± 5.6 ‡  5 11.8 ± 7.3    10.0 ± 5.5   
Alkaline Phosphatase
&
 
 
   
 
           
 
   
 
     Febrile 11 71.7 ± 27.4    11 82.3 ± 70.5  131 66.8 ± 31.4   3 68.7 ± 13.8    68.0 ± 35.4   
     Defervescence 15 91.7 ± 82.9    22 56.9 ± 34.0  215 64.6 ± 35.3 †  5 56.2 ± 15.2    63.7 ± 34.9   
     Convalescence 14 92.8 ± 60.2    21 72.2 ± 55.2  210 73.9 ± 36.9   5 62.8 ± 16.0    73.6 ± 38.5   
Total Protein
#
 
 
  
 
 
          
 
 
  
 
 
     Febrile 11 65.3 ± 7.9    11 66.1 ± 7.4  131 67.4 ± 8.3   3 73.7 ± 4.2    67.5 ± 8.2   
     Defervescence 15 59.9 ± 4.2    22 62.0 ± 4.8  215 61.9 ± 6.9   5 66.8 ± 9.1    62.0 ± 6.8   
     Convalescence 14 67.1 ± 9.9    21 72.7 ± 7.1  210 73.2 ± 8.7 †  5 74.0 ± 6.8    73.2 ± 8.5 † 
Albumin
#
 
 
  
 
 
          
 
 
  
 
 
     Febrile 11 34.6 ± 5.1   11 38.4 ± 4.5  131 37.9 ± 4.5   3 39.0 ± 1.0    38.0 ± 4.4   
     Defervescence 15 32.1 ± 5.0   22 34.2 ± 3.5  215 34.1 ± 3.9   5 35.4 ± 7.3    34.2 ± 4.0   
     Convalescence 14 35.9 ± 8.3   21 40.6 ± 3.5  210 40.5 ± 4.9 †  5 39.6 ± 6.1    40.5 ± 4.8   
Globulin
#
                     
     Febrile 11 30.7 ± 5.8   11 27.7 ± 4.9  131 29.5 ± 6.3   3 34.7 ± 4.5     29.5 ± 6.2   
     Defervescence 15 27.9 ± 4.1   22 27.7 ± 4.8  215 27.7 ± 4.9   5 31.4 ± 4.2    27.8 ± 4.9   
     Convalescence 14 31.3 ± 4.8   21 32.0 ± 5.7  210 32.7 ± 6.4   5 34.4 ± 4.3    32.7 ± 6.3   
Alanine Aminotransferase
&
                     
     Febrile 11 53.6 ± 47.9    11 77.4 ± 47.7  131 90.6 ± 84.0   3 43.0 ± 9.0    88.6 ± 81.1   
     Defervescence 15 75.3 ± 77.4    22 95.0 ± 95.4  215 115.8 ± 112.7   5 67.2 ± 42.7    112.9 ± 110.4   
     Convalescence 14 51.9 ± 27.8     21 77.9 ± 55.9   210 90.5 ± 72.5   5 94.2 ± 96.9     89.5 ± 71.5  
^
 Independent student t-test with Bonferroni correction. 'Non-Dengue' control group. 
Level of Significance: † ≤0.05; ‡ ≤0.01 
*
 umol/L ; 
& 
U/L ; 
#
 (g/L) 
Note: Significant associations were not detected between Without & With Warning groups. 
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Table 5B.
 Vital Statistic Profile of Source Study Participants by 2009 WHO Dengue Diagnostic Scheme from Hospital 
Ampang, 2010.
^
 
 
 
 Non-Dengue
 
  
Without Warning
 
 
With Warning
 
 
Severe
 
  
Total Dengue
 
Profile Component n
 
Avg. ± S.D.
 
 
 
 
 
n
 
Avg. ± S.D.
 
 
 
n
 
Avg. ± S.D.
 
 
 
n
 
Avg. ± S.D.
 
 
 
 
 
Avg. ± S.D.
 
Temperature (˚C)                   
     Febrile 15 38.9 ± 0.7    18 38.6 ± 0.8  148 38.7 ± 0.8  4 39.0 ± 0.9    38.7 ± 0.8 
     Defervescence 18 37.0 ± 0.3    22 37.1 ± 0.2  186 37.1 ± 0.3  2 36.7 ± 0.4    37.1 ± 0.3 
     Convalescence 4 37.0 ± 0.6    4 37.2 ± 0.3  7 36.9 ± 0.1  1 37    37.0 ± 0.3 
Systolic Blood Pressure
#
 
 
   
 
          
 
  
 
     Febrile 15 123.8 ± 30.2    18 122.4 ± 16.9  148 121.7 ± 15.2  4 99.0 ± 18.1    121.5 ± 17.2 
     Defervescence 18 124.4 ± 20.3    21 115.7 ± 13.2  173 118.2 ± 12.5  2 118.0 ± 25.5    118.5 ± 13.5 
     Convalescence 4 109.8 ± 11.6    5 109.0 ± 5.5  5 117.4 ± 19.2  0 -    112.2 ± 13.0 
Diastolic Blood Pressure
#
 
 
  
 
 
         
 
 
 
 
 
     Febrile 15 73.3 ± 15.7    18 73.9 ± 10.9  148 75.2 ± 12.0  4 60.0 ± 17.2    74.6 ± 12.4 
     Defervescence 18 75.9 ± 7.7    20 72.6 ± 11.8  173 75.8 ± 9.7  2 67.0 ± 9.9    75.4 ± 9.8 
     Convalescence 4 75.0 ± 7.0    5 72.0 ± 9.3  5 66.8 ± 5.1  0 -    71.0 ± 7.6 
Pulse Rate
*
 
 
   
 
          
 
  
 
     Febrile 15 96.3 ± 19.6    18 93.8 ± 17.6  147 93.2 ± 16.4  4 106.3 ± 9.1    93.8 ± 16.7 
     Defervescence 0 -    0 -  0 -  0 -    - 
     Convalescence 4 75.5 ± 9.0     4 80.8 ± 17.4   5 79.6 ± 7.2   0 -     78.7 ± 10.9 
^
 Independent student t-test with Bonferroni correction.  
*
 mmHg ; 
#
 beats per minute 
Note: Significant associations were not detected with control group as 'Non-Dengue' or 'Without Warning.' 
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Appendix C: SAS® Code for Statistical Analysis 
 
***********************************************************************
********************* 
SAS Program for Benjamin Klekamp's thesis: 2011 
 Defended May 17th, 2011 
 Uses SAS dataset: Thesis_Final 
***********************************************************************
*********************; 
*Importing the datset; 
libname perm "C:\Users\Desktop\Ben\Thesis\" ; 
Data data1 ; Set perm.thesis_final ; run; 
 
*Hemagglutination inhibition results - collaspsing into primary and 
secondary infection 
*Only outputs primary and secondary infections 
*HemIn - is hemagglutination inhibition (exposure) variable (binary 
(1&2)) ; 
Data data2 ; Set data1 ; 
if HI = 'p2' then HemIn = 2 ; 
else if HI = '2' then HemIn = 2 ; 
else if HI = '1' then HemIn = 1 ; 
else if HI = 'p1' then HemIn = 1 ; 
else HemIn = 0 ; 
if HemIn ne 0 then output; 
run; 
 
*Some participants did not have a blood profile conducted during 
defervescence phase of illness 
*Absolute Monocyte Count (part of the blood profile) is the outcome 
variable 
*mono2 - was the variable representing absolute monocyte count during 
defervescence 
*Only those participants who have a recorded value for mono2 are 
output; 
Data Data3; Set Data2; 
if mono2 ne . then output; run; 
 
*Creating a variable to be used in the secondary aim analysis 
*HEM_VL = absence (0) or presence (1) of hemorrhage and/or vascular 
leakage; 
Data Data4; Set Data3; 
VL=0; 
Hem=0;        *VL = vascular 
leakage; 
HEM_VL=0;       *HEM = hemorrhage; 
if HCT1 ne . and HCT2 ne . then do; *HCT1 = febrile hematocrit;  
HCTp = (HCT1 - HCT2)/HCT1*100;  *HCT2 = defervescence 
hematocrit; 
if HCTp ge 20 then VL = 1;   *HCTp = hematocrit percent 
change; 
if HCTp le -20 then VL = 1;    
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if PE = 1 then VL = 1 ;    *PE = absence (0) or presence 
(1) of pleural effusion; 
if ASC = 1 then VL = 1 ;   *ASC = absence (0) or 
presence (1) of ascites; 
if SBP2 lt 90 then VL = 1;   *SBP2 = systolic blood 
pressure at defervescence; 
if ((SBP2-DBP2)) le 20 then VL = 1; *DBP2 = distolic blood pressure at 
defervescence; 
end; 
 
if  
SGB  = 1 or   /*Spontaneous gum bleeding*/ 
EPIX = 1 or   /*Epistaxis*/ 
MNG  = 1 or   /*Menorrhagia*/ 
HEMT = 1 or   /*Hemetemesis*/ 
SCH  = 1 or   /*Subconjunctival haemorrhage*/ 
RH   = 1 or   /*Retinal haemorrhage*/ 
MEL  = 1      /*melena*/ 
then Hem = 1 ; 
 
if Hem = 1 or VL = 1 then HEM_VL = 1; run; 
 
*Age of patient is calculated; 
*Duration between first symptom and admission is calculated 
(Tadmission); 
*Duration of Hospitlization is calculated (Tdischarge); 
*Classifying age into youth - adult, non-youth - elderly; 
*Classifying distance between patient residence and Hospital Ampang by 
12.5km; 
*Combining manifestation variables for analysis ; 
Data Data5; Set Data4; 
AGE=(DATE2-DOB)/365.25; *Date2 = date of defervescence blood draw;  
*DOB = Date of birth; 
 
Tadmission=DOA - FEVD ; *DOA= Date of admission;  *FEVD= Date of first 
sysmptom; 
Tdischarge=DOD - DOA ;  *DOD= Date of Discharge;   
 
if Age ge 15 and Age lt 25 then Age1 = 1; 
else if Age ge 25 and Age lt 35 then Age1 = 2; 
else if Age ge 35 and Age lt 45 then Age1 = 3; 
else if Age ge 45 then Age1 = 4 ; 
 
if kilometers le 12.5 then KM = 0 ; 
else km = 1; 
 
if arth = 1 or mya = 1 then MYAR = 1 ; *arth= arthralgia; *mya= 
myalgia; 
 else myar = 0; 
if spleen = 1 or liver = 1 then HEPspl = 1 ; *spleen= Splenomegaly;  
*liver= Hepatomegaly; 
 else hepspl = 0 ; 
if nau = 1 or vom = 1 then nauvom = 1 ; *nau = nausea;  *vom=vomitting; 
 else nauvom = 0; 
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run; 
 
*Creation of a final permenent dataset to work off; 
Data perm.FINAL ; Set data5 ; run; 
 
***********************************************************************
********; 
*ANALYSIS OF THE DATASET; 
***********************************************************************
********; 
 
* Creating time to admission and time to discharge values; 
proc means data= perm.final; 
var Tadmission Tdischarge; run; 
proc sort data=perm.final; by hemin; run; 
proc means data= perm.final; 
by hemin; 
var Tadmission Tdischarge; 
run; 
proc sort data=perm.final; by hem_vl; run; 
proc means data= perm.final; 
by hem_vl; 
var Tadmission Tdischarge; 
run; 
 
*Table 1 was copied from previous report; 
 
*Creating values for Table 2; 
proc freq data = perm.final; 
table (sex race age1 km)*HemIn; run; 
PRoc freq data= perm.final; 
table (sex race age1 km)*Hem_vl ; run; 
 
*Creating Table 3; 
proc freq data = perm.final; 
table (dm HPT ckd ihd ccf)*HemIn; run; 
proc freq data = perm.final; 
table (dm HPT ckd ihd ccf)*hem_vl; run; 
 
*Creating Table 4 ; 
proc freq data = perm.final; 
table (AP MYAR dia HEPspl nauvom pgid rash cereb hepa hem vl)*HemIn; 
run; 
proc freq data = perm.final; 
table (AP MYAR dia HEPspl nauvom pgid rash cereb hepa)*Hem_vl; run; 
 
* Creating Table 5; 
proc means data = perm.final; 
var mono2 plt2 hct2 ; run; 
proc sort data=perm.final; by hemin; run; 
proc means data = perm.final; 
by hemin; 
var mono2 plt2 hct2 ; run; 
proc sort data=perm.final; by hem_vl; run; 
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proc means data = perm.final; 
by hem_vl; 
var mono2 plt2  hct2 ; run; 
 
****Assessing Distance for confounding; 
PRoc freq data=perm.final; 
table Hemin*km / chisq; 
run; 
proc sort data= perm.final; by km; run; 
proc means data=perm.final t prt mean std; 
var mono2; 
by km; 
run; 
PRoc freq data=perm.final; 
table Hem_vl*km / chisq; 
run; 
 
*Creating Table 6 - linear regression; 
proc reg  data = perm.final  ;  
model  mono2 =  HemIN age sex race ;  
output p=p r=r out=LinReg_base; 
attrib _all_ label=' '; 
title'Linear - Age continuous - without distance'; 
run; quit; 
 
axis1 order=-2 to 3 by 1; 
axis2 order=0.3 to 1.7 by 0.2; 
title'Linear - Age continuous - without distance'; 
Proc gplot data=LinReg_base; 
plot r*p / vaxis=axis1 haxis=axis2; 
run; quit; 
 
*Table 7 ; 
proc reg  data = perm.final  ;  
model  mono2 =  HemIN age sex race km ;  
output p=p r=r out=LnReg_KM; 
attrib _all_ label=' '; 
title'Linear - Age continuous - with distance'; 
run; quit; 
 
axis1 order=-2 to 3 by 1; 
axis2 order=0.3 to 1.7 by 0.2; 
title 'Linear - Age continuous - with distance'; 
Proc gplot data=LnReg_KM; 
plot r*p / vaxis=axis1 haxis=axis2; 
run; quit; 
**************************************************; 
*Table 8; 
proc reg  data = perm.final  ;  
model  mono2 =  HemIN age1 sex race ;  
output p=p r=r out=LnReg_Age3; 
attrib _all_ label=' '; 
title'Linear - Age by 10 years - without distance'; 
run; quit; 
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axis1 order=-2 to 3 by 1; 
axis2 order=0.3 to 1.7 by 0.2; 
title'Linear - Age by 10 years - without distance'; 
Proc gplot data=LnReg_Age3; 
plot r*p / vaxis=axis1 haxis=axis2; 
run; quit; 
 
*Table 9; 
proc reg  data = perm.final  ;  
model  mono2 =  HemIN age1 sex race km ;  
output p=p r=r out=LnReg_Age3km; 
attrib _all_ label=' '; 
title'Linear - Age by 10 years - with distance'; 
run; quit; 
 
axis1 order=-2 to 3 by 1; 
axis2 order=0.3 to 1.7 by 0.2; 
title'Linear - Age by 10 years - with distance'; 
Proc gplot data=LnReg_Age3km; 
plot r*p / vaxis=axis1 haxis=axis2; 
run; quit; 
 
****************************************************; 
*Creating Table 10 - logistic regression; 
proc logistic  data = perm.final  ;  
class    sex  race (descending) hemin / param =ref ref =last     ;  
model  hem_VL (EVENT='1')=  mono2 age sex  race hemin   / influence 
lackfit;  
output out=LogReg_base p=p reschi=PR; 
attrib _all_ label=' '; 
title'Logistic - Age continuous - without distance'; 
run; 
title'Logistic - Age continuous - without distance'; 
Proc gplot data=LogReg_base; 
plot pr*p  ; 
run; quit; 
 
*Table 11; 
proc logistic  data = perm.final  ;  
class  sex  race (descending) hemin km (descending)  / param =ref ref 
=last   ;  
model  hem_VL (EVENT='1')=  mono2 age sex  hemin race km / influence 
lackfit ;  
output out=LogReg_km p=p reschi=PR; 
attrib _all_ label=' '; 
title'Logistic - Age continuous - with distance'; 
run; 
title'Logistic - Age continuous - with distance'; 
Proc gplot data=LogReg_km; 
plot pr*p  ; 
run; quit; 
*************************************************; 
*Table 12; 
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proc logistic  data = perm.final  ;  
class  age1 (descending) sex  race (descending) hemin km (descending)  
/ param =ref ref =last   ;  
model  hem_VL (EVENT='1')=  mono2 age1 sex  hemin race / influence 
lackfit ;  
output out=LogReg_Age1 p=p reschi=PR; 
attrib _all_ label=' '; 
title'Logistic - Age by 10 years - without distance'; 
run; 
title'Logistic - Age by 10 years - without distance'; 
Proc gplot data=LogReg_Age1; 
plot pr*p  ; 
run; quit; 
 
*Table 13; 
proc logistic  data = perm.final  ;  
class  age1 (descending) sex  race (descending) hemin km (descending)  
/ param =ref ref =last   ;  
model  hem_VL (EVENT='1')=  mono2 age1 sex  hemin race km / influence 
lackfit ;  
output out=LogReg_Age1km p=p reschi=PR; 
attrib _all_ label=' '; 
title'Logistic - Age by 10 years - with distance'; 
run; 
title'Logistic - Age by 10 years - with distance'; 
Proc gplot data=LogReg_Age1km; 
plot pr*p  ; 
run; quit; 
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